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n
High-grade serous ovarian cancer (HGSC) is the most common and deadly
with
subtype of epithelial ovarian cancer. Understanding the molecular basis of HGSC will
a
improve diagnosis and treatment approaches. The Cancer Genome Atlas (TCGA)
grea
discovered that Forkhead Box M1 (FOXM1) transcription factor activation is the second
t
most frequent molecular alteration in HGSC (84% of cases), second only to mutations of
quot
TP53 (100%). We subsequently defined several genetic mechanisms that underlie
e
increased FOXM1 expression in HGSC, including genomic amplifications and RB-E2F
from
deregulation, and showed that FOXM1 promotes cell cycle progression in cell models
the
relevant to HGSC.
doc
TCGA analyses revealed that genomic instability, consisting of frequent copy
ume
number alterations, as key defining molecular features of HGSC and basal breast, more
nt or
than any other TCGA cancer type. DNA replication stress results from uncoupling of the
use
replicative helicase and polymerase and is a key mechanism of genomic instability.
this
FOXM1 expression is linked to genomic instability but the underlying mechanism is
spa
unclear; induction of DNA replication stress could explain this association. In this context,
ce
we revealed novel functions of FOXM1 using fallopian tube epithelial (FTE) cells, an
to
HGSC precursor cell model. We showed that FOXM1 increased DNA fork rate, origin
emp
firing, and DNA damage. Furthermore, Cyclin E1 cooperated with FOXM1 to increase its
hasi
transcriptional activity, which promoted cell cycle progression and genomic instability. In
ze a
key
poin

[

v

agreement, TCGA HGSC tumors with both FOXM1 and CCNE1 copy number gain show
increased FOXM1 and CCNE1 expression and genomic instability.
FOXM1 shares a bidirectional promoter with RHNO1 but this genetic interaction
has never been studied in any context. Knowledge of this interaction is important for
understanding the molecular mechanism of HGSC. We investigated FOXM1 and RHNO1
expression using large-scale genomic datasets from normal and pan-cancer tissues and
validated these findings with HGSC cell lines and tissues. FOXM1 and RHNO1 showed a
highly significant correlation in all comparisons suggesting a potential for cooperativity.
Importantly, we showed that FOXM1 and RHNO1 cooperate to promote cell survival and
chemoresistance in HGSC cells. Collectively, these studies support in vivo studies
focusing on the cooperativity of FOXM1 and RHNO1 bidirectional gene partners, to further
understand their contribution to HGSC development and progression.
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CHAPTER 1: INTRODUCTION

Human Ovarian Cancer
Ovarian cancers
Ovarian cancer is the most lethal gynecological malignancy and is the fifth leading
cause of cancer-related deaths in women in the United States, accounting for 14,070
estimated deaths and 22,240 estimated new cases in 2018 (6). The 5-year survival rate
for women diagnosed with cancer localized to the ovary exceeds 90%; however, more
than 60% of cases are diagnosed after cancer cells have metastasized from the primary
tumor to distant sites, and the 5-year survival rate for these patients is less than 30% (7).
These dire statistics reflect the lack of an effective screening test for early stage diagnosis
of ovarian cancer and highlight difficulties in the successful treatment of advanced-stage
disease (8).
Ovarian cancer is a generic term that can be used for any cancer involving the
ovaries. Ovarian cancers can be divided into 3 major categories based on cell of origin:
epithelial, germ cell, and stromal cell tumors. Epithelial cancers are most common and
account for at least 90% of ovarian cancer. Epithelial tumors can be further categorized
based on histological subtype. Histology-based classification of ovarian cancer was
developed by the World Health Organization (WHO) system (9,10). Based on these
criteria, epithelial ovarian cancers (EOC) are currently divided into five main types: highgrade serous (70%), endometrioid (10%), mucinous (3%), clear-cell (10%), and low-grade
serous (3%) (Figure 1) (11).
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Staging and grading of epithelial ovarian cancer
According to the International Federation of Obstetricians and Gynecologists
(FIGO) system, ovarian cancer can be classified into Stage I to Stage IV (11). Stage I
ovarian cancer is defined as tumors confined to the ovaries and peritoneal fluid/washings
(11). Stage II ovarian cancer is defined as extension or metastasis to pelvic organs and
may include curable tumors that have directly extended to adjacent organs but have not
yet metastasized (11). Stage III ovarian cancer is defined as tumors characteristically
spread along peritoneal surfaces involving both pelvic and abdominal peritoneum
including the omentum, surfaces of the small and large bowel, mesentery, paracolic
gutters, diaphragm, and peritoneal surfaces of the liver and spleen (11). Stage IV ovarian
cancer is defined as distant metastasis and includes patients with parenchymal
liver/splenic metastases and extra-abdominal metastases (11).
According to the FIGO grading system, ovarian cancers can also be classified into
three grades to indicate the degree of tumor cell differentiation (12). Grade 1 is most like
normal ovarian tissue; Grade 2 is moderately differentiated tumors; and Grade 3 cancer
cells are poorly differentiated or undifferentiated (13). This three-grade system can be
applied to all ovarian carcinomas. Low grade serous ovarian cancer is typically grade 1
and high-grade serous ovarian cancer is grade 2 and 3 (13-15).
Prognosis of ovarian cancer is strongly associated with the stage at diagnosis, but
the histologic grade also plays a prognostic role, particularly in predicting recurrence (16).
Poor prognostic factors include age older than 65 years, clear cell or mucinous tumors
(histology), extensive disease (advanced stage), large residual tumor volume, lower global
quality-of-life score, and poor cell differentiation (high grade) (16). Even though the overall
5-year survival rate of women with ovarian cancer indicates some recent improvement for
women diagnosed between 2002 to 2008, compared to the 1970s and 1980s, these gains
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are rather modest (17). Due to difficulties in early detection, most ovarian cancers are
diagnosed at an advanced stage, and most of the patients show a poor prognosis because
of recurrence after chemotherapy.

Diagnosis of epithelial ovarian cancer
Although the 5-year survival rate of women with localized ovarian tumors exceeds
90%, only as few as 15% of ovarian cancers are confined to the ovaries at diagnosis (17).
Furthermore, the diagnosis of ovarian cancer may be difficult because of nonspecific
symptoms (16). Patients with ovarian cancer may have abdominal pain, swelling, or
nonspecific gastrointestinal symptoms for more than six months before diagnosis (16).
When a patient presents with these symptoms, a pelvic examination should be performed.
However, the physical examination is not sensitive for detecting ovarian masses (16,18).
Additionally, physical examinations are often nonspecific for ovarian cancer, further testing
should be performed in women older than 40 of age who have persistent unexplained
gynecologic or gastrointestinal symptoms (16). Laboratory tests in these patients should
include a complete blood count, comprehensive metabolic panel, and measurement of
serum CA125 levels (16). CA125 (MUC16) is a high-molecular mass (1 MDa) glycosylated
transmembrane mucin that is expressed in 80% of ovarian cancers (8,19). CA125 is shed
from ovarian cancers and circulates in serum allowing for detection without invasive
procedures (8,20). It is the first useful biomarker for monitoring the response of ovarian
cancer to chemotherapy (8,20). CA125 levels are elevated in 90% of patients with
advanced disease, but in only 50% of those with stage I tumors (16,21).
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High-Grade Serous Ovarian Cancer
Origins of high-grade serous ovarian cancer
Until recently, the ovarian surface epithelium (OSE) was the assumed origin of the
majority of HGSC (Figure 1) (13).The OSE is a single layer of epithelial cells that line the
surface of the ovary (22). The OSE was thought to be the origin of HGSC based on the
incessant ovulation hypothesis: the extravagant ovulations in the human female, which
involves repeated rupture and repair of the ovarian surface following exposure to the
estrogen-rich follicular fluid (23). The incessant ovulation hypothesis was further
supported by epidemiological studies that demonstrated a relationship between the
number of ovulations and a woman’s probability of developing ovarian cancer (23).
A recent paradigm shift based on new clinical and molecular evidence suggests
that a majority of HGSC cases originate in the fallopian tube epithelium (FTE) (Figure 1).
Initial evidence for this theory is based on a study done in 2001, when tubal segments
were removed from women undergoing a risk-reducing bilateral salpingo-oophorectomy
or the removal of the fallopian tube and ovaries (24). In this study, 12 specimens were
examined, and six showed areas of cellular dysplasia in the tubal epithelium, and five
displayed hyperplastic lesions, compared to normal fallopian tubes (24). Remarkably, both
the hyperplastic and dysplastic lesions histologically resembled high-grade serous ovarian
cancer, but without invasion (24). In addition, BRCA mutations were found in both ovarian
cancers and fallopian tube malignancies (25). Based on these data, it was hypothesized
that most hereditary serous carcinomas originated from the FTE (26) (Figures 1 and 2).
Gene expression and DNA methylome analyses have since shown that HGSC is more
similar to FTE than OSE (27,28). More recently, evolutionary genomic analyses were
performed on tissues isolated from HGSC precursor lesions in the fallopian tube lesions,
p53 signatures and serous tubal intraepithelial carcinomas (STICs), as well as primary
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HGSC tumors and metastases from nine patients (Figure 2) (29). Genomic analysis
showed that STIC lesions had overlap in tumor-specific alterations (TP53, BRCA1,
BRCA2 or PTEN) that were present in primary and metastatic ovarian cancers, thus
providing further evidence that HGSC originates in the fallopian tube (Figure 2).

Genomic features of high-grade serous ovarian cancer
HGSC is broadly characterized by genomic instability, specifically high copy
number abnormalities but few recurrent somatic mutations. Defects in the homologous
repair pathway occur in ~50% of tumors due to frequent BRCA1/2 mutations (30,31). TP53
mutations are present in 100% of tumors and these occur early in HGSC based on the
detection of p53 signatures in the fallopian tube (Figure 2) (30,31). Additionally, RB-E2F
deregulation occurs in ~70% of HGSC through loss of CDKN2A and RB1, and activation
of cyclin D and E, and agrees with the increased proliferation that is observed in STICs
and HGSC tumors as shown by increased Ki67 staining (Figure 2) (30).
TCGA analyses revealed that genomic instability is a key defining molecular
feature of HGSC and basal breast cancer, more than any other TCGA cancer type (32,33).
One mechanism is deficient homologous recombination DNA repair (HR), exemplified by
BRCA1/2 mutations and promoter methylation, which occur in ~33% of HGSC cases (30).
However, all HGSC cases show genomic instability, therefore additional factors contribute
to this phenotype. One potential example is cyclin E1 (CCNE1) amplifications, which occur
in ~20% of HGSC and are mutually exclusive with HR deficiency (34). CCNE1 induces
DNA replication stress and CNA in some cell models, suggesting it could contribute to
genomic instability in the context of HGSC (35). Furthermore, FOXM1 pathway activation
occurs in ~84% of HGSC (30,36). Notably, FOXM1 is a member of a 25 gene signature
for chromosomal instability in a pan-cancer analysis (CIN25 signature) (37). In addition,
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FOXM1 is a top biomarker for poor prognosis in solid tumors, potentially consistent with a
protein promoting genomic instability (38,39). However, the mechanistic basis for the link
between FOXM1 and genomic instability is unknown (40). Genomic instability contributes
to tumor evolution and treatment resistance; thus, it is critical to reveal causative factors
that drive genomic instability in HGSC (41,42).

Treatment of high-grade serous ovarian cancer
Conventional therapy for ovarian cancer is surgical tumor debulking followed by
combination chemotherapy (16). Ovarian cancer is one of the few malignancies where
surgeons will perform cytoreductive operation to eliminate macroscopic tumor before
chemotherapy (8,43). Surgery can be performed after neoadjuvant chemotherapy if
optimal cytoreduction is not considered feasible at initial diagnosis (8,44). However, there
is no reliable evidence that chemotherapy before debulking surgery is superior to
conventional treatment in women with advanced epithelial ovarian cancer (16). Primary
chemotherapy for newly diagnosed ovarian cancer after cytoreductive surgery consists of
six cycles of combination carboplatin/paclitaxel chemotherapy (8). Carboplatin is an
alkylating agent that binds covalently to DNA, creating adducts that form intrachain and
interchain cross-links (8). Paclitaxel binds non-covalently to microtubules and increases
their stability, interfering with mitotic spindle formation (8). Despite the initial response of
first-line chemotherapy in HGSC patients, more than 70% of patients will experience
disease recurrence, and become candidates for second-line chemotherapy within 12 to
18 months (8). Persistent elevation of CA125 after chemotherapy indicates residual
disease with more than 90% accuracy (8). Retreatment with carboplatin and paclitaxel is
associated with a 20-50% response when platinum-sensitive disease recurs more than 6
months after primary chemotherapy (8). Although recurrent disease is not curable, drug
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combinations, such as liposomal doxorubicin and etoposide, can prolong survival in these
patients (8).
The discovery of BRCA1/2 mutations and HR deficiency in HGSC led to the first
clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors (45). PARP inhibitors
have been found to induce synthetic lethality in BRCA-mutated HGSC (45,46). Synthetic
lethality occurs between two genes when cells with mutation or loss of either gene alone
are viable but mutation or loss of both genes leads to cell death (47). PARP1 is a DNA
repair enzyme that is involved in the base excision repair (BER) pathway (45,46). It is
believed that PARP inhibitors induce DNA replication stress by trapping PARP on genomic
DNA and/or inhibiting BER, which creates a dependency on BRCA1/2 for cell survival
(45,48,49). Studies have shown that loss of both HR and BER forces cells to use nonhomologous end-joining (NHEJ) DNA repair, which is error-prone, thus causing an
accumulation of DNA damage and cell death (45). In clinical trials, PARP inhibitors have
shown selective toxicity toward tumor cells with BRCA1/2 germline mutations as well as
some without germline BRCA1/2 mutations, which is likely due to somatic defects in other
components of the HR pathway (50-52). In 2014, the PARP inhibitor olaparib received
FDA approval for the treatment of germline BRCA-mutated ovarian cancers after third-line
therapy based on a non-randomized study of olaparib monotherapy in BRCA-mutated
cancer (53,54). Furthermore, PARP inhibitors have shown selectivity for BRCA1/2mutated cancers, however, only a fraction of BRCA1/2 mutant cancers respond to PARPi
therapy and responders typically develop resistance (48,55-57). Thus, a strategy to
overcome PARPi resistance in BRCA-mutant cancers is needed to improve this otherwise
promising targeted therapy.
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FOXM1
Genomic configuration, protein domains and regulation
FOXM1 was previously known in the literature as Trident (in mouse), WIN or INS1 (in rat), FKHL-16, MPP-2 (partial human cDNA) or HFH-11 (in human). FOXM1 was
initially identified as MPP-2 during a cDNA screen as a protein phosphorylated during the
mitotic phase of the cell cycle (58). A subsequent publication by Han Clevers group
reported that the team had cloned FOXM1 and determined it had a sequence motif similar
to the conserved DNA binding domain of the Forkhead family of transcription factors (59).
FOXM1 is now recognized as a member of the Forkhead box (FOX) transcription factor
family, which is unified by a conserved winged helix DNA binding domain (DBD, Figure 3)
(60). In addition to the DNA binding domain, FOXM1 protein contains a transactivation
domain at the C terminus, which is important for activating target gene expression (Figure
3) (61). The binding specificity of FOXM1 relative to other family members is in part
achieved via an atypical chromatin interaction mechanism in which FOXM1 is bridged to
DNA by the Myb-MuvB (MMB) transcriptional activator complex (62). Human FOXM1 is
located at 12p13.33 and has ten exons, nine of which are coding. Alternative splicing of
exons Va (A1) and VIIa (A2) give rise to three FOXM1 variants: FOXM1a, FOXM1c, and
FOXM1b (figure 3). FOXM1a contains exons Va and VIIa with the latter disrupting the
transactivation domain, making this isoform transcriptionally inactive (Figure 3) (63).
However, the addition of alternative exon A1 does not alter the binding of FOXM1c and
FOXM1a (64).
FOXM1 is expressed in a cell cycle-dependent manner and regulated by posttranslational modifications throughout the cell cycle via phosphorylation by many different
kinases (60). Phosphorylation by ERK on Ser331 and Ser704 in the Pro-Gly-Ser-Pro
(PGSP) motif regulates the nuclear translocation downstream of mitogen signaling. This
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is highlighted by the observation that non-phosphorylated FOXM1 localizes to the
cytoplasm, but phosphorylated FOXM1 is primarily located in the nucleus (65).
Additionally, FOXM1b lacks exon A1, which contains an ERK1/2 target sequence
(Ser331). In contrast FOXM1a/c contain exon A1 and Ser331 must be phosphorylated
before they can translocate to the nucleus. Therefore, FOXM1b is thought to be
constitutively active because it is proficient for nuclear translocation independent of this
phosphorylation event.

FOXM1 function and expression in normal cells
FOXM1 protein was first identified because it was phosphorylated during mitosis
and expressed in cycling cells. Further studies determined FOXM1 to be a transcription
factor important for cell cycle progression through the G1/S and G2/M checkpoints in
normal cells (58). Early studies showed FOXM1 to be critical for mitotic progression,
whereby FOXM1-knockout MEFs had slower proliferation, failed to properly enter mitosis,
accumulated mitotic defects, and eventually underwent progressive cellular senescence
(66,67). Consistent with these phenotypes, FOXM1 has been demonstrated to play an
essential role in the maintenance of appropriate chromosomal segregation and its loss
resulted in genomic instability and accumulation of polyploid cells (68,69). Numerous
studies have reported transcriptional targets of FOXM1 that allow mitotic progression,
proper assembly of the mitotic spindles, accurate chromosome segregation and
cytokinesis (66,70,71). Cell cycle regulation (G1-S and G2-M transitions) is the most
characterized pathway that is influenced by the transcriptional activity of FOXM1 (40,60).
The expression and the transcriptional activity of FOXM1 are highly dependent on
the cell cycle phase (72). FOXM1 mRNA and protein levels are low in quiescent cells, but
are upregulated when cells enter the S-phase of the cell cycle and persist throughout the
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G2 and M-phases (59). The transcriptional activity of FOXM1 correlates with its
phosphorylation level. Both gradually increase as cells progress through the cell cycle
reaching maximum levels at the G2/M transition. FOXM1 is initially phosphorylated in G1
and then further phosphorylated in a sequential order by multiple protein kinases, including
Cdk-cyclin complexes and mitogenic kinases in the S and G2/M phases of the cell cycle,
generating the hyperphosphorylated and fully active form of FOXM1 by the G2/M-phase
(72). Moreover, FOXM1 is overexpressed and activated in many human cancers and
possesses oncogenic activity in vitro and in vivo (40). Mechanisms accounting for FOXM1
expression in cancer are diverse and include p53 (73,74), Rb (74) and FOXO3 loss (2,75),
Myc, HIF-1, Gli1, SP1, STAT3 and E2F activation (76-81), and genomic amplification (82).

Oncogenic features of FOXM1
FOXM1 has been linked to many hallmarks of cancer through its role as a
transcription factor, activating target genes that functionally promote oncogenic
phenotypes (40). By far, the most common phenotype associated with FOXM1 is the
deregulation of the cell cycle to promote cellular proliferation. FOXM1 is necessary for
tumor formation, which would be expected since it is an essential gene in normal cells;
therefore, mice with FOXM1 knockout in all tissue types are not viable (69,83). This lethal
phenotype agrees with the in vitro studies showing that loss of FOXM1 results in mitotic
defects and eventually cellular senescence (66,68). Conversely, transgenic models show
that FOXM1 expression alone is not sufficient for tumor formation (84). When FOXM1 is
overexpressed in spontaneous and genetically engineered models of cancer, it results in
shorter time to tumor formation and larger tumor size, supporting its oncogenic role in
cellular proliferation (84).
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FOXM1 associates with many hallmarks of cancer, but its link to genomic instability
is not fully understood (40). The first association between FOXM1 expression and
genomic instability is highlighted by its inclusion in the CIN25 signature, a gene expression
profile predictive of chromosomal instability in cancer and patient clinical outcome (37).
Surprisingly, many of the CIN25 genes are targets of FOXM1. FOXM1 was among the
top-ranking genes whose expression correlated with chromosomal instability in in a pancancer analysis. Furthermore, FOXM1 overexpression in human keratinocytes induced
genomic instability in the form of CNAs, and upregulated the protein levels of phosphop38, phospho-p53, p21 and cleaved PARP1, suggesting induction of DNA damage by an
unknown mechanism (85). In this context, FOXM1 is a transcriptional regulator of genes
involved in DNA replication initiation (86,87), and overexpression of genes involved in
DNA replication have been linked to DNA replication stress (88). Furthermore, FOXM1
enabled the accumulation of genomic instability by promoting cell cycle progression
downstream of DNA damage induced by nicotine or UVB exposure (85,89). Similarly,
FOXM1 was shown to function downstream of DNA damaged induced by MYC activation
in human keratinocytes, which by itself impaired cell division due to mitotic defects (90).
However, overexpression of FOXM1 rescued the proliferative capacity of MYC cells
exhibiting high levels of DNA damage, thus promoting genomic instability (90). Together,
these data suggest that FOXM1 activation could alter DNA replication dynamics inducing
DNA replication stress but also enable cells with damaged DNA to evade the G2/M
checkpoint, resulting in genomic instability. Lastly, FOXM1 is implicated in DNA repair via
direct transcriptional regulation of genes involved the repair process (91). However, based
on the literature described above, it seems that aberrant FOXM1 expression promotes
genomic instability rather than reduces it (85,89).
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DNA Replication Stress
Sources, cellular response and implications for cancer
DNA replication stress is caused by impediments in DNA replication, leading to
fork stalling and/or collapse. DNA replication stress results from the uncoupling of the
replicative helicase and polymerase, and leads to generation of ssDNA and, potentially,
DNA damage (92-94). Both extrinsic and intrinsic mechanisms can cause DNA replication
stress, and the latter includes oncogene-induced DNA replication stress. Oncogeneinduced DNA replication stress is a major driver of cancer genomic instability, including
copy number changes such as genomic duplications (95,96). The normal cellular
response to DNA replication stress involves activation of cell cycle checkpoints that
promote fork stabilization, fork restart, and DNA repair. Landmark studies over a decade
ago showed that circumvention of the DNA replication stress response leads to dsDNA
breaks and is a critical early event in oncogenesis (97). ATR activates CHK1 in response
to damaged DNA generated from the resection of DNA double strand breaks (DSBs) and
DNA replication stress, resulting in cell cycle arrest at S and G2/M checkpoints, inhibition
of DNA replication and initiation of DNA repair (98,99). Although ATR responds to single
stranded DNA (ssDNA) at sites of DSBs, it has a more extensive role in responding to
DNA replication stress (99). The initial step in the activation of ATR in response to DNA
damage occurs when ssDNA is coated with replication protein A (RPA), which allows for
the independent recruitment of ATR by ATRIP (ATR interacting protein) and loading of the
9-1-1 (Rad9, Rad1, Hus1) checkpoint clamp by Rad17 (Figure 4) (99). Once the 9-1-1
complex is loaded onto DNA, TOPBP1 and RHNO1 interact with Rad9 and ATR, bringing
TOPBP1 in close proximity to ATR allowing for its activation (Figure 4) (5,100). Once
activated, ATR phosphorylates and activates CHK1 to mediate this signaling cascade
through phosphorylation of numerous downstream targets (101,102). CHK1 regulates the
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G2/M checkpoint by phosphorylating CDC25A, targeting it for proteasomal degradation
(101). Since CDC25A activates the CDK1-CCNB1 complex to facilitate mitotic entry, cells
arrest in the G2 phase upon CDC25A degradation (101).
In addition to serving as a barrier to transformation, numerous studies have now
shown that tumor cells have elevated levels of constitutive DNA replication stress. These
observations provide the rationale for therapies that target the DNA replication stress
response, as the DNA replication stress response contributes to DNA repair and cancer
cell survival (103,104). In particular, given the frequent impairment of ATM-p53 in cancer
cells, tumor cells have heightened dependence on ATR-CHK1, the main DNA replication
stress response pathway, for survival (105). In this regard, several emerging approaches
that target the DNA replication stress response have entered clinical testing. These
strategies include inhibitors of the ATR, CHK1, and WEE1 kinases (94,104,106). Inhibitors
of ATR and CHK1 have anti-cancer activity, including in ovarian cancer, by inducing cell
death and sensitizing cells to chemotherapeutic agents such gemcitabine, etoposide,
topotecan, veliparib, and cisplatin (107,108). ATR inhibitors, AZD6738 and VE-822, are
currently undergoing Phase I clinical trials (NCT02223923 and NCT02157792,
respectively). VE-822 was the first ATR inhibitor to enter clinical development and is an
analogue of VE-821, which was the first potent and selective inhibitor of ATR (109). Loss
of p53, a frequent event in cancer and ubiquitous in HGSC, disrupts the G1 checkpoint,
forcing cells to be dependent on ATR-CHK1 signaling and the G2/M checkpoint for DNA
repair (110). It is proposed that tumors with p53 loss select for functional ATR-CHK1
signaling to sustain survival and proliferation (97,111).
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Bidirectional Promoters
Genomic configuration and features
Bidirectional promoters are flanked by two genes arranged in a head to head
orientation on opposite strands of genomic DNA with less than 1,000 bp between their
transcription start sites (112). However, nearly 67% of head-to-head promoters have
intervening sequences that are less than 300 bp in length (113). Trinklein et al conducted
the first genome-wide computational analysis of bidirectional promoters (114). Of a total
of 23,752 annotated genes, >10% were found to be in a bidirectional configuration sharing
common promoter regions that were less than 1,000 bp apart. Ortholog mapping of
bidirectional promoters in human and mouse showed that most bidirectional promoter
arrangements are conserved across human and mouse genomes, which suggests this
orientation supports a critical function (115). Mapping of gene orthologues across nine
vertebrates species showed selective pressure for the retention of bidirectional gene pairs
(head-to-head genes) compared to tail-to-tail genes spaced within 1,000 bp of each other,
supporting a possible regulatory and functional need for this arrangement (116). Genomic
features of a bidirectional promoter include the presence of a CpG island and lack of a
TATA box (112,114,117). It was recently shown that bidirectional promoters are enriched
with histone modifications H3K4me3, H3K9ac, H3K27ac, and H3K4me2 (118).
Bidirectional promoters are overrepresented with the following transcription factor motifs:
GABPA, MYC, E2F1, E2F4, NRF-1, CCAAT, and YY1 (119). Bidirectional promoters are
devoid of repetitive elements, further suggesting that gene partners often play a functional
role as housekeeping genes (113). Bidirectional genes are often co-expressed, and their
function is enriched in processes such as cell cycle and DNA repair (114,117,120).
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RHNO1
Genomic configuration and protein domains
Human RHNO1 is located at 12p13.33 and consists of three exons, two of which
are coding (Figure 5). Protein blast analysis indicates that RHNO1 orthologs exist only in
vertebrates with the highest conservation being in the N- and C-termini of the protein (100),
which agrees with conservation of the FOXM1-RHNO1 bidirectional promoter in
vertebrates (115,116). RHNO1 protein contains a conserved APSES (Asm1p, Phd1p,
Sok2p, Efg1p and StuAp) DNA binding domain at the N-terminus, which is necessary for
interaction with the 9-1-1 complex (100) (Figure 5). Additionally, the C-terminus is required
for binding the 9-1-1 complex and TopBP1, localizing to sites of DNA damage and
promoting efficient HR (100). RHNO1 was previously identified to be a substrate of
ATM/ATR kinases in a high-throughput proteomics screen following treatment with
ionization radiation (121). This hit was followed up after the function of RHNO1 was
identified and mutation of the potential ATM/ATR sites did not affect its localization to sites
of DNA damage or disrupt protein-protein interactions (100).

Contribution to ATR-CHK1 signaling and homologous recombination
Prior to 2011, RHNO1 was classified as an ORF with unknown function, formerly
known as C12orf32 (chromosome 12 open reading frame 32) and information on this
molecule was limited to a single publication (122). In 2011, RHNO1 was identified in a
high-throughput siRNA screen investigating the DNA damage response (100). Loss of
RHNO1 abrogated the G2/M checkpoint, allowing cells to enter mitosis with damaged
DNA. Further biochemical studies established its interaction with the 9-1-1 complex,
required for the full activation of ATR, hence the name change from C12orf32 to RHNO1
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(Rad9, Rad1, Hus1 interacting nuclear orphan). The activation of ATR is dependent on
the direct interaction of TOPB1 and RHNO1, which ultimately bridges the protein-protein
interaction between ATR and the 9-1-1 checkpoint clamp (Figure 4) (5,123). Furthermore,
the loss of RHNO1 also decreased HR proficiency although to a lesser extent than what
was observed with ATR loss, which agrees with its role as a modifier to ATR activation
(100). In agreement, depletion of RHNO1 and Rad17, a protein that recruits the 9-1-1
checkpoint clamp to chromatin after DNA damage, had similar impairment of HR
proficiency which suggests that RHNO1 primarily promotes HR through the ATR-CHK1
pathway (100). The observation that the RHNO1 gene is only present in vertebrate
genomes indicates it is a unique regulatory factor of the ATR-CHK1 pathway (100).

Oncogenic phenotypes of RHNO1
The study of RHNO1 in cancer is limited to a single publication that found the
mRNA to be overexpressed in breast cancer and protein was localized to the nucleus
(122). Subsequent knockdown of RHNO1 in two different breast cancer cell lines
decreased colony formation and increased the number of sub-G1 cells, suggesting
RHNO1 depletion promotes cell death (122). These data suggest that RHNO1 is an
oncogene that is important for cancer cell survival. Although these studies were done prior
to the discovery of its functional role in ATR-CHK1 signaling, the phenotypes associated
with RHNO1 loss agree with its more recently identified function.

17

DISSERTATION OBJECTIVES

Since the initial discovery of FOXM1 in 1994, it has been reported to contribute to
many normal and cancer phenotypes. However, a role for FOXM1 in HGSC was not
proposed until 2012 when TCGA reported that FOXM1 transcription factor activation as
the second most frequent molecular alteration in HGSC (84% of cases), second only to
mutations of TP53 (100%). Therefore, further study of FOXM1 is critical to define its
potential role in HGSC biology and to address the following knowledge gaps: 1) FOXM1
transcriptional pathway is activated in HGSC, but genetic mechanisms that contribute to
FOXM1 expression in HGSC are not known; 2) FOXM1 expression is associated with
genomic instability and genomic instability is a defining feature of HSGC, yet this
relationship has not been explored in HGSC nor is the mechanism known in any context;
and 3) FOXM1 shares a bidirectional promoter with RHNO1, but the cooperativity between
these gene partners has never been explored. To address these knowledge gaps, we
propose the following specific aims:

SPECIFIC AIM 1: Determine the genetic contribution to FOXM1 expression in high-grade
serous ovarian cancer.

SPECIFIC AIM 2: Determine the relationship between FOXM1 expression and genomic
instability in high-grade serous ovarian cancer.

SPECIFIC AIM 3: Determine the functional contribution of FOXM1 and RHNO1 to survival
and chemoresistance in high-grade serous ovarian cancer.
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Figures

Figure 1. Epithelial ovarian cancer (EOC) histological subtypes. The upper panels
show the presumed tissues of origin for EOC histological subtypes. The lower panels show
images of H&E staining for the different histological subtypes. Adapted from: (1).
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Figure 2. HGSC precursor lesions in the fallopian tube. Images represent H&E or IHC
staining of tissues from different lesions as indicated on the left and top of the figure.
HGSC = invasive cancer or primary tumor on the ovary, not within the fallopian tube.
Precursor lesions start with normal FTE to the left and proceed to the right with the
acquisition of additional malignant features. Lesions are detected in the distal end of the
fallopian tube. Adapted from: (2).
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Figure 3. FOXM1 mRNA and protein. FOXM1 mRNA is displayed at top showing 10
exons with intervening introns. The red boxes highlight the alternative exons, A1 and A2,
which give rise to the different exons shown below. FOXM1 isoforms are shown below
along with their protein domains. The N-terminus has a repression domain (NRD). The
forkhead DNA binding domain, DBD, immediately following the NRD. FOXM1a and
FOXM1c possess alternative exon A1. The C terminus contains the transactivation
domain (TAD). FOXM1a possesses alternative exon A2, which disrupts the function of the
TAD.
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Figure 4. ATR-CHK1 activation in response to DNA damage. DNA damage generates
single stranded which serves as a scaffold for the recruitment of the 9-1-1 checkpoint
clamp. Through protein-protein interactions, the 9-1-1 checkpoint clamp recruits ATR
allowing for its activation. ATR kinase then phosphorylates downstream effector proteins
to signal the DNA damage response and promote cell cycle arrest and DNA repair.
Adapted from: (5).
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Figure 5. RHNO1 mRNA and protein. RHNO1 mRNA is displayed at top showing three
exons with intervening introns. The N-terminus, in light blue, contains the DBD, which has
a sequence similar to the APSES (ASM-1, Phd1, StuA, EFG1, and Sok2) domain, a DNA
binding domain found in fungi and homologous to the KilA-N domain found in eukaryotic
viruses. The N-terminus interacts with 9-1-1 checkpoint proteins including TOPB1. The
SWV region, when mutated, impairs RHNO1 for interaction with 9-1-1 checkpoint proteins.
The C-terminus, in dark blue, is not essential for these interactions.
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CHAPTER 2: MATERIALS AND METHODS

Human Tissue Samples
Bulk normal ovary (NO) tissues and EOC samples (n=143) were obtained from
patients undergoing surgical resection at Roswell Park Comprehensive Cancer Center
(RPCCC) under Institutional Review Board-approved protocols, as described previously.
Pathology specimens were reviewed at RPCCC, and tumors were classified according to
World Health Organization criteria (124) Flash-frozen bulk tumor tissue samples were
crushed using liquid nitrogen pre-chilled mortar and pestles. Genomic DNA was isolated
from approximately 20 mg of powdered tissue using the Puregene Tissue Kit (Qiagen).
Upon the addition of cell lysis buffer, the tissue powder was immediately homogenized
using VWR Pellet Mixer (VWR International) with disposable microtube pestles (Argos
Technologies). Total RNA was extracted by TRIzol reagent (Invitrogen) from
approximately 20 mg of powdered tissue. The tissue was immediately homogenized in
TRIzol by an electric homogenizer with disposable microtube pestles. Total protein was
extracted using radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris HCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing Protease
Inhibitor Cocktail (SIGMA), Phosphatase Inhibitor Cocktail 1 (SIGMA) and Phosphatase
Inhibitor Cocktail 2 (SIGMA). Upon the addition of RIPA buffer, the frozen tissue powder
was immediately homogenized using an electric homogenizer with disposable microtube
pestles. The solution was further sonicated with a Bioruptor (Diagenode).

Cell Lines
COV362 and COV318 cell lines (Sigma) were cultured in DMEM (Corning)
supplemented with 10% fetal bovine serum (FBS, Invitrogen), 2 mM glutamine (Life
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Technologies),

and

1%

penicillin-streptomycin

(pen-step,

Life

Technologies).

KURAMOCHI and OVSAHO (Japanese Collection of Research Bioresources Cell Bank)
and SNU-119 (Korean Cell Line Bank) cell lines were cultured in RPMI-1640 (Hyclone)
supplemented with 10% FBS and 1% pen-strep. The OVCAR4 cell line (National Cancer
Institute Division of Cancer Treatment and Diagnosis Cell Line Repository) was cultured
in RPMI-1640 supplemented with 10% FBS and 1% pen-strep. The OVCAR8 cell line
(National Cancer Institute Division of Cancer Treatment and Diagnosis Cell Line
Repository) was cultured in DMEM (Corning) supplemented with 10% FBS, and 1%
penicillin-streptomycin (pen-step, Life Technologies). The OVCAR3 cell line (American
Type Culture Collection) was cultured in DMEM with 10% FBS and 1% pen-strep. Caov3
and OVCAR5 cell lines were generous gifts from Professor Anirban Mitra (Indiana
University) and were cultured in DMEM with 10% FBS and 1% pen-strep. UWB1.289,
UWB1-SyR12 and UWB1-SyR13 cell lines were generous gifts from Professor Lee Zou
(Massachusetts General Hospital Cancer Center) and were cultured in RPMI
1640/Mammary Epithelial Growth Media (1:1; Hyclone/PromoCell) supplemented with 3%
FBS, MEGM growth factors and 1% pen-step. Primary hOSE cells (ScienCell) were
cultured in Ovarian Epithelial Cell Medium (ScienCell, 7311). HGSC precursor cells or
immortalized fallopian tube epithelial (FTE; FT190, FT282-E1 and FT282) cells were a
generous gift from Professor Ronny Drapkin (University of Pennsylvania) and were
cultured in DMEM-Ham’s F12 50/50 (Corning) supplemented with 2% USG (Pall
Corporation) or 10% FBS and 1% pen-strep (Figure 6). IOSE-T (IOSE-21, hOSE
immortalized with hTERT) cells (125) were a generous gift from Professor Francis Balkwill
(Cancer Research UK) and were cultured in Medium 199/MCDB105 (1:1, Sigma)
supplemented with 15% FBS, 1% pen-strep, 10 ng/mL human epidermal growth factor
(Life Technologies), 0.5 μg/mL hydrocortisone (Sigma), 5 μg/mL bovine insulin (Cell
Applications), and 34 μg protein/mL bovine pituitary extract (Life Technologies). IOSE-SV
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(IOSE-121, hOSE immortalized with SV40 Large T antigen) were a generous gift from
Professor Nelly Auersperg (University of British Columbia) and were cultured in Medium
199/MCDB105 (1:1) supplemented with 10% FBS and 25 µg/ml gentamicin (Life
Technologies). mOSE cells and floxed p53 and Rb variants (126) were a generous gift
from Professor Barbara Vanderhyden (Ottawa Hospital Research Institute) and were
cultured in Alpha Modified MEM (Corning) containing 10% FBS, 0.05% pen-strep, 1 μg/ml
gentamicin, and 1% insulin–transferrin–sodium–selenite solution (ITSS, Roche).
HEK293T cells (American Type Culture Collection) was cultured in DMEM with 10% FBS
and 1% pen-strep. U2OS-DR-GFP (282C) cells were a kind gift from Professor Jeremy
Stark (City of Hope) and grown in McCoy’s 5A (Corning), 10% FBS and 1% pen-strep
(127,128). OVCAR8-DR-GFP cells were a kind gift from Professor Larry Karnitz and
Professor Scott Kaufmann (Mayo Clinic) and grown in the same conditions as the
OVCAR8 parental cells as described above (108). All cell lines were maintained at 37 °C
in a humidified incubator with 5% CO2. Cell culture medium was changed every 3-5 days
depending on cell density. For routine passage, cells were split at a ratio of 1:3-10 when
they reached 85% to 90% confluence. Cell lines were authenticated by short tandem
repeat (STR) analysis at the DNA Services Facility, University of Illinois at Chicago, and
confirmed to be for Mycoplasma free by RT-qPCR at the Epigenetics Core Facility,
University of Nebraska Medical Center. Doxycycline inducible cells were treated every 48
hours with doxycycline (Sigma, solubilized in water) unless otherwise noted.

Pharmacologic Inhibitors
Cells were treated with the following inhibitors: PARPi (olaparib, ABT-888,
solubilized in DMSO) from SelleckChem, ATRi (VE-822, VX970) from SelleckChem,
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hydroxyurea (HU) from Sigma or etoposide (Etop, E1383, solubilized in DMSO) from
Sigma.

DNA, RNA and Protein Extracts from Cell Lines
Genomic DNA was isolated from cell lines using the Puregene Tissue Kit (Qiagen).
Total RNA was purified using TRIzol (Invitrogen). Total protein was extracted with RIPA
buffer. Nuclear and cytosolic proteins were extracted from cell samples using the NE-PER
Nuclear and Cytoplasmic Extract kit (Pierce Biotechnology). Protease Inhibitor Cocktail
(Sigma), Phosphatase Inhibitor Cocktail 1 (Sigma) and Phosphatase Inhibitor Cocktail 2
(Sigma) were added to protein lysis buffers.

Bulk RNA Sequencing (RNA-seq) Analysis
RNA was isolated from cell lines according to the method described above. The
RNA samples were transported to the UNMC DNA Sequencing Core Facility. RNA
samples were analyzed with respect to purity and potential degradation. Purity and
concentration were assessed by measurement of the A260/280 ratios using a Nanodrop
instrument (Thermo Scientific, Nanodrop Products, Wilmington, DE) instrument and only
those samples with values of 1.8 to 2.0 underwent further processing. Potential
degradation of the samples was assessed by analysis of 200 ng of the RNA with an
Advanced Analytical Technical Instruments Fragment Analyzer (AATI, Ames, IA) and only
intact RNA samples were used to generate sequencing libraries. Sequencing libraries
were generated by the UNMC NGS Core beginning with 1 µg of total RNA from each
sample using the TruSeq V2 RNA sequencing library kit from Illumina following
recommended procedures (Illumina Inc., San Diego, CA). Resultant libraries were
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assessed for size of insert by analysis of an aliquot of each library on a Bioanalyzer
instrument (Agilent Technologies, Santa Clara, CA). Each library had a unique indexing
identifier barcode allowing the individual libraries to be multiplexed together for efficient
sequencing. Multiplexed libraries (12 samples per pool) were sequenced across 2 lanes
of the HiSeq 2500 DNA Analyzer (Illumina) to generate a total of approximately 20 million
75 bp single reads for each sample. During sequencing the quality was continually
monitored regarding cluster number and fluorescence intensity and percentages of reads
passing filter with a Q30 score. Following sequencing, samples were demultiplexed to
produce FASTQ files. The UNMC Epigenomics Core Facility processed the resulting
sequence files based on the following steps. Adaptor sequences and low quality (Phred
score: 20) ends were trimmed from sequences using the Trim Galore software package
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Resulting FASTQ files
were aligned to the human genome (NCBI37/hg19) using the software TopHat (v2.0.8)
(http://ccb.jhu.edu/software/tophat/index.shtml).

The

software

Cufflinks

(v2.1.1)

http://cole-trapnell-lab.github.io/cufflinks/ was used to estimate the expression values, and
Cuffdiff (v2.1.1) was used to determine differential expression. Geneset enrichment
analysis (GSEA) was performed using the GSEA software version 3, build 0160, available
from the BROAD Institute (http://www.broadinstitute.org/gsea/index.jsp) (129). Bulk RNAseq datasets, with genes ranked by log2 fold-change, were compared against the
Hallmark

Signature

genesets

(http://software.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=H) or a custom
CIN70 geneset based on the CIN70 gene expression signature (37). Output data included
normalized enrichment score (NES) and FDR (q-value). Statistical significance was set at
an FDR < 0.25. NES was used for comparing enrichment because it accounts for
differences in gene set size and in correlations between gene sets and the expression
dataset.
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Single-Cell RNA Sequencing (scRNA-seq) Analysis
FT282 and OVCAR8 cells were seeded at day 0 at ~50% and ~30% confluency,
respectively, then harvested at day 2 at ~80% confluence. Cells were trypsinized and
suspensions were pipetted several times and passed through a 40 μm cell strainer to
ensure a single cell suspension. Cell viability (Trypan blue exclusion) was confirmed to be
greater than 90% using the TC20 Automated Cell Counter (Bio-Rad). Cell pellets were
washed twice in PBS containing 0.04% BSA, then resuspended in PBS and 0.04% BSA
to ~500,000 cells/ml and transported to the UNMC DNA Sequencing Core Facility for
single cell capture, library preparation and scRNA-sequencing. As per manufacturer
instructions, approximately ~2,750 cells were loaded per channel to achieve a target of
~1,500 captured cells. Single cells were loaded on a Chromium Single Cell Instrument
(10x Genomics) to generate single cell Gel Bead in Emulsions (GEMs) for the partitioning
of samples and reagents into droplets. GEMs contain oligos, lysed cell components and
Master Mix. GEMs were processed as following: briefly, cells were lysed, RNA extracted,
and reverse transcribed to generate full-length, barcoded cDNA from the poly A-tailed
mRNA transcripts. Barcoded cDNA molecules from every cell were PCR-amplified in bulk
followed by enzymatic fragmentation. The Qubit was then used to measure and optimize
the insert size of the double-stranded cDNA prior to library construction. Single cell cDNA
and RNA-Seq libraries were prepared using the Chromium Single Cell 3’ Library and Gel
Bead Kit v2 (10x Genomics) and the products were quantified on the 2100 Bioanalyzer
DNA High Sensitivity Chip (Agilent). Each fragment contains the 10x Barcode, UMI and
cDNA insert sequence used in data analysis. During library construction Read 2 is added
by Adapter ligation. Both single cell libraries were sequenced using the Illumina NextSeq
550 system using the following parameters: pair-end sequencing with single indexing, 26
cycles for Read1 and 98 cycles for Read2. FT282 cells produced a total of 85.6 million
reads and OVCAR8 produced 82 million reads, and both had an overall Q30 for the run
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of 87.6%. Sequencing data were transferred to the Bioinformatics and Systems Biology
Core Facility for analysis. The Cell Ranger Single Cell Software (10X Genomics) was used
to process raw bcl files to perform sample demultiplexing, barcode processing and single
cell 3’ gene counting (https://software.10xgenomics.com/single-cell/overview/welcome).
Each dataset was aligned to a combined human (hg19) reference and only cells that were
identified as aligned to human in the “filtered” output of the Cell Ranger count module were
used in the analysis.

Statistical Impute of Transcript Dropouts in Single-Cell RNA Sequencing Datasets
The statistical method scImpute was used to accurately and robustly impute the
transcript dropouts (zero values) that exist in scRNA-seq data from sequencing small
amount

of

RNA

(130).

The

scImpute

R

package

was

downloaded

from

https://github.com/Vivianstats/scImpute and was run in R with default settings. FT282 and
OVCAR8 scRNA-seq raw gene expression matrix files (.mtx) were converted into dense
expression matrices using `cellRanger mat2csv` command. The scImpute input data
consisted of a scRNA-seq matrices with rows representing genes and columns
representing cells, and output data consisted of an imputed count matrix with the same
dimension.

Reverse Phase Protein Array (RPPA)
RPPA was performed at the RPPA Core Facility at MD Anderson Cancer Center
(https://www.mdanderson.org/research/research-resources/core-facilities/functionalproteomics-rppa-core.html). The protein lysates were prepared according to the Core's
instructions and sent to them for the profiling. Briefly, immortalized fallopian cell lines
engineered for doxycycline inducible expression were grown in the presence of
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doxycycline for 72 hours then harvested for protein. Proteins were extracted by adding
RIPA buffer to monolayer cultures on ice. Protein concentrations were measured by the
BCA assay then normalized to 1 μg/ml in 1X sample loading buffer containing betamercaptonethanol. Samples were incubated 95 C for 5 minutes then stored at -80 C until
they were submitted to the Core for the analysis. All samples were run in biological
triplicate. The Core stained the slides with 304 unique antibodies (RPPA antibody set 145Present). Stained slides were analyzed on Array-Pro then by supercurve R ×64 2.15.1.
There were 14 sets of replicated antibodies and 3 negative controls for secondary
antibodies among 243 slides. QC tests were performed for each antibody staining (slide).
All the data points were normalized for protein loading, transformed to linear values and
subsequently transformed to log2 values (NormLog2) and then median-centered for
hierarchical clustering analysis (NormLog2_MedianCentered). Heat maps were generated
using the online software Morpheus (http://broadinstitute.org) as hierarchical clusters with
normalized log2, median centered RPPA data using the one minus Pearson Correlation
metric and average linkage method.

Cell Viability Measurements
Cells were seeded at a density of 500-1,000 cells per well in quadruplicate into
sterile 96-well plates and treated with the indicated drug for 96 hours. AlamarBlue
(BioRad) was used to assess cell viability. Background values from empty wells were
subtracted and data were normalized to vehicle-treated control.
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Homologous Recombination (HR) Reporter Assay
U2OS and OVCAR8 cells were previously generated for stable integration of
DR-GFP, an HR substrate that generates a functional green fluorescent protein (GFP)
upon successful HR after I-SceI cutting (108,128,131). U2OS and OVCAR8 cells were
grown in the presence of doxycycline for 48 hours to induce shRNA expression. U2OS
cells were transfected with pCBASceI (Addgene; #26477) in the presence of 1 µg/ml
doxycycline. Media containing doxycycline was changed 3 hours post transfection and
cells were kept in culture for an additional 48 hours. OVCAR8 cells were transduced for 8
hours with AdNGUS24i, an adenovirus expressing I-SceI (Drs. Frank Graham and Phillip
Ng). Cells were harvested and fixed with 10% formaldehyde, washed and analyzed by
FACS to determine the fraction of GFP positivity.

In Vitro Clonogenic Survival Assay
To assess colony formation, cells were trypsinized, counted and seeded at a
density of 500-1,000 cells per well in 6-well dishes in single-cell suspension and allowed
to form colonies for 8-12 days. Following incubation, cells were simultaneously fixed and
stained in PBS containing 10% methanol and 0.5% crystal violet for 30 minutes at room
temperature, rinsed with water and air dried overnight. Colonies containing over 50 cells
were manually counted with an inverted light microscope.

Comet Assay
The Comet Assay Kit (Trevigen) was used according to the manufacturer's
instructions. Briefly, cells were suspended in low melt agarose, layered onto treated slides
to promote attachment (500 cells per slide), lysed, and subjected to electrophoresis (1
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V/cm) under alkaline conditions using the Comet Assay Electrophoresis System II
(Trevigen). Samples were then fixed, dried, and stained with SYBR Gold. Images were
acquired with a 10X objective lens using the EVOS FL Cell Imaging System
(ThermoFisher). Comet tail size was quantified using Comet Analysis Software (Trevigen).

Flow Cytometry
Cells were fixed in 70% ethanol overnight for cell cycle and γ-H2AX expression
analysis. Fixed cells were washed with PBS and incubated overnight in PBS containing 1%
BSA, 10% goat serum and pS139-H2AX antibody (Millipore), washed and incubated in goat
anti-mouse Alexa Fluor 647 antibody for 30 minutes at RT. Cells were incubated in 50 μg/mL
propidium iodide and 100 μg/mL RNase A for 30 minutes, and 10,000 cells per sample were
analyzed on a BD FACSarray (BD Biosciences) using 532- and 635-nm excitations and
collecting fluorescent emissions with filters at 585/42 nm and 661/16 nm (yellow and red
parameters, respectively).

Production of Lentiviral Particles and In Vitro Lentiviral Transduction
Replication-deficient lentivirus was produced by transient transfection of psPAX2
(Addgene; 12260), pDM2G (Addgene: 12259) and transfer plasmid into HEK293T cells.
Viral supernatant was collected at 48 hours and filtered. Select cell lines were transduced
with serially diluted viral supernatant followed by antibiotic selection for functional titration.
Cells were expanded from the viral dilution well that resulted in 30% survival following
antibiotic selection.
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MOSE Cell In Vitro Adenoviral Transduction
Recombinant adenovirus expressing enhanced GFP (Ad-eGFP, control) or both
eGFP and Cre recombinase (AdCre-eGFP) were purchased from the University of Iowa
Gene Transfer Vector Core. mOSE cells were transduced at a MOI of 200.

MOSE Cell Genotyping and Detection of Recombination
Genomic DNA was isolated using the Puregene Tissue Kit (Qiagen). DNA was
resuspended in Tris-EDTA (50 mM, pH 6.8). Genotyping was performed as previously
described (30). PCR was performed with an annealing temperature of 60 °C and 30 cycles
for all primer pairs. Primer sequences are listed in Table 2.

Plasmid Constructs and RNA Interference
Tables 2 and 3 contains a list of all plasmids, siRNAs, shRNAs, and sgRNAs. All
cloning was sequence verified. Plasmids were transfected with Lipofectamine 2000 (Life
Technologies), according to the manufacturer’s instructions. siRNAs were transfected with
Lipofectamine RNAiMax reagent (Life Technologies), according to the manufacturer’s
instructions.

Site-Directed Mutagenesis
FOXM1c DNA binding domain was mutated as following, R286A, H267A, and
S290A, rendering FOXM1 deficient in DNA binding (132). All plasmids were sequence
verified. Primers were designed using QuikChange Primer Design software (Agilent
Technologies) and are listed in Table 2.
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Murine Ovarian Tumor Model
Trp53loxP/loxP/Rb1loxP/loxP mice (floxed Trp53 and Rb1) were a kind gift from
Professor Kenneth Gross (RPCCC). All mice were maintained identically, following
recommendations of the Institutional Laboratory Animal Use and Care Committee (at
RPCCC). Intrabursal injections of recombinant adenovirus expressing both enhanced
GFP and Cre recombinase (AdCre-eGFP) or eGFP alone (Ad-eGFP) as the contralateral
control (University of Iowa Gene Transfer Vector Core) were performed on adult mice in
estrus as previously described (133). Mice were determined to be in estrus by vaginal
cytology. The original viral stock solution was diluted with PBS to 3.5x109 pfu/mL
immediately before injection of 10 µL. Mice were euthanized and subjected to necropsy
when tumor mass exceeded 1 cm or the animal exhibited other signs of sickness, such as
abdominal distension and moribund behavior. Tumor samples were dissected and snap
frozen in liquid nitrogen and stored at -80 °C. Frozen tumor samples were ground into a
powder with a mortar and pestle over liquid nitrogen and immediately processed for RNA
(mRNAeasy Mini Kit, Qiagen) and whole cell protein cell extracts were prepared with RIPA
buffer (1X PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with
protease and phosphatase inhibitors, and centrifuged at 4 °C for 10 minutes at 14,000 g.
RNA was treated for contaminating DNA using the TURBO DNA-free Kit (Ambion), and
integrity was determined using a bioanalyzer (Agilent). One µg of DNase treated RNA was
converted to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad).

Immunohistochemistry of Mouse Tumor Tissue Samples
Formalin-fixed paraffin blocks were cut into 4 µm sections, placed on charged
slides, and dried at 60 °C for one hour. Slides were cooled to room temperature,
deparaffinized in three changes of xylene, and rehydrated using graded alcohols. For
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antigen retrieval, slides were heated in a steamer for 20 minutes in citrate buffer pH=6
(BioCare Medical, B910) for Smooth Muscle Actin or target retrieval solution pH=9 (Dako,
S2367) for Cytokeratin and allowed to cool for 20 minutes, endogenous peroxidase was
quenched with aqueous 3% H2O2 for 10 minutes, and the slides were washed with PBS/T.
Slides were loaded on a Dako autostainer and serum-free protein block (Dako, X0909)
was applied for 5 minutes, blown off and the corresponding antibody was applied. Smooth
Muscle Actin antibody (Abcam, ab5694) was applied at 1:125 (Rabbit IgG) for one hour.
Powervision poly HRP anti-rabbit IgG (Leica; catalog #PV6119) was then applied for 30
minutes. L- DAB (Leica; catalog #PV6126), applied for 5 minutes, was used for chromogen
visualization. Pan-Cytokeratin antibody (Dako, Z0622) was applied at 1:1750 (Rabbit IgG)
for one hour. Rabbit Envision/ labeled polymer HRP anti -rabbit (Dako; catalog #K4003)
was then applied for 30 minutes. DAB (Dako; catalog #K3468), applied for 10 minutes,
was used for chromogen visualization. Lastly, the slides were counterstained with
hematoxylin, rinsed, and cover slipped.

Reverse Transcription Quantitative PCR (RT-qPCR)
Total RNA was purified using TRIzol (Invitrogen) and quality was determined by
RNA denaturing gel. Briefly, one μg of RNA was DNase-treated using the DNA-free kit
(Ambion) or treated in column during purification with the Zymo Pure RNA Isolation Kit.
RNA was converted to cDNA using the iScript cDNA Synthesis Kit (BioRad). One µl of 1:5
cDNA sample dilutions were used for qPCR reactions. Standard curves were prepared
using gel-purified end-point RT-PCR products. All samples were run in triplicate using the
CFX Connect Real-Time System (Bio-Rad Laboratories) and all gene expression data
were normalized to 18s rRNA. PCR was performed with an annealing temperature of 60
°C and a total of 45 cycles for all primer pairs. Dissociation curves were performed to
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confirm specific product amplification. RT-qPCR standards for each gene were generated
from a mixture of human or mouse cell cDNA via end-point RT-PCR then gel purification,
using the appropriate primer pair. Gradient PCR reactions were performed with the C1000
Touch Thermal cycler (Bio-Rad Laboratories) to determine the annealing temperatures for
each primer set. Primer sequences are listed in Table 2. Primer sequences corresponding
to each gene for the mRNA expression analysis were designed using NCBI Primer Blast
(134) or selected from those previously reported in the literature.

Microarray Analysis of FOXM1 and E2F1 Expression
Affymetrix HG 1.0ST arrays were used to determine the expression of FOXM1 and
E2F1 in EOC. Probe generation, array hybridization, and expression analyses were
performed by the Next Generation Sequencing and Expression Analysis Core Facility at
the University at Buffalo Center for Excellence in Bioinformatics. Samples included 40
primary EOC tissues.

Western Blot
Whole cell protein extracts were prepared with RIPA buffer [1X PBS, 1% NP40,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)] supplemented with
protease and phosphatase inhibitors (Sigma) and centrifuged at 4 °C for 10 minutes at
14,000 g. Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic
Extraction Kit (Thermo Scientific) supplemented with protease and phosphatase inhibitors.
Protein concentration was determined by the BCA protein assay (Thermo Scientific).
Equal amounts of protein (30-50 µg) were fractionated on 4-12% gradient SDSpolyacrylamide gel electrophoresis gels (Invitrogen) and transferred to PVDF membranes
(Roche). Membranes were stained with Ponceau S to confirm efficient transfer and equal
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loading then blocked with 5% nonfat dry milk in Tris-buffered saline Tween-20 (TBST) for
1 hour at room temperature. The membranes were incubated with primary antibodies in
5% nonfat dry milk in TBST at 4 °C overnight followed by incubation with secondary
antibody in 5% nonfat dry milk in TBST for 1 hour at room temperature. Primary antibodies
are listed in Table 4. Enhanced chemiluminescence (Thermo Fisher Scientific) was used
for protein detection. Quantification of protein expression was performed using ImageJ
software (Image Processing and Analysis in Java, National Institute of Health) (135).

Co-Immunoprecipitation
Cells expressing empty vector, and Flag- or HA-tagged ORFs were lysed with MPER (Pierce) containing Halt Protease and Phosphatase Cocktail (Pierce), and Nuclease
S1. Lysates were mixed end over end at 4 ºC for 30 minutes then centrifuged at 4 °C for
10 minutes at 14,000 g to eliminate cellular debris. Protein concentration was determined
by the BCA protein assay (Thermo Scientific). Immunoprecipitation was performed with
anti-Flag or HA magnetic beads and 500 µg total protein. Samples were incubated
overnight at 4 ºC with end over end mixing. The next day the magnetics beads were
washed, and protein eluted with sample loading buffer. The entire sample was loaded on
the Western blot along with 5% total protein as input.

Illumina Infinium Human Methylation 450K Datasets
The TCGA pan-cancer DNA methylation (HumanMethylation450K) dataset was
downloaded from UCSC Xena (http://xena.ucsc.edu), consisting of 9,753 samples. The
TCGA pan-cancer dataset contains the DNA methylation 450K array beta values,
compiled by combining available data from all TCGA cohorts. The GDSC1000 collection
(The Genomics of Drug Sensitivity in Cancer Project, Welcome Sanger Institute) was
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downloaded from NCBI GEO (GSE68379) (136). The NCI-60 cell line DNA methylation
450K dataset (NCBI GEO: GSE66872) was downloaded from CellMiner (137,138). For all
datasets, the DNA methylation profile was measured experimentally using the Illumina
Infinium HumanMethylation450 platform and Infinium HumanMethylation450 BeadChip
Kit. The method consists of approximately 450,000 probes querying the methylation status
of CpG sites within and outside CpG islands. The DNA methylation score of each CpG is
represented as a beta value, which is a normalized value between 0 (fully-unmethylated)
and 1 (fully-methylated).

Sodium Bisulfite DNA Sequencing
Sodium bisulfite DNA sequencing was used to determine the methylation status of
the FOXM1/RHNO1 bidirectional promoter (139). Sanger sequencing analysis was
performed by the University of Nebraska Medical Center DNA Sequencing Core Facility.
Genomic DNA was isolated using the Puregene Tissue Kit (Qiagen) as described above,
and then were chemically converted with sodium bisulfite using the EZ DNA Methylation
Kit (Zymo Research Corp.). The FOXM1 and RHNO1 bidirectional promoter containing a
CpG island was amplified from the bisulfite-converted DNA using methylation PCR
specific primers, designed using MethPrimer (Table 2) (140). Gradient PCR reactions
were analyzed using a C1000 Touch Thermal cycler (Bio-Rad) to optimize annealing
temperatures for the primer set. After gel purification using the QIAquick Gel Extraction
Kit (QIAGEN), PCR products were cloned using either the TOPO TA Cloning Kit
(Invitrogen). Between 9 and 15 individual clones were sequenced for each sample. DNA
sequence information was analyzed using the Lasergene SeqMan Pro program
(DNASTAR, Inc.).
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5’ RNA Ligase-Mediated Rapid Amplification of cDNA Ends (RLM-RACE) Mapping
The transcription start site of FOXM1 and RHNO1 in different cell lines was
determined using the FirstChoice RLM-RACE Kit (Ambion), according to the
manufacturer's instructions. RNA for RLM-RACE analysis was isolated using TRIzol
reagent (Invitrogen) followed by purification with Direct-zol RNA MiniPrep with in column
genomic DNA digestion. RLM-RACE assay allows for the specific amplification of 5'
capped RNA, which is found only on full-length mRNA transcripts. The specific outer and
inner (nested) primers in combination with adaptor-specific primers were used for
amplifying the 5’ ends of FOXM1 and RHNO1 mRNA. The 5’ end specific primers are
listed in Table 2. As negative controls, non-tobacco alkaline phosphatase (TAP)-treated
aliquots from each RNA source were utilized; in all cases, this did not yield any specific
product amplification (data not shown). In contrast, FOXM1- and RHNO1-specific PCR
products of various sizes were yielded from TAP-containing reactions. PCR products were
separated on 2% agarose gels, excised, and subsequently purified using the QIAquick gel
extraction kit (Qiagen). Gel-purified PCR products were cloned using the TOPO TA
Cloning Kit (Invitrogen), and individual clones were sequenced using standard methods.

Promoter Activity Luciferase Reporter Assay
Firefly and Renilla luciferase activities were measured between 24 hours after
transfection using the Dual-Luciferase® Reporter Assay System (Promega) and
luminometer. Bidirectional promoter studies were normalized with secreted embryonic
alkaline phosphatase (SEAP) activity present in the culture medium was measured at the
same time using the Phospha-Light System (Applied Biosystems). All transfections were
performed in triplicate within each individual experiment. Firefly and Renilla luciferase
activities were expressed in arbitrary units as displayed on the luminometer after a 10
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second integration time and normalized against SEAP production in the individual
transfected 24-well dishes.

University of California Santa Cruz (UCSC) Genome Browser
The genomic region of FOXM1 and RHNO1 was retrieved from UCSC Genome
Browser (http://genome.ucsc.edu) (141) using the human genome build hg19 with
genomic coordinates chr12:2,966,265-2,999,264. The following tracks were selected and
displayed in the Genome Browser: FOXM1 and RHNO1 mRNA, CpG island, Encode
E2F1, H3K4Me3 and H3K27Ac ChIP-seq tracks, and conserved genome tracks from 100
vertebrates and mammalian genomes. The Genome Browser screen shot tool was used
to obtain images.

DNA Fiber Assay
DNA fiber analysis was performed as previously described with minor
modifications (142,143). Briefly, FTE cells were seeded at 50% confluency. The next day,
cells were first pulsed with 8 g/ml chlorodeoxyuridine (CldU) for 30 minutes, washed 3X
with pre-warmed 1X PBS, and then pulsed with 90 g/ml iododeoxyuridine (IdU) for 30
minutes. Three microliters of cell suspension containing approximately 3105 cells were
mixed with 7 l lysis buffer (200 mM Tris-HCl pH 7.4, 50 mM EDTA, 0.5% SDS) on glass
slides and incubated at room temperature for 8 minutes. The slide was then tilted to allow
spreading of fibers at approximately a 45o angle to allow the drop to slowly run down the
slide. Fibers were air dried for 2-3 hours and then fixed in methanol/acetic acid (3:1) at 4
C overnight, rehydrated by PBS and denatured in 2.5 M HCL for 1 hour. After rinsing
away HCL by PBS, slides were blocked in PBS with 5% BSA for 1 hour and incubated
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overnight at 4 ºC overnight with anti-BrdU antibody (Mouse, #347580, Becton Dickinson,
1:100 dilution) to detect IdU and anti-BrdU antibody (Rat, ab6326, Abcam, 1:500 dilution)
to detect CldU. Slides were rinsed with PBS with 0.1% Tween-20 (PBST) and incubated
with AlexaFluor488-conjugated (green) anti-mouse IgG secondary antibody and
AlexaFluor594-conjugated (red) anti-rat IgG secondary antibody for 1 hour at room
temperature. Slides were rinsed with PBST and mounted by mounting media (Prolong
Gold, Invitrogen). Images were taken in Zeiss Axio Imager Z1 microscope and fiber length
was measured by ImageJ software (NIH). For data analysis, the length of each labeled
DNA tract (IdU and CldU) determined by ImageJ was then converted to kb using a
conversion factor of 2.59 kb/μm. Fork rate was calculated by dividing the length of the tract
by the labeling time (kb/min). Percentage of origins fired was calculated by counting DNA
fibers with the following with the following staining pattern (G = green and R = red), GRG,
G, GRG, G, and RG, then using this equation: (GRG + G) / (GRG + G + RG). See Figures
7 and 8 for the interpretation of the data.

The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE),
Genotype-Tissue Expression (GTEx), and RIKEN Fantom5 Datasets
TCGA, CCLE and GTEx genomic profiled datasets were retrieved from cBioPortal
or UCSC Xena Browser. TCGA and CCLE RPPA data were obtained from UCSC Xena
(https://xenabrowser.net) or The Cancer Proteome Atlas (144,145). TCGA Provisional
datasets were used for analyses because they contain published data plus data from new
samples that have since been profiled, thus increasing the sample size. FOXM1 mutation
and somatic copy-number alterations were analyzed in pan-cancer datasets. The genomic
profile of FOXM1 and RHNO1 were further analyzed in the HGSC (Ovarian Serous
Cystadenocarcinoma-TCGA Provisional) dataset for putative somatic copy-number
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alterations from GISTIC (146) using Onco Query Language (OQL) and mRNA expression
(RNA seq V2 RSEM). In brief, GISTIC predicts gene copy number alterations according
to sample specific thresholds generated by comparing chromosomal segments with
median chromosomal arm copy numbers. High gains (Amp) are segments with copy
number that exceed the maximum median chromosomal arm copy number for that sample
by at least 0.1; low gains (Gain) are segments with copy numbers from 2.1 to the high gain
threshold; neutral segments (Diploid) have copy numbers between 1.9 and 2.1; shallow
losses (Hetloss) have copy numbers between 1.9 and the deep deletion threshold; and
deep deletions (Homdel) have copy numbers that are below the minimum median
chromosomal arm copy number for that sample by at least 0.1. Overall patient survival
was graphed in Kaplan-Meier survival curves. Fraction of genome altered by copy number
data was downloaded from cBioPortal and was previously calculated as following: length
of segments with log2 CNA value larger than 0.2 or less than -0.2 divided by the length of
all segments measured. Mutation burden is the sum of all mutations detected from the
exome-seq data. These values were used as a basic measurement of genomic instability
in the form of CNA and mutations. CAGE (Cap Analysis of Gene Expression) analysis of
mouse tissues in RIKEN FANTOM5 project (RNA-seq) dataset was retrieved from
www.ebi.ac.uk.

FOXM1 and RHNO1 Correlation in Public Single-Cell RNA Sequencing Datasets
Single-cell RNA-sequencing datasets from mouse normal colon epithelium
(GSE92332) (147) and human melanoma (GSE72056) (148) were downloaded from NCBI
GEO. Single-cell RNA sequencing data for human high-grade serous ovarian cancer
tissue was obtained from a published dataset (149). Single-cell RNA sequencing data
were normalized with sclmpute (150).
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Genome-Wide Correlation of FOXM1 and ORC2 Occupancy
ORC2 (GSE70165) and FOXM1 ChiP-seq (GSE105524) datasets were retrieved
from NCBI GEO (151,152). Both ChiP-seq experiments were performed using K562 cells
and mapped to human genome build hg19. The StereoGene C++ source code was
downloaded from http://stereogene.bioinf.fbb.msu.ru/. StereoGene was run to determine
the statistical overlap of genome-wide co-occupancy between FOXM1 and ORC2 in the
publicly available ChiP-seq datasets (153). FOXM1 ChIP-seq bed files and ORC2
significant Broadpeak files were input into the StereoGene program and analysis
performed with the contig settings set at default. Final data output consists of the following
correlations: 1) foreground distribution, which is calculated from a set of paired windows
with the same genome positions and the matched windows are compared, and 2)
background distribution, which is a shuffling procedure that is randomly match windows
on one profile to the windows on another profile.

Statistical Analyses
Student’s t-test was used to compare differences between means of two groups.
Mann-Whitney test was used to compare differences between medians of two groups.
One-way analysis of variance (ANOVA) with a post-test for linear trend was used to
compare two or more groups. For all analyses, significance was inferred at P < 0.05 and
P values were two-sided. GraphPad Prism statistical software (GraphPad Software, Inc)
was used for statistical analysis.
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Figures

Figure 6. Generation of immortalized fallopian tube epithelial cells (FTE; FT282).
Fallopian tube epithelial cells were dissociated from the lining of the fallopian tube.
Fallopian tube secretory cells (FTE) were immortalized by transduction with lentivirus
expressing mutant p53 and retrovirus expressing hTERT. These cells can grow long term
on plastic but are not transformed and model the p53 signature lesion found within the
distal end of the fallopian tube. Adapted from: (4).
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Figure 7.
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Figure 7. DNA fiber assay using DNA spreading. A. Asynchronous culture of cells is
labeled in two pulses with washing between. The first pulse in this example is with IdU
(red) and the second pulse is with CldU (green). B. A drop of prelabeled cells is transferred
to a positively coated microscope slide and lysed. C. The slide is then tilted at a 25–60degree angle to allow DNA spreading down the slide. D. DNA is then fixed with
methanol/acetic acid. E. The slide containing fixed DNA is first immunostained with
primary antibodies that recognize CldU and IdU then immunostained with fluorescently
conjugated secondary antibodies. F. DNA fibers are visualized through a fluorescent
microscope and data analysis can be performed with ImageJ. Adapted from: (3).
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Figure 8. Schematic showing the different replication events that can be detected
with DNA fiber analysis. Nucleotide analog labeling scheme according DNA fiber in
Figure 7. IdU is incorporated as the first nucleotide analog followed by CldU incorporated
as the second analog. Representative DNA fibers are shown on the left and their
interpretations on the right. The color of the DNA fibers corresponds to the fluorescence
emission from the secondary antibody that recognizes either IdU or CIdU. Adapted from:
(3).
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Table 1: List of plasmids.
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Table 2: List of primers.
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Table 3. List of siRNAs, shRNAs, and sgRNAs.
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Table 4. List of antibodies.

52

CHAPTER 3: GENETIC DETERMINANTS OF FOXM1 OVEREXPRESSION IN HIGHGRADE SEROUS OVARIAN CANCER1

Introduction
TCGA recently reported mRNA and miRNA expression, CNA, promoter
methylation, and mutational data for HGSC, which led to classification into sub-groups
based on these molecular criteria (30). CNA is prominent in HGSC and occurs at a higher
frequency than in any other TCGA-profiled tumor type (30,31,154). It was also notable
that TP53 was mutated in virtually all HGSC, suggesting p53 as a “gatekeeper” for this
disease (30). Other tumor suppressors and oncogenes implicated in HGSC include
BRCA1/2, Rb, PI3K, Ras, and CCNE1 (30,34,155). Finally, FOXM1 pathway activation is
a highly frequent alteration in HGSC, second only to TP53 mutation (30).
FOXM1 is a member of the Forkhead box (FOX) transcription factor family, which
is unified by a conserved winged helix DNA binding motif (60). FOXM1 plays a wellestablished role in cell cycle progression, promoting G1/S and G2/M transitions by
transactivation of genes regulating these checkpoints (40,60). Furthermore, FOXM1 is
overexpressed and activated in many human cancers and possesses oncogenic activity
in vitro and in vivo (40). Mechanisms accounting for FOXM1 overexpression in cancer
cells and tissues are diverse and include: p53, Rb, and FOXO3 loss (2,73-75), Myc, HIF1, Gli1, SP1, STAT3 and E2F activation (76-81), and gene amplification (82).

1

Part of the data presented in this chapter were previously published: 36.
Barger
CJ,
Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, et al. Genetic determinants of
FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle
progression. Oncotarget 2015;6:27613-27
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The goal of the current study was to begin to define the genetic determinants of
FOXM1 overexpression in HGSC, to analyze its expression across cancer types and
during EOC disease progression, and to investigate its role in EOC cell cycle progression.
For this task, we utilized publicly available TCGA datasets, primary human EOC tissues,
immortalized ovarian surface epithelial (OSE) cell models (murine and human),
immortalized human fallopian tube epithelial (FTE) cell models, a transgenic murine
ovarian cancer model, and human HGSC cell lines.

Results
FOXM1 shows highest expression in HGSC compared to other TCGA tumor types
FOXM1 is overexpressed and activated in many human cancers. However, the
expression of FOXM1 protein has not been characterized in HGSC nor has it been
compared across other cancer types. To determine the level of FOXM1 protein expression
in TCGA cohorts, we retrieved the level 4 TCGA RPPA dataset from The Cancer Proteome
Atlas (TCPA) (145). This dataset was a reprocess of raw TCGA RPPA data using a novel
approach, called ‘replicates-based normalization’ (RBN) to correct for batch effects and
ultimately allow for the merging of samples across 19 different cancer types for pan-cancer
analyses (156). We then analyzed this dataset for FOXM1 protein expression across 19
TCGA cancer cohorts. Notably, we observed that FOXM1 protein expression was the
highest in HGSC as compared to all other TCGA cohorts (Figure 9). This suggests that
HGSC has distinct genomic features that gives rise to increased FOXM1 expression.
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FOXM1 gene amplification correlates with increased FOXM1 expression and
reduced survival in HGSC
HGSC exhibits more frequent copy number alterations than other TCGA cancer
types. FOXM1 is located at chromosome 12p13.33, a known amplified region in cancer
(53,99,100). Therefore, we hypothesized that FOXM1 is altered in copy number in HGSC
thus contributing to its increased expression. To determine if 12p13.33 is a genomic region
with significant copy number increase in HGSC, we downloaded the TCGA HGSC copy
number analysis (GISTIC2) data from the Broad TCGA Genomic Data Analysis Center
(GDAC)-Firehose data portal. Upon review of the TCGA HGSC GISTIC data, we observed
that 12p13.33 is one of the 33 significant focal amplifications in HGSC as highlighted with
the black arrow (Figure 10) and FOXM1 was among the 33 genes in this amplicon (Table
5). We then determined the frequency of FOXM1 amplification among the different cancer
types using TCGA datasets. Notably, amongst all tumor types with TCGA data, FOXM1
was most frequently amplified in HGSC, with ~12% of tumors affected (Figure 11A).
Together, 57% of HGSC cases showed either copy number gain or amplification,
suggesting FOXM1 as an HGSC oncogene (Figure 11B). To determine if FOXM1 copy
number status correlates with expression, we compared FOXM1 mRNA and protein
expression versus FOXM1 copy number in TCGA HGSC data. We observed a progressive
increase in FOXM1 mRNA and protein expression with copy number status that was highly
statistically significant (Figure 11C-D). Furthermore, we compared FOXM1 mRNA and
protein expression and observed a strong correlation (Figure 11E), suggesting that copy
number contributes to increased FOXM1 mRNA expression thus resulting in a
corresponding increase in protein expression. Together these data support our pancancer analysis of FOXM1 expression, which showed that HGSC had the highest level of
FOXM1 protein expression. We additionally compared overall survival (OS) to FOXM1
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CNA and FOXM1 mRNA and protein expression and observed that only the former
showed a significant correlation with OS (Figure 11F-H). This finding suggests that
additional genes located at the amplified region of 12p13.33 may contribute to OS in
HGSC, and/or that FOXM1 activation levels may be more relevant than expression levels
for impacting OS. Finally, our analysis of TCGA mutational data did not reveal FOXM1
mutations in HGSC (data not shown).

TCGA HGSC and basal breast cancer exhibit similar FOXM1 copy number status
and level of expression for FOXM1
The TCGA report and subsequent pan-cancer analyses have shown that HGSC
and basal breast subtype have very similar genomic features including TP53 mutations in
the majority of cases and more genomic instability, in the form of copy number alterations,
than other subtypes of breast and ovarian cancer or most other TCGA cancer types
(32,33). Therefore, we hypothesized that basal breast cancer and HGSC would show
similar FOXM1 copy number status and expression. In our earlier TCGA pan-cancer
comparisons (Figure 9 and11A), breast cancer showed lower frequency of FOXM1
amplification and lower protein expression as compared to HGSC. A caveat to this
comparison was that it did not differentiate between breast cancer molecular subtypes. To
address the possible differences between molecular subtypes, we retrieved the TCGA
PAM50 expression subtype data for TCGA breast cancer and categorized samples based
on molecular subtype. We compared FOXM1 copy number and expression between
subtypes in respect to HGSC. Our analysis of FOXM1 amplification showed that basal
breast and HGSC have an increased frequency of FOXM1 amplification, while the other
breast molecular subtypes showed infrequent FOXM1 amplification (Figure 12A).
Because HGSC and basal breast showed very similar frequency of FOXM1 amplification,
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we next compared FOXM1 copy number status. We observed a striking similarity in copy
number status between these two cancer types (Figure 12B). To determine if breast
molecular subtypes and HGSC have similar FOXM1 expression, we compared FOXM1
mRNA and protein expression among normal breast, breast molecular subtypes and
HGSC. Again, in agreement with the copy number data, HGSC and basal breast showed
the highest level of FOXM1 mRNA and protein expression compared to the other breast
subtypes and normal breast tissue (Figure 12C-D). These data validate our observation
that FOXM1 copy number status contributes to its frequent expression in HGSC and agree
with previous reports that HGSC and basal breast subtype have similar genomic features.
Most importantly, these data further support our hypothesis that HGSC has unique
genomic features that contribute to the frequent overexpression of FOXM1 that we have
observed.

FOXM1 expression in relation to EOC type and progression status, and FOXM1
isoform expression in HGSC
The FOXM1 transcriptional factor pathway was initially reported to be activated in
HGSC by the TCGA (30). The reported FOXM1 pathway activity in HGSC was based on
the degree of overlap between FOXM1 expression and the expression of its reported
transcriptional targets. However, the extent of FOXM1 overexpression in HGSC as
compared to a normal control, such as FTE or OSE, was not determined. To address this,
we retrieved the provisional TCGA HGSC microarray mRNA expression dataset and
compared FOXM1 expression in normal ovary tissue, primary and recurrent HGSC
tumors. We observed a significant increase in FOXM1 expression for primary and
recurrent tumor as compared to normal ovary tissue, showing that FOXM1 is
overexpressed in HGSC (Figure 13A). FOXM1 mRNA expression data was then
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compared by stage and grade. We found that FOXM1 expression was increased in high
grade (grade 2 and 3; HGSC) but we did not observe a significant difference by stage
(Figure 13B-C). FOXM1 has three known splice variants: FOXM1a, b, and c, which
encode proteins with varying activities (10). Furthermore, current knowledge of FOXM1
isoform expression in different cancer types is inconsistent and the isoform expression is
not known in HGSC. To address these issues and determine FOXM1 isoform expression
in HGSC, we then retrieved the TOIL TCGA RNA-seq dataset from UCSC Xena. The TOIL
dataset was a reprocess of raw TCGA RNA-sequencing data to correct for batch effects
and to allow for the merging of samples across all TCGA datasets for pan-cancer analyses
(157). We then analyzed the TOIL HGSC RNA-seq dataset and compared FOXM1 isoform
expression in primary tumors samples and found that FOXM1c is the predominant isoform
expressed in HGSC, followed by FOXM1b and FOXM1a (Figure 13D). Furthermore, we
analyzed TOIL TCGA pan normal and cancer tissue RNA-seq dataset to determine if
FOXM1 isoforms are differentially expressed across pan-normal and -cancer tissues and,
more importantly, how the expression compares with HGSC tissues. In agreement with
the HGSC isoform expression data, pan-normal and -cancer tissues show that FOXM1c
is the predominant isoform expressed, followed by FOXM1b and FOXM1a (Figure 13E).
These data suggest that FOXM1 isoform ratios are relatively similar in normal and cancer
tissues; therefore, the observed increase in FOXM1 expression in cancer is not the result
of the differential expression of only a single isoform.
We next validated the TCGA HGSC FOXM1 expression using our own
independent set of EOC tissues with diverse histology, stage, and grade (158,159). RTqPCR analysis demonstrated that FOXM1 is frequently overexpressed in different EOC
histological subtypes relative to normal ovary (NO), and furthermore shows increased
expression in both late-stage and high-grade EOC (Figure 14A-C). To validate the
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expression of FOXM1 isoforms we observed in TCGA HGSC, we used FOXM1 isoformspecific primers and performed RT-qPCR to quantify their expression, and in agreement
with the TCGA HGSC data, we found that FOXM1c is the predominant isoform expressed
in HGSC, followed by FOXM1b and FOXM1a (Figure 14D). Similarly to the mRNA,
FOXM1 protein expression was elevated in EOC as compared to NO (Figure 14E).
Together, these data agree with our TCGA analysis, showing that EOC and HGSC
exhibits frequent overexpression of FOXM1.

FOXM1 expression in HGSC cell models
Thus far, our analyses have been performed with HGSC tumors which are subject
to genetic heterogeneity. We next used clinically relevant cell models of human HGSC to
examine genetic influences on FOXM1 expression (160). All cell lines used have TP53
mutations as well as additional genetic alterations relevant to HGSC (Figure 15A). We
found that FOXM1 mRNA expression was elevated in all but one cancer cell line as
compared to hOSE cells and was heterogeneous in the HGSC cell types (Figure 15B).
Notably, highest FOXM1 expression was observed in the two cell lines (SNU-119,
COV362) in which the FOXM1 locus is amplified. Isoform-specific RT-qPCR revealed
highest expression of FOXM1c, moderate expression of FOXM1b, and low expression of
FOXM1a in HGSC cell lines. FOXM1c expression was highest in the SNU-119 and
COV362 lines, in which FOXM1 is amplified (Figure 15C). The relative expression of the
three FOXM1 isoforms agrees with our data using primary HGSC tumors (Figure 13C). In
further agreement, FOXM1 protein expression was highest in cell lines with increased
copy number status (Figure 15D).
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Disruption of Rb and p53 induces FOXM1 expression in murine and human OSE
cells
The OSE is a potential tissue of origin for EOC, and primary OSE cells are useful
for exploring EOC relevant processes (161,162). We first used established murine OSE
(mOSE) cell models to examine mechanisms regulating FOXM1 expression. We focused
on TP53 and RB1, as these disruptions are recurrent in HGSC (30). Trp53 and Rb1
knockout was achieved through Ad-Cre infection of mOSE cells as described previously
(Figure 16A) (163). While loss of either tumor suppressor gene (TSG) alone resulted in a
modest upregulation of Foxm1, combined p53 and Rb loss led to a robust induction (Fig
16B). Similar effects were observed for FOXM1 protein expression (Figure 16C). We next
investigated the potential role of p53 and Rb in FOXM1 regulation in human OSE (hOSE)
cells by measuring FOXM1 expression in hOSE cells immortalized with either SV40 Large
T antigen (IOSE-SV), which leads to potent inactivation of p53 and Rb, or hTERT (IOSET), which leaves both proteins intact (125). IOSE-SV cells showed significantly higher
levels of expression of both FOXM1 mRNA and protein as compared to IOSE-T or primary
(non-immortalized) human OSE cells (Figure 16D-E). These data reveal that Rb and p53
play a major role in regulating FOXM1 expression in OSE cells.

FOXM1 is overexpressed in murine ovarian cancer driven by combined p53/Rb1
disruption
To complement the OSE cell studies described above, we measured FOXM1
expression in murine ovarian tumors developing after dual disruption of p53 and Rb in the
OSE. As shown in Figure 17A-B, FOXM1 mRNA and protein expression were significantly
increased in ovarian tumors as compared to the mouse normal ovary control. These in
vivo data provide further support that loss of p53 and Rb contribute to FOXM1
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overexpression in ovarian cancer. Notably, immunohistochemistry (IHC) analyses of the
ovarian tumors arising in this model indicated that the tumors were negative for cytokeratin
expression and positive for smooth muscle actin (Figure 17C). This finding suggests that
cancer in this model may represent leiomyosarcoma, and not EOC, as was reported
previously (163).

E2F1 and FOXM1 expression in OSE cells and EOC
Transcriptional activation of FOXM1 following Rb loss suggests that E2F
transcription factors may contribute to FOXM1 overexpression. To test this, we used
IOSE-SV and COV362 cells, which have high FOXM1 expression as well as alterations in
p53 and Rb. Following E2F1 knockdown by siRNA (Figure 18A), FOXM1 mRNA
expression in both cell types was significantly reduced, as compared to the non-targeting
siRNA control (Figure 18B). To validate this finding in the primary disease setting, we
tested whether FOXM1 correlates with E2F1 expression in human EOC. As shown in
Figure 18C-D, in both the TCGA HGSC dataset and in our independent set of EOC
tissues, expression of FOXM1 and E2F1 were highly correlated. Together, these data
implicate E2F1 in promoting FOXM1 expression in EOC.

Deregulation of the Rb-E2F pathway contributes to FOXM1 overexpression in
fallopian tube epithelial cells
Thus far we determined that FOXM1 expression was increased with loss of p53
and Rb in OSE models, while FOXM1 expression was decreased with knockdown of
E2F1. We next validated these findings in a more relevant HGSC precursor cell model
system (Figure 6), TERT-immortalized fallopian tube epithelial cells, engineered to
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overexpress mutant p53-R175H (FT282), large T antigen (FT190) or Cyclin E1 (FT282E1). Similarly to our data in IOSE-T, the large T-expressing FTE cells showed increased
FOXM1 mRNA and protein expression, as compared to FTE cells expressing mutant p53
alone (Figure 19A-B). Interestingly, the Cyclin E1 expressing cells showed the highest
expression of FOXM1 and thus revealed a new upstream regulator of FOXM1 (Figure
19A-B). To improve upon these models, we used the TERT-immortalized FTE-expressing
mutant p53 as a model to introduce temporal genetic modifications to the Rb-E2F pathway
to further understand upstream regulators of FOXM1 expression. To determine the impact
of RB loss, we modified the widely used lenti-CRISPR vector into an inducible system and
engineered FTE cells for RB1 knockout using a previously characterized guide RNA to
human RB1 (164,165). We doxycycline treated FTE cells engineered with inducible
CRISPR-Cas9 targeted to RB1 for 72 hours then sorted cells based on positive GFP
expression to enrich for knockout. These cells were then expanded in the absence of
doxycycline for one week and harvested for RNA and protein. We then characterized the
mRNA and protein expression for RB1 and FOXM1, and we observed a significant
increase in FOXM1 expression with RB knockout (Figure 19C-D). Similarly, we
overexpressed E2F1 in FTE cells using a doxycycline inducible lentiviral vector to
complement our prior results when we knocked down E2F1 with a siRNA. FTE cells
engineered for E2F1 inducible expression were doxycycline treated for 72 hours then
analyzed for E2F1 and FOXM1 mRNA and protein expression. In agreement with previous
data, we observed increased FOXM1 expression when E2F1 was overexpressed (Figure
19E-F). Cyclin E1 is frequently amplified in HGSC, resulting in its overexpression (155).
Furthermore, when Cyclin E1 interacts with its kinase, CDK2, this complex phosphorylates
RB to release E2F1. Since we observed in increase in FOXM1 expression in the FTE cells
engineered for constitutive Cyclin E1 expression, we next overexpressed Cyclin E1 in
fallopian cells in an inducible manner and observed that it increased FOXM1 expression
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in a dose-dependent manner (Figure 19G-H). Collectively, these data indicate that
deregulation of the Rb-E2F pathway contributes to the frequent overexpression of FOXM1
in HGSC precursor lesions and primary tumors.

Functional contribution of FOXM1 to EOC cell cycle progression and target gene
expression
To determine if FOXM1 plays a functional role in EOC cells, we explored its
canonical function in cell cycle progression using knockdown and overexpression
approaches. Knockdown of FOXM1 was efficient in IOSE-SV cells and led to accumulation
of cells in G2-M, with concomitant decreases in both G1 and S (Figure 20A and C).
Interestingly, in COV362 cells, FOXM1 knockdown also led to decreased cells in S phase
but caused accumulation of cells in G1 with no significant alteration of G2-M (Figure 20B
and D). These data suggest that FOXM1 regulates both the G1/S and G2/M checkpoints,
but in a cell context-dependent manner. To determine whether the observed effect of
FOXM1 knockdown on cell cycle progression coincided with altered expression of relevant
FOXM1 target genes, we analyzed SKP2, PLK1, and CCNB1 expression. SKP2 promotes
G1-S transition, while PLK1 and CCNB1 promote G2-M transition, both downstream of
FOXM1 (66,68,166). In agreement with our cell cycle data, FOXM1 knockdown in IOSESV and COV362 downregulated these genes, with the lone exception of PLK1 in COV362
(Figure 20E-F).
In addition to FOXM1 knockdown, we overexpressed FOXM1b or FOXM1c using
a stable doxycycline inducible system in primary hOSE cells. Interestingly, while the
mRNA expression levels were identical, the FOXM1c protein appeared to be more stable
than FOXM1b in these cells (Figure 21B). FOXM1c overexpression in hOSE led to
increased cells in S and G2/M, with a decrease in G1 (Figure 21C). In contrast,
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overexpression of FOXM1b did not alter cell cycle (data not shown). To determine whether
the effect of FOXM1c overexpression on cell cycle coincided with altered expression of
relevant FOXM1 target genes, we again analyzed SKP2, PLK1, and CCNB1.
Overexpression of FOXM1c in hOSE cells led to upregulation of PLK1 and CCNB1, while
SKP2 was unaffected (Figure 21D). These data are consistent with the functional impact
of FOXM1 in EOC cell cycle regulation and suggest that this activity may be mediated by
FOXM1’s function as a transcriptional regulator. Although the effects of FOXM1c on cell
cycle was modest, this could be due to the primary hOSE cell model used, which is
assumed to have a functional p53 pathway. In agreement, the specific effect of FOXM1
overexpression on cell cycle progression in primary hOSE are reminiscent of that reported
in cancer cells, although the effects were more robust in cancer cells (167,168).

Summary
Together, our data implicate gene amplification, p53 inactivation, and Rb-E2F
deregulation in FOXM1 overexpression in HGSC. FOXM1 amplification and expression
are highest in HGSC compared to other TCGA cancer types but comparable to basal
breast subtype. Among FOXM1 isoforms, FOXM1c showed highest expression in HGSC
cells and tumors. FOXM1 was overexpressed in late-stage, high-grade disease, and
FOXM1 gene amplification, but not expression, correlated with reduced HGSC survival.
Finally, we demonstrate that FOXM1 activates target genes that positively regulate
progression through the G1/S and G2/M checkpoints, and this functionally contributes to
cell cycle progression in OSE and HGSC cell models. Finally, we identified CCNE1 as a
new upstream activator of FOXM1 expression.
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Figures and Tables

Figure 9. FOXM1 protein expression (RPPA, RBN normalized) across TCGA cancer
types. TCGA cancer cohorts are listed on the x-axis and ranked according to median
FOXM1 expression with the highest expression on the left. Median lines are shown for
each cancer cohort. HGSC = OV.
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Figure 10.
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Figure 10. Recurrent sites of DNA copy number amplification in HGSC determined
by GISTIC. The GISTIC plot shows 33 recurrent sites of DNA copy number amplification
in 579 TCGA HGSC samples. The x-axis displays statistical significance as FDR q-value.
The black vertical line indicates the threshold for significance, which is set with an FDR qvalue less than 0.25. Chromosomes listed on the left are arranged from chromosome 1
on top to chromosome X on the bottom. Significantly amplified cytobands are listed on the
right. The 12p13.33 peak is highlighted on the plot. The GISTIC data was retrieved on
8/21/2015 from the Broad Institute TCGA Genome Data Analysis Center. TCGA HGSC
SNP6 Copy number analysis (GISTIC2).
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Table 5: List of genes contained at the TCGA HGSC 12p13.33 amplicon.
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Figure 11.
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Figure 11. FOXM1 copy number alterations (CNA) and overall survival in HGSC. A.
FOXM1 amplification frequency in TCGA datasets, showing the 19 cancer types from
Figure 7. Arrow indicates HGSC. B. FOXM1 CNA in HGSC TCGA datasets as determined
by GISTIC. C. FOXM1 mRNA expression (RNA Seq V2 RSEM, log2) compared to FOXM1
copy number in HGSC TCGA datasets. D. FOXM1 protein expression (RPPA) compared
to FOXM1 copy number in HGSC TCGA datasets. E. FOXM1 mRNA expression (RNA
Seq V2 RSEM, log2) correlated with FOXM1 protein expression (RPPA) in HGSC TCGA
datasets. F-H. Overall survival as a function of F. FOXM1 amplification, G. FOXM1 mRNA
expression (dichotomized by group median) and H. FOXM1 protein expression (RPPA)
(dichotomized by group median) in HGSC TCGA datasets. The p value for Logrank test
is shown. The p value for ANOVA with post-test for linear trend is shown. Lines represent
group medians.
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Figure 12. FOXM1 copy number alterations (CNA) and expression in TCGA HGSC
vs breast tissues. A. FOXM1 amp frequency in HGSC vs breast molecular subtypes. B.
FOXM1 copy number status in HGSC vs basal breast. C-D. FOXM1 expression in HGSC
vs breast molecular subtypes C. mRNA expression (RNA-seq) and D. protein expression
(RPPA). Lines represent group medians.
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Figure 13.
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Figure 13. FOXM1 expression in TCGA high-grade serous ovarian cancer. A. FOXM1
mRNA expression HGSC primary and recurrent tumor as compared to normal ovary
(RNA-seq) B. FOXM1 mRNA expression in serous ovarian cancer as function of
pathological grade. C. FOXM1 mRNA expression in serous ovarian cancer as a function
of disease stage (RNA-seq). D-E. FOXM1 isoform expression in D. TCGA HGSC tissues
and E. TCGA pan-normal and -cancer tissues is represented as percentage of total
FOXM1 transcript levels measured by RNA-seq. Lines represent group medians. The
Mann-Whitney test P value is shown. P value designation: **** < 0.0001, *** < 0.001, ** <
0.01, * < 0.05.
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Figure 14. FOXM1 expression in EOC tissues. A. FOXM1 expression measured with
RT-qPCR (log10) in EOC histological subtypes as compared to normal ovary (NO).
FOXM1 expression was normalized to 18s rRNA. B. FOXM1 expression in NO and in
EOC as a function of disease stage. C. FOXM1 expression in NO and in EOC as a function
of pathological grade. Lines represent group medians. Mann-Whitney test p values are
shown. D. FOXM1 isoform specific RT-qPCR (log10) measured in HGSC tissues. E.
FOXM1 Western blot analysis in NO and EOC. Ponceau S staining is shown as a loading
control. Lines represent group medians. The Mann-Whitney test P value is shown. P value
designation: **** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 15. FOXM1 expression in HGSC cell lines. A. Relevant genetic alterations in
HGSC cell lines. Data were retrieved from the CCLE dataset and copy number alterations
were visualized with IGV as described in Methods. B. FOXM1 mRNA expression in HGSC
cell lines and hOSE cells (control) was measured by RT-qPCR. C. Isoform specific
FOXM1 mRNA expression in HGSC cell lines was measured by RT-qPCR (log10). D.
FOXM1 protein expression in HGSC cell lines and hOSE (control) was measured by
Western blot. For B-C, bars represent mean ± SD.
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Figure 16.

76

Figure 16. FOXM1 expression in murine and human OSE cells following Rb and/or
p53 abrogation. A. PCR genotyping of mOSE cells following infection with recombinant
adenovirus expressing enhanced GFP (Ad-eGFP, control) or Cre recombinase + eGFP
(AdCre-eGFP). B-C. FOXM1 expression in Rb and/or p53 floxed (control) and knockout
(post-Cre infection) mOSE cells. B. Foxm1 RT-qPCR with respective fold-change relative
to the floxed control. Data represent mean ± SD. Students t-test p value is shown. C.
FOXM1 Western blot with respective fold change relative to the floxed control, performed
with nuclear lysates. Ponceau S staining is shown as a loading control. D-E. FOXM1
expression in primary and immortalized human OSE cells (hOSE and IOSE-T or IOSESV). Cell line descriptions are provided in the Methods. D. FOXM1 RT-qPCR. Data
represent mean ± SD. E. FOXM1 Western blot. β-actin is shown as a loading control.
Students t-test p values: **** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 17. FOXM1 expression in Rb1/Trp53 knockout-driven murine ovarian cancer.
A-B. FOXM1 expression in Rb1/Trp53 knockout murine ovarian tumor tissues (T) and
murine normal ovary control tissue (N). The mouse model is described in Methods. A.
Foxm1 RT-qPCR. Data represents means ± SD. B. FOXM1 Western blot. β-actin is shown
as a loading control. C. Ovarian tumor histology in Rb/p53 knockout mice. Paraffin
sections of the tumors were stained with H&E or specific antibodies to pan-cytokeratin
(Pan-CK) or smooth muscle actin (SMA). Images were captured using 20X objective.
Antigen detection is indicated by the presence of a brownish-red stain.
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Figure 18. E2F1 and FOXM1 expression in IOSE-SV, EOC cells, and EOC tissues. AB. siRNA knockdown of E2F1 (10nM) in IOSE-SV and COV362 cells for 72 hours. A. E2F1
Western blot. β-actin is shown as a loading control. B. FOXM1 RT-qPCR, normalized to
18s rRNA. Data represent mean ± SD. Student’s t-test p value is shown. C-D. E2F1 and
FOXM1 expression correlation in human EOC tissues. C. Correlation in 263 HGSC tissues
from TCGA datasets (gene expression determined by RNA seq V2, log2). D. Correlation
in an independent set of 40 EOC tissues (gene expression determined by Affymetrix HG
1.0ST microarray, log2).
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Figure 19.
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Figure 19. FOXM1 expression in FTE cells engineered for deregulation of the RbE2F pathway. A-B. FOXM1 mRNA and protein expression were measured by RT-qPCR
and Western blot, respectively, in FTE cells. β-actin is shown as a loading control. C-D.
FOXM1 expression by RT-qPCR and Western blot, respectively, in RB1 CRISPR KO
FT282 cells. E-F. FOXM1 expression by RT-qPCR and Western blot, respectively, in
E2F1-inducible FTE cells. G-H. FOXM1 expression by RT-qPCR and Western blot,
respectively, in CCNE1-inducible FTE cells. Bars represent mean ± SD. Student’s t test p
values are shown. P value designation: **** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 20.
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Figure 20. Impact of FOXM1 knockdown on cell cycle progression and target gene
expression in IOSE-SV and COV362 cells. Transient siRNA-mediated knockdown of
FOXM1 (20nM) was completed for 72 hours. A-B. Validation of FOXM1 protein
knockdown in A. IOSE-SV cells and B. COV362. FOXM1 protein expression was
determined by Western blot, and β-actin is shown as a loading control. C-D. Cell cycle
analysis of C. IOSE-SV and D. COV362 cells following FOXM1 or control siRNA
treatment. E-F. FOXM1 target gene expression determined by RT-qPCR in E. IOSE-SV
and F. COV362 cells, following FOXM1 or control siRNA treatment. Expression data are
shown for SKP2, PLK1, and CCNB1, each normalized to 18s rRNA. Bars represent mean
± SD. Student’s t test p values are shown. P value designation: **** < 0.0001, *** < 0.001,
** < 0.01, * < 0.05.
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Figure 21. Impact of FOXM1 overexpression on cell cycle progression and target
gene expression in hOSE cells. A-B. Doxycycline inducible FOXM1b and FOXM1c
overexpression in primary hOSE cells after 72 hours of doxycycline treatment as indicated.
A. FOXM1 RT-qPCR (log10). B. FOXM1 Western blot. β-actin is shown as a loading
control. C. Cell cycle analysis following doxycycline inducible FOXM1c overexpression in
primary hOSE cells after 72 hours of treatment. Cells treated with 250ng/ml and 1000ng/ml
doxycycline were combined for analysis and compared against the control without
treatment. D. FOXM1 target gene expression was measured by RT-qPCR in hOSE cells
following 72 hours of doxycycline treatment to induce FOXM1c. Expression data are
shown for SKP2, PLK1, and CCNB1, each normalized to 18s rRNA. Data represents mean
± SD. Student’s t-test p values are shown. P value designation: **** < 0.0001, *** < 0.001,
** < 0.01, * < 0.05.
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CHAPTER 4: FOXM1 AND GENOMIC INSTABILITY IN HIGH-GRADE SEROUS
OVARIAN CANCER

Introduction
While FOXM1 is linked to several cancer hallmarks, its role in genomic instability
has not been explored in HGSC, a disease that exhibits frequent FOXM1 activation and
has genomic instability as a key defining molecular feature (30). Additionally, we have
shown that HGSC has the highest level of FOXM1 expression among TCGA cancer types
and an early pan-cancer analysis observed that FOXM1 expression is associated with
genomic instability (37). FOXM1 is a transcriptional activator of genes involved in DNA
replication initiation and cell cycle progression (68,86,130,166), and when dysregulated,
such genes may promote DNA replication stress and genomic instability (88). These
observations suggest that aberrant FOXM1 expression and transcriptional activity may
induce DNA replication stress and promote genomic instability in HGSC. The objective of
the current study was to determine the functional consequence of aberrant FOXM1
expression on DNA replication stress and genomic instability in HGSC. For this task, we
utilized publicly available TCGA datasets, immortalized human FTE cell models, and
human HGSC cell lines.

Results
FOXM1 associates with markers of DNA replication stress and genomic instability
in HGSC tissue and cell lines
FOXM1 expression has been associated with genomic instability (37,85), but it is
unclear whether FOXM1 causes this phenotype and, if so, by what mechanism.
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Oncogene-induced DNA replication stress is linked to genomic instability (88,92,97,169).
We hypothesized that FOXM1 expression promotes DNA replication stress, providing a
mechanistic link to genomic instability. To test the possibility that FOXM1 induces DNA
replication stress, we first analyzed TCGA HGSC cancer datasets to determine the
association of FOXM1 expression with the expression of P-CHK1-S345, an established
marker of DNA replication stress (58). Notably, FOXM1 mRNA significantly correlated with
P-CHK1-S345 protein expression (Figure 22A). The comparison between FOXM1 protein
and P-CHK1-S345 protein expression did not show a significant correlation but it did show
a direct correlation (Figure 22B). The discrepancy in correlation for FOXM1 mRNA and
protein expression may be due to technical differences in the assays (e.g. RNA-seq vs
RPPA) or differences in samples and sample size. We next analyzed TCGA HGSC
datasets to determine if FOXM1 expression showed a relationship with genomic instability
in the form of total mutation count in coding regions of the genome (mutation burden) or
genome wide CNAs as a fraction of the total genome (fraction of copy number altered
genome). Analysis of TCGA HGSC data showed a signification correlation between
FOXM1 mRNA and protein expression and genome wide copy number alterations, a
marker of genomic instability (Figure 22E-F). In contrast, FOXM1 expression did not show
a significant correlation with the mutation burden (Figure 22C-D), suggesting FOXM1 may
promote global copy number alterations but not mutations. Controlling for FOXM1 copy
number, which we have shown contributes to FOXM1 expression in HGSC (36), we made
similar comparisons using samples with diploid FOXM1 copy number status and again we
observed a significant correlation between FOXM1 protein expression and genome wide
copy number alterations (Figure 22H). The correlation of CNA with FOXM1 mRNA showed
a direct relationship but did not reach statistical significance, possibly due to smaller
sample size (Figure 22G). These data suggest that FOXM1 may promote DNA replication
stress and genomic instability in HGSC.
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To expand and independently confirm these observations, we analyzed the Cancer
Cell Line Encyclopedia (CCLE) pan-cancer and ovarian cancer cell line datasets. Notably,
FOXM1 protein significantly correlated with P-CHK1-S345 protein expression in both
CCLE pan-cancer and ovarian cancer cell lines (Figure 23A-B). We then measured total
FOXM1 protein along with canonical DNA replication stress response markers in a panel
of HGSC cell lines as compared to an immortalized FTE cell line which represents the p53
signature precursor lesion in HGSC (Figures 2 and 6). We observed that HGSC cells
showed increased basal levels of phosphorylated CHK1 and RPA2 as compared to the
FTE cells (Figure 24A). We also observed that FOXM1 protein expression was increased
in HGSC cells as compared to FTE (Figure 24A). We next overexpressed FOXM1 in FTE
cells then measured the expression of P-CHK1-S345 to determine the relationship in their
expression. We found a dose dependent response between FOXM1 and P-CHK1
expression (Figure 24B). These data support the idea that FOXM1 induces DNA
replication stress in HGSC, potentially contributing to genomic instability.

FOXM1 transcriptional activity is required for the induction of DNA replication
stress and DNA damage in FTE cells
Our central hypothesis is that FOXM1 induces DNA replication stress thereby
promoting genomic instability. To test whether FOXM1-induced DNA replication stress is
dependent on its transcriptional activity, we generated a FOXM1 DBD mutant where three
key residues in the FOXM1 DNA binding domain (DBD) were changed to alanine. These
amino acid residues were shown to be essential for FOXM1 to bind DNA based on
previous reports using X-crystallography and ChIP-seq (132,170). We next overexpressed
FOXM1 wild-type and DBD mutant in FTE cells using a doxycycline inducible system to
determine if FOXM1-induced DNA replication stress is linked to its transcriptional activity.
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We first validated the functional activity of FOXM1 wild-type and DBD mutant by
measuring the endogenous expression of a canonical target gene, CCNB1, and by the
widely used 6X FOXM1 luciferase reporter assay (171). Following doxycycline induction
of wild-type FOXM1 in FTE cells and transfection of the the 6X FOXM1 reporter construct,
we observed a significant increase in luciferase activity, but not for the DBD mutant (Figure
25A). In agreement, we observed a dose dependent increase in CCNB1 mRNA
expression, but we did not see a significant increase in CCNB1 mRNA with the induction
of FOXM1 DBD mutant (Figure 25B). Most importantly, following doxycycline induction,
we observed that wild-type FOXM1 increased P-CHK1-S317 and -S345 but the FOXM1
DBD mutant did not (Figure 25C). These data demonstrate that FOXM1 transcriptional
activity is related to its ability to induce DNA replication stress in a relevant HGSC
precursor cell model.
The above data show that FOXM1 is capable of inducing a DNA replication stress
response in FTE cells. Therefore, we hypothesized that FOXM1 not only induces DNA
replication stress but also induces DNA damage. To test this, we asked whether FOXM1
expression in human immortalized FTE cells leads to detectable levels of DNA damage
measured at single cell resolution with the Comet assay. Following doxycycline induction,
we observed an increased percentage of Comet tail DNA in FTE cells expressing wildtype FOXM1, as compared to FTE cells expressing FOXM1 DBD mutant, suggesting that
transcriptional activity is required for this phenotype as well (Figure 25D).

FOXM1 and CCNE1 produce comparable levels of DNA damage in FTE cells
FOXM1 is associated with genomic instability but the mechanistic link has not been
demonstrated. Oncogene-induced DNA replication stress is linked to genomic instability
in many various cell types (88). Thus far, we observed that FOXM1 expression shows a
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direct relationship with markers of DNA replication stress and genomic instability in TCGA
HGSC. In addition, FOXM1 expression induced the expression of DNA replication stress
markers and increased DNA damage as measured with the Comet assay. We extended
these studies by comparing the DNA damage phenotypes between FTE cells expressing
FOXM1 or CCNE1, an oncogene known to induce DNA replication stress and DNA
damage in FTE cells (155). We observed that both FOXM1 and Cyclin E1 showed
increased and comparable levels of γ-H2AX and percentage of Comet tail DNA, but
CCNE1 showed a greater increase in P-CHK1 (Figure 26A-C). Furthermore, we used Flow
Cytometry as an independent readout of DNA damage by measuring the levels of γ-H2AX
in S-phase cells, or the DNA damage occurring during DNA replication. In agreement with
the Comet data, we observed that FOXM1 expressing cells showed increased expression
of γ-H2AX in S-phase as compared to vector control (Figure 26D). These results agree
with the DNA replication stress phenotype we observed for wild-type and DBD mutant
FOXM1, suggesting that DNA replication stress links FOXM1 to genomic instability.

FOXM1 promotes cell cycle progression in fallopian tube epithelial cells
Thus far in our cell models, FOXM1 overexpression in FTE cells activated ATRCHK1 signaling with a corresponding increase in DNA damage, indicative of DNA
replication stress. When cells experience DNA replication stress, the ATR-CHK1 signaling
pathway is activated, thereby promoting fork stabilization and restart, and inducing cell
cycle arrest in the S and G2 phases allowing time for damaged DNA to be repaired prior
to entering mitosis (88). Therefore, the FTE cells with FOXM1-induced DNA replication
stress and DNA damage might have increased cells in the S and G2/M phases although
FOXM1 is known to promote G2-M progression. To test this, we overexpressed FOXM1
wild-type, FOXM1 DBD mutant, and Cyclin E1 in FTE cells and performed cell cycle
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analysis after 72 hours of doxycycline induction (Figure 27A). Unexpectedly, the FTE cells
expressing the FOXM1 DBD mutant showed an increased number of cells in the G2/M
phase of the cell cycle (Figure 27B). In contrast, FTE cells expressing wild-type FOXM1
showed an increase in G1 and S phases but a decrease in the G2/M phase, suggesting
FOXM1 promoted cell cycle progression through the G2/M checkpoint, which agrees with
its canonical function in cell cycle regulation (Figure 27B). In agreement with previous
reports using other cell types, we observed that FTE cells expressing Cyclin E1 showed
a decreased G1 phase with increased S and G2/M phases (Figure 27B). This suggests
that Cyclin E1 promoted cell cycle progression though the G1/S checkpoint but the
resulting DNA replication stress leads to cell cycle arrest in S and G2/M phases (172).
Finally, the failure of FOXM1-expressing FTE cells to arrest in S and G2/M either suggests
that FOXM1 does not induce a traditional DNA replication stress phenotype or the
canonical function of FOXM1 has an opposing force on the ATR-CHK1-mediated cell cycle
arrest, and thus the cells fail to arrest and instead progress into mitosis.

FOXM1 promotes replication fork progression in fallopian tube epithelial cells
We observed that wild-type FOXM1 expression activates markers of DNA
replication stress while promoting cell cycle progression. To determine how FOXM1
associates with these phenotypes, we performed DNA fiber analysis, which is the gold
standard for measuring DNA replication stress and the most comprehensive method for
assessing the DNA replication dynamics among a population of mammalian cells
(169,173). We performed DNA fiber spreading with FTE cells engineered for doxycycline
inducible expression of empty vector (control), wild-type FOXM1, DBD mutant FOXM1,
and Cyclin E1, an oncogene shown to cause DNA replication stress in other cell types by
DNA fiber analysis (172,174,175). Inducible FTE cells were grown in the presence of

90

doxycycline for 72 hours prior to labeling them with nucleotide analogues for DNA fiber
analysis. Cells were harvested for DNA fiber and we measured fork rate and the number
of origins fired. As expected, based on previous reports for other cell types, Cyclin E1
expression in FTE cells decreased fork rate and increased origin firing (Figure 28A-C)
(120,122,123). Unexpectedly, we observed that wild-type FOXM1 not only promoted
increased fork rate in FTE cells, but it increased origin firing (Figure 28A-C). Also
surprising, but in agreement with the cell cycle data, the FOXM1 DBD mutant decreased
fork movement (Figure 28A-C), the phenotype that results from cells experiencing DNA
replication stress. DNA replication stress is more generally defined by the replication fork
dynamics where there is an observed slowing or stalling of the replication forks (169). This
is also the accepted definition for oncogene-induced DNA replication stress and this type
of phenotype is often reported in the literature for most oncogenes (88). However, based
on this recent review, not all oncogenes that promote DNA replication stress promote fork
stalling (88). In fact, some oncogenes increase fork speed while inducing DNA damage
although the activation of ATR-CHK1 signaling in these studies was not characterized
(176-179). Given this knowledge and our recent data, we hypothesized that FOXM1 may
activate target genes involved in DNA replication or chromatin remodeling that facilitate
fork movement.

FOXM1 activates target genes involved in the regulation of the G2/M cell cycle
checkpoint
Oncogenes, such as Ras, Myc, and Cyclin E, deregulate E2F-dependent G1/S
transcription to drive progression into S phase and promote DNA replication (180,181).
Specifically, Cyclin E1 expression enhanced a global transcriptional program, causing
increased DNA replication stress, and this phenotype was rescued by either transcription
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or CDK inhibition (175,180). However, the mechanism for how Cyclin E1 causes DNA
replication stress in FTE cells is not known. Furthermore, DNA replication can be affected
by the expression and interplay between different chromatin factors and histone
modifications to promote rapid replisome progression (182). In this context, FOXM1 can
bind DNA and activate target gene expression, but the FOXM1 DBD mutant is deficient in
this function. Additionally, FOXM1 wild-type increases DNA fork rate and FOXM1 DBD
mutant decreases DNA fork rate. Therefore, FOXM1 wild-type might activate the
expression of genes involved in DNA replication initiation and elongation, and chromatin
remodeling, thus facilitating fork movement.
To identify a possible mechanism for FOXM1-induced fork movement, as well as
Cyclin E1-induced fork stalling, we performed RNA-seq analysis with FTE cells expressing
empty vector (control), FOXM1 and Cyclin E1 (Figure 29A-B). GSEA analysis for Cyclin
E1-expressing FTE cells showed an enriched gene expression signature for DNA
replication and initiation (Figure 30A). This suggests that Cyclin E1 expression promotes
increased DNA replication initiation or origin firing, a condition which can lead to depletion
of nucleotide pools, and eventually fork stalling and DNA replication stress (169).
Interestingly, we observed that the FTE cells expressing Cyclin E1 show a significantly
enriched FOXM1 pathway gene expression signature (Figure 30B) and this is consistent
with our prior data (Figure 19G-H). Gene Set Enrichment Analysis (GSEA) of FTE cells
expressing FOXM1 showed an enriched expression signature for FOXM1 target genes,
specifically those involved in the regulation of the G2/M checkpoint and mitosis, rather
than a gene expression signature of DNA replication or chromatin remodeling (Figure 30CD). We validated the FOXM1 target gene expression by RT-qPCR and found that FTE
cells expressing FOXM1 or Cyclin E1 both showed increased mRNA expression for
FOXM1 target genes (Figure 31A-C). Although BRCA2 mRNA was not differentially
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expressed in our RNA-seq analysis for FTE cells expressing FOXM1, we measured the
expression of BRCA2 mRNA by RT-qPCR because it has been reported to be a FOXM1
target gene (91). Furthermore, RNA-seq analysis showed that BRCA2 mRNA expression
was increased in FTE cells expressing CCNE1. These data support a functional role for
FOXM1 in the G2/M checkpoint downstream of Cyclin E1 and suggest that FOXM1
transcriptional activity does not directly explain the increase in fork movement.

Analysis of RPPA functional proteomics data confirms the involvement of FOXM1
in the G2/M checkpoint
Our RNA-seq analysis did not identify gene expression changes that may
contribute to the FOXM1-induced fork movement, therefore, we decided to investigate
proteomic changes as the possible cause of this phenotype. Reverse phase protein arrays
(RPPA) provide a large-scale measurement of a defined number of total proteins, and
phosphorylated and cleaved proteins that can provide insight into post-transcriptional
changes in multiple signaling pathways, including receptor tyrosine kinases, PI3K‐AKT
and MAPK cascades, as well as DNA repair, cell cycle and apoptosis/autophagy
regulators (156,183). We performed RPPA to characterize the proteomic profile in the FTE
cells expressing FOXM1 and Cyclin E1 to determine if there are differences in these select
signaling pathways, potentially providing insight for the increased fork rate in FTE cells
expressing wild-type FOXM1. We overexpressed FOXM1 wild-type, FOXM1 DBD mutant,
and Cyclin E1 in an inducible manner by growing cells FTE cells in the presence of
doxycycline for a period of 72 hours. Proteins were harvested and sent to the RPPA Core
at MD Anderson for analysis. We used the normalized log2, median centered RPPA data
to generate heat maps for visualization of the data. Vector control, FOXM1 wild-type,
FOXM1 DBD mutant and Cyclin E1-expressing FTE cells were compared by using
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unsupervised hierarchical clustering. Interestingly, FOXM1 wild-type and DBD mutant
clustered together and were more similar to FTE-expressing V control than FTE cells
expressing Cyclin E1 (Figure 32A). The clustering of FOXM1 wild-type and DBD mutant
is surprising, considering that FOXM1 DBD does not appear to be transcriptionally active
and should therefore be more similar to V control. This clustering suggests that the FOXM1
DBD mutant retains functions independent of FOXM1 transcriptional activity. Furthermore,
Cyclin E1-expressing FTE cells did not cluster with the other cell types suggesting it has
a signaling profile that is distinct. Next, the heatmaps were sorted based on ranked
expression by either FOXM1 wild-type, FOXM1 DBD mutant or Cyclin E1, and the top 10
proteins were compared (Figure 32B-D). We observed that Cyclin E1 showed very
dramatic changes in the expression of proteins involved in regulation of the G1/S and
G2/M checkpoints (Figure 32D). FOXM1 wild-type showed very few changes in cell cycleassociated proteins except for Cyclin B1, which promotes G2/M progression (Figure 32B).
Lastly, the FOXM1 DBD mutant did not show changes in the expression of proteins that
promote G2/M progression (Figure 32C).

FOXM1 directly interacts with proteins involved in DNA replication and epigenetic
modification
Our analysis of FOXM1 RNA-seq and RPPA did not identify obvious changes in
gene or protein expression that could explain the increased fork movement and origin
firing in FTE cells expressing FOXM1. This suggests that this phenotype is independent
of FOXM1 transcriptional activity or changes in defined downstream protein levels or
signaling pathways. We next hypothesized that FOXM1 may interact with chromatin or
proteins involved in DNA replication or chromatin modification, potentially facilitating fork
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movement. In this context, a recent high-throughput proteomics study characterized
protein-protein interactions for several transcription factors, including FOXM1 (184).
Intriguingly, FOXM1 was shown to interact with MCM and ORC proteins, proteins involved
in DNA replication initiation and elongation, along with known interactions related to its
canonical function in the activation of target gene expression (184). Furthermore, pathway
analysis showed that FOXM1 protein interactions were enriched in processes such as
chromatin modification, DNA replication and transcription (184). FOXM1 protein interacts
with proteins that modify chromatin such as DNMT3b (185), and besides this recent report,
its interaction with proteins involved in DNA replication has not been explored. FOXM1
could interact with DNA replication proteins and thus alter fork movement as we observed
(Figure 28). To this this hypothesis, we performed co-immunoprecipitation (co-IP) studies
with HA-tagged FOXM1 wild-type isoforms (a, b and c) and FOXM1 DBD mutant
constructs expressed in 293T FOXM1 knockout cells (Figure 33A-B). Surprisingly, all
FOXM1 isoforms, including the DBD mutant, similarly interacted with DNA replication
proteins (Figure 33C). Our studies were performed with total cell protein so it’s possible
that the interactions exist within different compartments of the nucleus such as soluble
and chromatin fractions. More so, the FOXM1 DBD mutant could be interacting with these
proteins but the protein complexes are not able to bind DNA, thus interfering with their
functions at chromatin. In an independent experiment, we previously investigated the
interaction between FOXM1 and DNA methyltransferases (DNMTs) based on a previous
report showing the interactions of these proteins (185). We indeed observed that FOXM1
interacts with DNMT1, DNMT3A and DNMT3B, further supporting the protein-protein
interactions between FOXM1 and proteins involved in DNA replication (Figure 33D).
However, we do not know yet if these protein-protein interactions occur in the nucleus, on
chromatin, or at sites of DNA replication. In agreement with these data and support for the
localization of the protein-protein interactions, we retrieved publicly available FOXM1 and
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ORC2 ChiP-seq datasets generated from K562 cells and determined the genome-wide
correlation in their DNA binding. We observed that FOXM1 and ORC2 show a highly
significant correlation in their DNA binding, indicated by the shifted foreground peak
compared to background for both replicates (Figure 34A-B). Together, these data suggest
that FOXM1 interacts with ORC2 on chromatin and possibly at sites of DNA replication.

FOXM1 functions downstream of Cyclin E1 to promote cell cycle progression
Thus far, our data shows that Cyclin E1 promotes progression through the G1/S
checkpoint, which contributes to DNA replication stress and DNA damage, ultimately
leading to arrest in G2. Furthermore, FOXM1 target genes are activated downstream of
Cyclin E1 in FTE cells. Based on the FOXM1 gene expression signature and cell cycle
data, we hypothesized that FOXM1 may cooperate with Cyclin E1 to overcome G2
blockage and allow unscheduled entry into mitosis with damaged DNA, thus contributing
to genomic instability. To test this, we expressed FOXM1 wild-type or DBD mutant in the
backdrop of Cyclin E1 expression in FTE cells (Figure 35A). These cells were doxycycline
induced for a period of 72 hours then harvested for cell cycle analysis (Figure 35A-B).
Importantly, we observed that FOXM1 wild-type promoted cell cycle progression through
the G2/M checkpoint, as shown by the increase in G1 phase and decrease in G2/M phase
compared to the empty vector control (Figure 35B). Conversely, the FOXM1 DBD mutant
compounded the Cyclin E1-mediated G2/M arrest as shown by the increased G2/M cells
(Figure 35B). Notably, these data suggest that FOXM1 functions downstream of Cyclin E1
in a cooperative fashion to promote cell cycle progression in cells experiencing oncogeneinduced DNA replication stress, allowing premature mitotic entry with damaged DNA,
promoting genomic instability.
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FOXM1 transcriptional activity is enhanced by Cyclin E1 in FTE cells
We previously observed that FOXM1 is expressed downstream of Cyclin E1 in
FTE cells (Figure 19G-H). Furthermore, FOXM1 and many of its targets were shown to be
overexpressed in our RNA-seq analyses of FTE cells expressing Cyclin E1, and GSEA
showed the FOXM1 pathway to be a significantly enriched gene expression signature
(Figure 30A-B). Therefore, based on previous reports showing that Cyclin E1-CDK2
phosphorylates FOXM1, increasing its transcriptional activity (186-188), we hypothesized
that FOXM1 would be more transcriptionally active in the FTE cells when co-expressed
with Cyclin E1. To test this, we engineered FTE cells for doxycycline inducible expression
of Cyclin E1 and vector control, or Cyclin E1 and FOXM1 wild-type. We grew cells in the
presence of doxycycline for 48 hours then proceeded with RNA-seq analysis to determine
if Cyclin E1 enhances FOXM1 transcriptional activity (Figure 36A-B). We then compared
the top differentially expressed genes that clustered together in the heat map to determine
if there was visual difference in overall transcriptional activity between FTE cells
expressing FOXM1 or Cyclin E1 alone, or FOXM1 and Cyclin E1 together. We observed
that FTE cells expressing both FOXM1 and Cyclin E1 have a striking gene expression
pattern showing increased transcriptional activity compared to FOXM1 or Cyclin E1 alone
(Figure 37A). To validate these findings, we performed RT-qPCR to measure the
expression of FOXM1 canonical target genes. We observed that FTE cells expressing
both wild-type FOXM1 and Cyclin E1 showed the highest expression for FOXM1 target
genes, but the expression of Cyclin E1 with FOXM1 DBD mutant did not show a difference
when compared to Cyclin E1 alone (Figure 37B-D). These data and the cell cycle data
suggest that Cyclin E1 increases the transcriptional activity of FOXM1, thus promoting
increased cell cycle progression.
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Dual FOXM1 and Cyclin E1 expression induces an enriched genomic instability
gene expression signature in FTE cells
FOXM1 expression has been linked to genomic instability by its inclusion in the
CIN25/CIN70 expression signature (37). However, the mechanistic relationship between
FOXM1 and genomic instability is not known. Furthermore, the CIN70 expression
signature contains many of the FOXM1 target genes and has been used as a readout for
genomic instability. Therefore, we hypothesized the FTE cells expressing FOXM1 may
show an enriched gene expression signature for CIN70, which is an extended version of
the CIN25 gene expression signature. To test this, we generated a GSEA CIN70 geneset
and performed GSEA analysis with the RNA-seq data from FTE cells expressing FOXM1.
We observed a significantly enriched CIN70 gene expression signature when FOXM1 was
expressed in FTE cells (Figure 38A). Our data show that Cyclin E1 expression in FTE
cells induced DNA replication stress, DNA damage and showed an enriched FOXM1
pathway gene expression signature. We next performed GSEA analysis to determine if
FTE cells expressing Cyclin E1 have an enriched CIN70 gene expression signature. We
observed that Cyclin E1 expression showed a significantly enriched CIN70 gene
expression, and the enrichment was greater than FOXM1 (Figure 38B). We have shown
that Cyclin E1 enhances the transcriptional activity of FOXM1, thus promoting increased
cell cycle progression. Therefore, we hypothesized that FTE cells expressing both FOXM1
and Cyclin E1 would have the greatest enrichment in the CIN70 gene expression
signature. We performed GSEA analysis and observed that FTE cells expressing both
FOXM1 and Cyclin E1 had greater enrichment in the CIN70 gene expression as compared
to Cyclin E1 or FOXM1 alone (Figure 38C). We next generated a heatmap to compare the
overall expression of the CIN70 genes among FTE cells expressing FOXM1, Cyclin E1 or
both FOXM1 and Cyclin E1. Visually, FTE cells expressing both FOXM1 and Cyclin E1
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showed the greatest expression of CIN70 genes followed by Cyclin E1 and FOXM1
(Figure 38D).

HGSC tumors with overexpression of both FOXM1 and Cyclin E1 show increased
genomic instability
Our data show that Cyclin E1 induces FOXM1 expression and enhances its
transcriptional activity, promoting cell cycle and genomic instability. This phenotype is
stronger when FOXM1 is overexpressed together with Cyclin E1. To determine this
relationship in HGSC, we compared the frequency of FOXM1 and CCNE1 copy number
gains in TCGA HGSC to determine if they tend to co-exist. We found that FOXM1 and
CCNE1 copy number gain and amplification have a highly significant tendency to co-occur
in HGSC (Figure 39A). We then tested if the co-occurring copy number gain contributed
to increased FOXM1 and Cyclin E1 protein expression. We found that HGSC tumors with
both FOXM1 and Cyclin E1 copy number gain and amplification showed the highest level
of FOXM1 and Cyclin E1 protein expression (Figure 39B) compared to either one alone.
Furthermore, FOXM1 and Cyclin E1 protein expression showed a highly significant direct
correlation thus providing additional support for cooperativity in HGSC (Figure 39C). FTE
cells expressing both FOXM1 and Cyclin E1 showed increased enrichment in the CIN70
gene expression signature (Figure 38C-D). We hypothesized that HGSC tumors with both
FOXM1 and CCNE1 copy number gain would have increased genomic instability as
compared to either one alone. To test this, we compared the fraction of the copy number
altered genome among HGSC tumors that had copy number amp/gain for both FOXM1
and CCNE1, FOXM1 or CCNE1 alone, or neither. In agreement with the GSEA analysis
for CIN70 enrichment in FTE cells, we found that HGSC tumors with both FOXM1 and
CCNE1 copy number increase had a significantly higher level of genomic instability,
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followed by Cyclin E1 alone then FOXM1 alone and neither (Figure 39D). Collectively,
these data suggest that FOXM1 and Cyclin E1 may cooperate to promote genomic
instability in HGSC.

Summary
In this study we compared the expression of FOXM1 and markers of genomic
instability and DNA replication stress. We found that FOXM1 expression correlates with
genomic instability and DNA replication stress markers, thus providing a mechanism link
between FOXM1 and genomic instability. We next overexpressed FOXM1 in fallopian tube
cells and found increased expression of P-CHK1, a marker of DNA replication stress.
Furthermore, FOXM1 expression in FTE cells resulted in increased DNA damage
measured with -H2AX expression and Comet assays. Cell cycle analysis revealed a
phenotype that suggested cell cycle progression, not DNA replication stress. However,
the expression of the FOXM1 DBD mutant showed a cell cycle profile indicative of DNA
replication stress. Therefore, we next performed DNA fiber analysis in fallopian tube
engineered for doxycycline inducible expression of FOXM1 wildtype and DBD mutant, and
Cyclin E1 to characterize the DNA replication dynamics. We unexpectedly observed that
FOXM1 expression in FTE cells increased fork rate and origin firing, but even more
surprising, the FOXM1 DBD mutant decreased fork rate. To determine how FOXM1 may
increase fork rate, we performed RNA-seq analysis to identify gene expression signatures
contributing to this phenotype. We found that FOXM1 showed enriched gene expression
for canonical FOXM1 target genes, specifically that promote G2-M progression and
mitosis, but we did identify enriched genesets for DNA replication or chromatin
modification. FOXM1 has recently been reported to interact with proteins involved in DNA
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replication, suggesting the increased fork rate and origin firing that we observed might be
independent of FOXM1’s canonical role as a transcription factor. We tested if FOXM1
interacted with proteins involved in DNA replication initiation and found that it not only
interacted with these proteins, but it also interacted with other chromatin modifying
proteins, DNA methyltransferases.
RNA-seq analysis revealed that the FOXM1 pathway is activated downstream of
Cyclin E1 overexpression in FTE cells. Cyclin E1 expression showed a strong DNA
replication stress phenotype and increased DNA damage. Taken together, this suggests
that FOXM1 might play dual oncogenic roles downstream of Cyclin E1: 1) to promote DNA
fork movement; and 2) to promote cell cycle progression and genomic instability. We found
that co-expression of FOXM1 with Cyclin E1 partially rescued the cell cycle abrogation but
both FOXM1 and Cyclin E1 expression promote DNA damage. These findings suggest
that FOXM1 promotes genomic instability downstream of Cyclin E1 by promoting mitotic
entry. In support, we found that co-expression of FOXM1 and Cyclin E1 produced a gene
expression signature that had a significant overlap with the CIN70 gene expression
signature. In agreement, TCGA HGSC tumors with copy number gain for both FOXM1
and CCNE1 showed increased genomic instability.

Figures
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Figure 22.
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Figure 22. FOXM1 relationship with DNA replication stress and genomic instability
in TCGA HGSC. A-B. FOXM1 A. mRNA (RNA-seq) and B. protein (RPPA) correlation
with P-CHK1-S345 protein (RPPA) in TCGA HGSC. C-D. FOXM1 C. mRNA (RNA-seq).
and D. protein (RPPA) correlation with mutation burden in TCGA HGSC. E-F. FOXM1. E.
mRNA (RNA-seq) and F. protein (RPPA) correlation with fraction of the copy number
altered genome in TCGA HGSC. G-H. FOXM1 G. mRNA (RNA-seq) and H. protein
(RPPA) correlation with fraction of the copy number altered genome in TCGA HGSC
FOXM1 diploid samples.
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Figure 23. FOXM1 relationship with markers of DNA replication stress in CCLE pancancer and ovarian cancer cell lines. A. FOXM1 protein expression (RPPA) correlation
with P-CHK1-S345 protein expression (RPPA) in CCLE pan-cancer cell lines. B. FOXM1
protein expression (RPPA) correlation with P-CHK1-S345 protein expression (RPPA) in
CCLE ovarian cancer cell lines.
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Figure 24. FOXM1 expression correlates with DNA replication stress markers in FTE
and HGSC cells. A. Western blot analysis of canonical markers of DNA replication stress
among a panel of HGSC cells compared to FTE cells. B. Western blot analysis of P-CHK1S345 for FTE cells with increasing FOXM1 expression.
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Figure 25. FOXM1 transcriptional activity is required for DNA replication stress and
DNA damage in FTE cells. A. 6X FOXM1 reporter activity with FTE cells expressing
FOXM1 wild-type (WT) or FOXM1 DBD mutant (MT). B. CCNB1 mRNA expression
measured by RT-qPCR for FTE cells expressing FOXM1 wild-type (WT) or FOXM1 DBD
mutant (MT). C. Western blot analysis of canonical DNA replication stress markers for
FTE cells expressing FOXM1 wild-type (WT) or FOXM1 DBD mutant (MT). D. Comet
assay comparing percent DNA in tail for FTE cells expressing FOXM1 wild-type (WT) or
FOXM1 DBD mutant (MT). t-test P value is shown. P value designation: **** < 0.0001, ***
< 0.001, ** < 0.01, * < 0.05.
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Figure 26. FOXM1 promotes DNA replication stress and DNA damage in FTE cells.
A. Western blot analysis for markers of DNA damage and replication stress in FTE cells
engineered for doxycycline inducible V control, FOXM1 and Cyclin E1 expression and
grown for 72 hours in presence of 1 µg/ml of doxycycline. B. Western blot analysis for
markers of DNA damage and replication stress with FTE cells engineered for constitutive
expression of V control, FOXM1 and Cyclin E1. 2 mM Hydroxyurea (HU) and 20 µM
etoposide were used as positive controls to induce DNA replication stress and DNA
damage. C. Comet Analysis for cells in panel B. D. FACS analysis of γ-H2AX positivity in
S phase for FTE cells engineered for constitutive expression of V and FOXM1. 20 µM
etoposide was used as positive control to induce DNA damage. t-test P value is shown. P
* < 0.05.
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Figure 27. Cell cycle analysis of FTE cells expressing FOXM1 or Cyclin E1. A.
Western blot analysis of FTE cells engineered for inducible expression of V, FOXM1 wildtype (WT), FOXM1 DBD mutant (MT), and Cyclin E1, and grown in the presence of
doxycycline for 72 hours. B. Cell cycle analysis of FTE cells engineered for inducible
expression of V, FOXM1 wild-type (WT), FOXM1 DBD mutant (MT), and Cyclin E1, and
grown in the presence of doxycycline for 72 hours.
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Figure 28. DNA fiber analysis in FTE cells. A. Fork velocity for inducible FTE cells
expressing V control, FOXM1 wild-type (WT), FOXM1 DBD mutant (MT) or Cyclin E1
grown in the presence of doxycycline for 72 hours. Data represents a composite of two
independent experiments. Median lines shown for all samples. B. The median fork velocity
for the above data. C. Origin firing for inducible FTE cells expressing V control, FOXM1
wild-type (WT), FOXM1 DBD mutant (MT) or Cyclin E1 grown in the presence of
doxycycline for 72 hours. Data represents the average of two experiments with at least
150 fibers analyzed for each group. P value designation: **** < 0.0001, *** < 0.001, ** <
0.01, * < 0.05.
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Figure 29. RNA-sequencing with FTE cells expressing V control, FOXM1 or CCNE1.
Inducible FTE cells expressing V control, FOXM1, or CCNE1 were grown in the presence
doxycycline for 48 hours and cells were harvested for RNA or protein. Sample were
prepared in triplicate for each group. A. Western blot analysis of FOXM1 and CCNE1
protein expression. B. RNA sequencing performance characteristics.
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Figure 30. FOXM1 and Cyclin E1 enriched pathway signatures. A-B. GSEA analysis
of the top two hallmark pathways for FTE cells expressing CCNE1. A. DNA replication
and B. FOXM1 pathway. C-D. GSEA analysis of the top two hallmark pathways for FTE
cells expressing FOXM1. C. FOXM1 pathway and D. G, G2/M phases. Enrichment as a
function of FTE cells expressing FOXM1 or CCNE1 using RNA-seq expression data.
Normalized enrichment score (NES), and false discovery rate q values (FDR) are shown.
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Figure 31. Validation of top differentially expressed genes from the RNA-seq
analysis for FTE cells expressing FOXM1 compared to FOXM1 knockdown and
CCNE1 expression. A-D. A. CCNA2 B. CCNB1 C. CDC25B and D. BRCA2 mRNA
expression measured by RT-qPCR from FTE cells expressing control or FOXM1 targeting
shRNA, empty vector, FOXM1 wild-type (WT), FOXM1 DBD mutant (MT) or Cyclin E1.
BRCA2 mRNA did not show differential expression in the RNA-seq analysis, but instead
was included used as a negative control.
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Figure 32. Heat-maps of RPPA data for FTE cells expressing V, FOXM1 wild-type,
FOXM1 DBD mutant, and Cyclin E1. A. Heat map showing unsupervised hierarchical
clustering of log2 normalized median centered RPPA from FTE cells grown in the
presence of 1 µg/ml doxycycline for 72 hours. Samples were performed in triplicate and
averaged. B-D. Top 10 proteins for FOXM1-wild-type (WT), FOXM1-DBD-mutant (MT)
and Cyclin E1, respectively.
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Figure 33. FOXM1 interacts with protein involved in DNA replication and chromatin
modification in 293T cells. A-B. 293T cells with CRISPR-mediated homozygous deletion
of FOXM1 using guide RNAs that targeted near the start and stop codons. Homozygous
deletion of FOXM1 was confirmed by A. PCR genotype and B. Western blot analysis. C.
293T FOXM1 knockout cells were transfected with empty vector, vector expressing HA
tagged GFP, FOXM1 isoforms a, b, c or FOXM1c DBD mutant (MT). Protein was
harvested 24 hours post transfection for co-IP and Western blot analysis. D. Parental 293T
cells were transfected with HA tagged GFP or FOXM1b. Protein was harvested 24 hours
post transfection for co-IP and Western blot analysis.
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Figure 34. Genome-wide correlation of FOXM1 and ORC2 DNA binding. A-B.
StereoGene plots showing correlation between FOXM1 and ORC2 DNA binding across
the genome using K562 ChIP-seq data retrieved from NCBI GEO. The x axis shows the
correlation value and y axis shows the density of genomic regions. The blue line
represents the foreground correlation or correlation between FOXM1 and ORC2 binding
the same genomic location. The red line represents background shuffling or correlation of
random genomic windows. The p value represents the difference between the foreground
and background distribution. ORC2 ChIP-seq vs FOXM1 ChIP-seq A. replicate 1 and B.
replicate 2.
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Figure 35. Cell cycle analysis of FTE cells expressing Cyclin E1 and/or FOXM1 wildtype and FOXM1 DBD mutant. A-B. Inducible FTE cells expressing CCNE1 and empty
vector control, CCNE1 and FOXM1 wild-type (WT) or CCNE1 and FOXM1 DBD mutant
(MT) were grown in the presence of doxycycline for 72 hours before harvesting cells for
protein or for cell cycle. A. Western blot analysis. B. Cell Cycle analysis. Data was
performed in duplicate replicates and repeated three times.
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Figure 36. RNA-sequencing with FTE cells expressing CCNE1 and V control or
CCNE1 and FOXM1 wild-type. Inducible FTE cells expressing CCNE1 and V control or
CCNE1 and FOXM1 were grown in the presence doxycycline for 48 hours and cells were
harvested for RNA or protein. Sample were prepared in triplicate for each group. A.
Western blot analysis of FOXM1 and CCNE1 protein expression. B. RNA sequencing
performance characteristics.
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Figure 37. Cyclin E1 enhances FOXM1 transcriptional activity. A. Heat map shows
647 genes with significant upregulation in FTE cells expressing FOXM1, CCNE1, or
FOXM1 and CCNE1. Heat map values represent log2 fold change from triplicate replicates
normalized to v control. Heat map color is normalized to the row. B. Validation of top
differentially expressed genes in the RNA-seq analysis B-D. B. CCNB1 C. CDC25B and
D. CCNA2 mRNA expression measured by RT-qPCR with FTE cells expressing empty
vector, FOXM1 wild-type, CCNE1 and FOXM1 wild-type (WT) or Cyclin E1 and FOXM1
DBD mutant (MT).
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Figure 38.

119

Figure 38. CIN70 enriched gene signatures in FTE cells expressing FOXM1 and
CCNE1. A-C. GSEA analysis of CIN70 geneset with RNA sequencing expression data
from FTE cells expressing A. FOXM1, B. CCNE1 or C. FOXM1 and CCNE1, normalized
to FTE cells expressing V control. Normalized enrichment score (NES), and false
discovery rate q values (FDR) are shown. D. Heat map for CIN70 genes comparing the
overall expression among FTE cells expressing FOXM1, CCNE1, or FOXM1 and CCNE1.
Heat map values represent log2 fold change from triplicate replicates normalized to vector
control. Heat map color is normalized to the row.
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Figure 39.
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Figure 39. Frequent FOXM1 and CCNE1 copy number gain and expression
associate with genomic instability in HGSC. A. FOXM1 and CCNE1 number status in
TCGA HGSC tissues. Log odds ratio for tumors with both FOXM1 and CCNE1 Amp/Gain
vs FOXM1 or CCNE1 alone, or neither. B. FOXM1 and CCNE1 protein expression (RPPA)
compared HGSC tumors with both FOXM1 and CCNE1 Amp/Gain, FOXM1 Amp/Gain
only, CCNE1 Amp/Gain only or neither. The p value for ANOVA with post-test for linear
trend is shown. Lines represent group medians. D. FOXM1 protein expression (RPPA) vs
CCNE1 protein expression (RPPA) in TCGA HGSC tissues. D. Fraction of the copy
number altered genome compared in HGSC tumors with both FOXM1 and CCNE1
Amp/Gain, FOXM1 Amp/Gain only, CCNE1 Amp/Gain only and neither. The p value for
ANOVA with post-test for linear trend is shown. Lines represent group medians.
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CHAPTER 5: FOXM1 AND RHNO1 BIDIRECTIONAL GENE PARTNERS PROMOTE
SURVIVAL AND CHEMORESISTANCE IN HIGH-GRADE SEROUS OVARIAN
CANCER

Introduction
Bidirectional gene partners make up approximately 10% of human genes and they
often function in similar pathways such as cell cycle and DNA repair (117). FOXM1 shares
an intergenic space with RHNO1, a protein that interacts with the 9-1-1 checkpoint clamp
to promote efficient ATR-CHK1 signaling in response to DNA replication perturbations and
contributes to the homologous recombination DNA repair pathway (100). FOXM1 has a
well-established role in cell cycle progression and proliferation but it has also been linked
to DNA repair and drug resistance via its ability to transactivate genes involved in these
phenotypes. However, our RNA-seq analysis of FTE cells engineered for FOXM1
overexpression did not show altered expression of genes involved in the DNA damage
response. Interestingly, we observed that FOXM1 promotes increased DNA replication
fork rate and interacts with proteins involved in DNA replication and chromatin
modification, suggesting that FOXM1 might promote fork movement via protein-protein
interactions. Furthermore, FOXM1 might promote fork progression in the presence of
endogenous or exogenous DNA damage, thus promoting proliferation in the presence of
damaged DNA. Together, considering our new findings for FOXM1 and the reported
function of RHNO1, we hypothesized that FOXM1 may play cooperative roles with RHNO1
in cell survival and chemotherapy resistance in HGSC. The objective of this study was 1)
to demonstrate that the intergenic space between FOXM1 and RHNO1 functions as a
bidirectional promoter; 2) to determine the relationship in expression between these
FOXM1 and RHNO1; and 3) to determine the functional contribution of FOXM1 and
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RHNO1 bidirectional gene partners to clonogenic survival, homologous recombination
DNA repair, and chemoresistance in HGSC cells.

Results
Genomic arrangement of FOXM1 and RHNO1 bidirectional partners at 12p13.33
We previously showed that FOXM1 is located at 12p13.33 and that this genomic
region is frequently amplified in HGSC. This region contains 32 other genes (Table 5), so
we performed analysis of the 12p13.33 region using UCSC Genome Browser and
observed that FOXM1 and RHNO1 are positioned in a head-to-head orientation with a
putative bidirectional promoter (Figure 40). This genomic configuration is observed in
approximately 10% of the human genes and is a feature of bidirectional genes pairs which
are frequently co-regulated and function in similar pathways (114,117,120). This
suggested that FOXM1 and RHNO1 have a bidirectional promoter and may be coregulated. The FOXM1/RHNO1 promoter region contains a CpG island which is a feature
of bidirectional promoters (Figure 40) (113,117,189). It was recently shown that
bidirectional promoters are enriched with histone modifications H3K4me3, H3K9ac,
H3K27ac, and H3K4me2 (118). Our analysis of ENCODE data revealed that
transcriptionally active histone marks, including H3K27Ac and H3K4me3, are enriched for
both FOXM1 and RHNO1, showing bimodal peaks, suggesting the bidirectional promoter
is active in both directions (Figure 40). In addition, the ENCODE data revealed the
presence of an E2F1 ChIP-seq peak in this region, which is consistent with E2F1’s known
involvement in bidirectional promoter regulation and our previous studies of FOXM1
(Figure 18-19) (81,190,191). These data suggest that FOXM1 and RHNO1 gene partners
share an active bidirectional promoter and therefore may be co-expressed.
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FOXM1 and RHNO1 expression in normal and cancer tissues
Based on the genomic arrangement of FOXM1 and RHNO1 bidirectional gene
partners, we hypothesized that their mRNA expressions would correlate in normal tissues
and cancer types. We first analyzed RNA-seq datasets from RIKEN normal mouse
tissues, GTEx normal human tissues, and TCGA pan-cancer tissues. We observed a
highly significant correlation between FOXM1 and RHNO1 mRNA expression in all
comparisons, showing this relationship is not restricted to normal or cancer tissues and is
conserved in mammals (Figure 41A-C). We next performed correlation of FOXM1 and
RHNO1 mRNA expression using the CCLE human pan-cancer cell line microarray dataset
to validate the correlation we observed in tissue samples. In agreement, the CCLE human
cancer cell lines showed a strong correlation between FOXM1 and RHNO1 mRNA
expression, and similar to normal and cancer tissues (Figure 41D).
We next used the TOIL TCGA dataset to compare the levels of FOXM1 and
RHNO1 mRNA expression in normal tissue versus primary, metastatic and recurrent pancancer tissues. We observed that FOXM1 and RHNO1 were overexpressed in primary,
metastatic and recurrent tumor as compared to normal tissue (Figure 42A). Furthermore,
we found that FOXM1 expression was lower than RHNO1 expression in normal tissues,
but the inverse was true in tumor tissues (Figure 42A). To follow-up this observation, we
used the TOIL TCGA GTEx dataset to compare the ratio of FOXM1 and RHNO1 mRNA
expression in normal and tumor tissues. In agreement, we observed that the expression
ratio was shifted toward RHNO1 in normal tissues but toward FOXM1 in tumor tissues
(Figure 42B). Based on these data, we hypothesized that tumors have an increased
proliferative index compared to normal tissue and FOXM1 is a proliferation associated
transcription factor; therefore, this ratio shift could be related to a difference in proliferative
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states. To test this, we normalized FOXM1 and RHNO1 mRNA expression to Ki67, a
canonical marker of proliferation, in TCGA normal and tumor tissues. In agreement with
our hypothesis, we observed that normalizing the FOXM1 and RHNO1 mRNA expression
to Ki67 resulted in similar expression ratios in normal and tumor tissues (Figure 42B).
These data suggest that increased proliferation, as indicated by Ki67 expression, has a
greater influence on FOXM1 expression than RHNO1 expression.

FOXM1 and RHNO1 expression in single cells from normal and cancer tissues
Our analysis of FOXM1 and RHNO1 mRNA expression has been limited to the
bulk RNA-sequencing data, which averages gene expression over a population of cells
and masks potential heterogeneity in expression. Our data thus far and previous studies
have shown bidirectional gene partners are frequently co-expressed (117,118,120);
however, it remains unknown if this correlation exists within single cells. Therefore,
measuring RNA expression at the single cell level would further the overall understanding
of bidirectional gene partners and, more importantly, provide data to test potential
cooperativity between FOXM1 and RHNO1. To test this, we analyzed publicly available
single cell RNA-seq datasets consisting of cells isolated from normal mouse intestinal
epithelium (Figure 43A), human melanoma (Figure 43B), and human high-grade serous
tumors (Figure 43C) (147-149). We observed a significant correlation between FOXM1
and RHNO1 mRNA expression at a single cell level (Figure 43A-C). Furthermore, the
correlation we observed among both bulk and single cell population was very similar
(Spearman r = 0.4 to 0.6) (Figures 41 and 43). These data show that FOXM1 and RHNO1
are expressed at the same time within a cell, thus providing additional support for potential
cooperativity.
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DNA methylation analysis of the FOXM1-RHNO1 bidirectional promoter
We observed that FOXM1 and RHNO1 expression were increased in cancer
compared to normal, and FOXM1 expression tended to show a more dramatic increase in
tumor samples. The FOXM1/RHNO1 promoter region contains a CpG island, and
promoter methylation has been shown to regulate other bidirectional promoters (192). We
hypothesized that differential methylation might contribute to these expression
differences. To test this, we performed in silico analysis of publicly available Illumina
Infinium HumanMethylation450 BeadChip Arrays performed on human cancer cell lines
(the GDSC1000 collection), as well as human normal and cancer tissues (TCGA). We
found the CpG island within the FOXM1/RHNO1 bidirectional promoter was
hypomethylated in all datasets (Figure 44). The 450K methylation array has a technical
limitation on the number of CpGs interrogated at a gene promoter, specifically within a
CpG island, so we next performed a comprehensive measurement of DNA methylation at
the FOXM1/RHNO1 bidirectional promoter using bisulfite clonal sequencing of normal and
EOC tumor tissues. In agreement with the 450K data, we found the promoter was
hypomethylated in both tissue (Figure 45). These data suggest that DNA methylation may
not regulate the FOXM1/RHNO1 bidirectional promoter, and that altered methylation does
not contribute to the increased FOXM1 and RHNO1 mRNA expression in human cancer
tissues (Figure 42A).

FOXM1 and RHNO1 copy number status and expression in HGSC
We previously made comparisons in FOXM1 and RHNO1 expression across
normal and pan-cancer tissue types and found a strong correlation, with increased
expression in tumor tissues. We next validated these findings in HGSC and determined if
copy number contributes to both FOXM1 and RHNO1 overexpression in HGSC. We first
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analyzed the TOIL TCGA GTEx RNA-seq dataset to compare FOXM1 and RHNO1
expression in normal fallopian tube tissue and primary HGSC tumors. We observed that
FOXM1 and RHNO1 were overexpressed and showed a strong correlation in their
expression (Figure 46A-B). We confirmed this correlation by measuring FOXM1 and
RHNO1 expression by RT-qPCR among a panel of HGSC tumors in our tumor bank
(Figure 46C).
We previously showed that FOXM1 is amplified in HGSC, contributing to its
increased expression. We next determined the copy number status for both genes, to test
as a contributing factor to their increased expression. We found that FOXM1 and RHNO1
copy number status was 100% concordant in HGSC tissues, suggesting that copy number
might contribute to their frequent overexpression (Figure 46D). To test if FOXM1 and
RHNO1 copy number status correlates with expression, we compared FOXM1 and
RHNO1 mRNA and copy number in TCGA HGSC data. We observed a progressive
increase in FOXM1 and RHNO1 expression with copy number status that was highly
significant (Figure 46E). This suggests that copy number contributes to the frequent
FOXM1 and RHNO1 expression in HGSC.
We next measured FOXM1 and RHNO1 mRNA in a panel of FTE, OSE, and
HGSC cells by RT-qPCR. In agreement with our comparison of GTEx fallopian tube and
TCGA HGSC tissues, we found that HGSC cells had significantly higher FOXM1 and
RHNO1 mRNA expression than FTE and OSE cells (Figure 47A). We tested the
relationship between FOXM1 and RHNO1 expression in CCLE HGSC cell lines and in
agreement, FOXM1 and RHNO1 showed a strong correlation (Figure 47B), which we
confirmed by RT-qPCR using a panel of HGSC cell lines (Figure 47C). Next, we
determined whether FOXM1 and RHNO1 exhibit similar copy number status in CCLE
HGSC cell lines. We observed 100% concordance in their copy number status (Figure
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47D), which agrees with the TCGA HGSC data. Additionally, we observed a striking
similarity in the frequency of FOXM1 and RHNO1 copy number in HGSC tissues and cell
lines (Figures 45D and 47D), which agrees with previous reports showing that these
HGSC cell lines are genomically similar to TCGA HGSC primary tumors (160). Further,
we found that copy number correlates with increased FOXM1 and RHNO1 mRNA
expression in cell lines (Figure 47E). To confirm these data, we compared FOXM1 and
RHNO1 mRNA expression by RT-qPCR using normal FTE and OSE, and HGSC cell lines
with differences in copy number status. We found that as FOXM1 and RHNO1 mRNA
expression increases as copy number increases (Figure 48A). We then measured FOXM1
and RHNO1 protein expression in a subset of these cell lines and, in agreement, protein
expression rises with copy number increases (Figure 48B). These data suggest that
increased copy number contributes to FOXM1 and RHNO1 overexpression in HGSC.

FOXM1 and RHNO1 expression in single FTE and HGSC cells
We previously made comparisons in FOXM1 and RHNO1 expression across
publicly available single cell RNA-seq datasets consisting of cells isolated from normal
mouse intestinal epithelium, and human melanoma and high-grade serous tumors (147149). We observed a significant correlation of FOXM1 and RHNO1 mRNA expression at
a single cell level. To directly test this relationship in FTE and HGSC cells, we performed
single cell RNA sequencing using immortalized fallopian tube epithelial cells and
OVCAR8, an HGSC cell line. We compared FOXM1 and RHNO1 mRNA expression in
FTE and OVCAR8 cells at the single cell level and observed a significant correlation
(Figure 49A-B), which agrees with the correlation that we observed from measuring
FOXM1 and RHNO1 mRNA by RT-qPCR from HGSC tissues and cell lines. Additionally,
we compared FOXM1 and RHNO1 expression between FTE and HGSC cells and, as
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expected, OVCAR8 cells had increased expression of both genes compared to FTE
(Figure 49C). Together, our expression data provide strong support of co-regulation and
potential cooperativity between FOXM1 and RHNO1.

FOXM1 and RHNO1 promoter shows bidirectional activity
We observed that FOXM1 and RHNO1 mRNA showed a strong correlation across
many cell and tissue types, in both bulk and single cell populations, including FTE and
HGSC; thus, we next tested their relationship in promoter activity in FTE and HGSC cell
models. We first performed 5’ RACE to determine the transcriptional start sites for both
genes, in order to experimentally define the bidirectional promoter, using immortalized
FTE and two HGSC cell lines. We found that the transcriptional starts sites and intergenic
distance are similar to those predicted by NCBI (Figure 50). Based on these data, we
cloned the FOXM1/RHNO1 bidirectional promoter into a reporter construct where FOXM1
drives the expression of Renilla luciferase and RHNO1 drives the expression of Firefly
luciferase (Figure 50 and 51A). This reporter construct and control constructs were cotransfected into immortalized FTE and a panel of HGSC cells. We first compared the
promoter activity in both directions and observed a direct correlation between FOXM1 and
RHNO1 promoter activities (Figure 51B). We next compared the promoter activity versus
endogenous mRNA expression for each gene and found a direct relationship between the
two, suggesting that the regulation of promoter activity contributes to the frequent coexpression of FOXM1 and RHNO1 (Figure 51C-D).
Thus far, we have measured activity of the FOXM1-RHNO1 bidirectional promoter
using a synthetic reporter construct. The endogenous FOXM1-RHNO1 bidirectional
promoter could be regulated differently, based on chromatin modifications and genomic
architecture. To overcome this limitation, we used a CRISPR activation system to study
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the endogenous bidirectional promoter, which uses a single guide RNA to recruit a
catalytically dead Cas9 fused to a transcriptional activator, VP64 (193). We designed
multiple guide RNAs to target within the bidirectional promoter and regions flanking it
(Figure 52A). We introduced the CRISPR activation system into FTE cells, which have
low FOXM1 and RHNO1 expression. Interestingly, we found that guide RNAs targeting
outside the bidirectional promoter, regions upstream of the transcriptional start site for one
gene and within the gene body for the other gene, induced the expression of the distal
gene (Figure 52B). In contrast, the guide RNA targeting within the bidirectional promoter
efficiently induced the expression of both FOXM1 and RHNO1 (Figure 52B). To
complement these findings, we tested if a CRISPR-KRAB system could repress the
bidirectional promoter in an HGSC cell line with high endogenous FOXM1 and RHNO1
expression. We selected the guide RNAs that targeted within the bidirectional promoter
and showed the strongest induction in gene expression in FTE cells and cloned them into
a CRISPR inhibition system, which uses a catalytically dead Cas9 fused to a
transcriptional repressor, KRAB (194). We then introduced the CRISPR inhibition system
into a high-grade serous cell line, OVCAR8, via lentiviral transduction. Importantly, we
found that the guide RNA targeting within the bidirectional promoter efficiently repressed
the expression of both FOXM1 and RHNO1 (Figure 52C). These data suggest that
frequent FOXM1 and RHNO1 expression is driven, in large part, by bidirectional promoter
regulation.

FOXM1 and RHNO1 promote HGSC cell clonogenic survival
An oncogenic role for FOXM1 has been reported in many different cancer types
including ovarian cancer; however, the contribution of RHNO1 to cancer, and particularly
the functional relationship between FOXM1 and RHNO1 has been unknown. We
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hypothesized that FOXM1 and RHNO1 contribute to growth and survival of HGSC cells,
as FOXM1 promotes cell cycle progression, and RHNO1 participates in the DNA
replication stress response (5,100). To test this, we engineered OVCAR8 and CAOV3 for
inducible FOXM1 and RHNO1 knockdown and performed clonogenic survival assays. In
agreement, either FOXM1 or RHNO1 knockdown suppressed the clonogenic survival of
OVCAR8 and CAOV3 HGSC cells (Figure 53A-C). To validate this finding, we conducted
CRISPR-Cas9 knockouts of FOXM1 and RHNO1 in two different HGSC cell lines
(OVCAR8 and CAOV3). In each case, we observed a significant diminishment in
clonogenic survival as compared to the sgRNA control (Figure 54A-C). Furthermore,
CRISPR-mediated knockout of FOXM1 or RHNO1 also increased the number of apoptotic
cells, supporting a specific role for each protein in cell survival (Figure 54D).
FOXM1 and RHNO1 knockdown and knockout both reduced HGSC cell
clonogenic survival. We next hypothesized that their combined loss may have a greater
impact on HGSC clonogenic survival than either alone. To test this, we engineered
OVCAR8 cells for dual FOXM1 and RHNO1 knockdown and performed clonogenic
survival assays in comparison to the individual knockdowns. We found that dual FOXM1
and RHNO1 inhibition had significantly reduced clonogenicity as compared to either single
knockdown (Figure 55A-C). These data suggest that FOXM1 and RHNO1 may cooperate
to promote cell survival.
To understand how FOXM1 and RHNO1 loss contributes to decreased survival,
we investigated the cell cycle dynamics following their loss. We observed that loss of
FOXM1 showed an increase of G2/M cells, which agrees with earlier FTE cell cycle data
for FOXM1 overexpression (Figure 56). RHNO1 loss showed an increase in S and G2
cells suggesting that its loss slowed progression through S phase (Figure 56). Importantly,
FOXM1 and RHNO1 loss together showed a greater increase in G2/M than either one
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alone (Figure 56). These data further support FOXM1 and RHNO1 cooperativity in the
growth and survival of HGSC cells.

FOXM1 transcriptional activity regulates genes involved in cell cycle and the G2/M
checkpoint
Unlike RHNO1, FOXM1 is linked to cell phenotypes through its function as a
transcription factor. Therefore, to better understand how the loss of FOXM1 reduced cell
survival, we performed RNA-seq analysis with OVCAR8 and CAOV3 cells following
FOXM1 knockdown (Figure 57A). We performed GSEA analysis with the RNA-seq
expression data, and both CAOV3 and OVCAR8 cells showed a significant enrichment in
a cell cycle gene expression signature, along with enriched mitotic and G2/M checkpoint
expression signatures, respectively (Figure 58A-D). The enriched G2/M checkpoint
signature agrees with our data obtained with FTE cells. Surprisingly, FOXM1 knockdown
did not show enriched gene expression signatures for DNA repair, which has been
reported for FOXM1 in other cell types, suggesting that FOXM1 has cell contextdependent differences in its transcriptional program (91,130). We validated the FOXM1
target gene expression by RT-qPCR and found that CAOV3 and OVCAR8 cells both
showed a decrease in target gene expression following FOXM1 knockdown (Figure 59AC). Furthermore, in agreement with our FTE data, RNA-seq analysis and RT-qCPR
measurement (Figure 59D) for HGSC cells with FOXM1 knockdown confirmed that the
DNA repair gene BRCA2 is not a target gene of FOXM1 in these cell models. Together,
this suggests that FOXM1 primarily regulates genes involved in cell cycle progression and
not DNA repair in HGSC cells.
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RHNO1 localizes to chromatin and interacts with the 9-1-1 complex to promote
efficient ATR-CHK1 signaling, genomic stability and cell survival in HGSC cells
RHNO1 was previously shown to contribute to the DNA replication stress response
by promoting ATR-CHK1 signaling via binding to the 9-1-1 clamp and TOPBP1 (21, 22).
Furthermore, we determined that RHNO1 loss in HGSC cells reduces clonogenic survival.
Therefore, we next investigated the role of RHNO1 in ATR-CHK1 signaling in FTE and
HGSC cells. To test whether RHNO1 augments the DNA replication stress response and
impacts DNA damage in FTE and HGSC cells, we knocked down RHNO1 using
doxycycline inducible shRNA in FTE and OVCAR8 cells, and measured P-CHK1-S345 by
Western blot. We observed ~2-fold reduction of P-CHK1-S345, a canonical readout of the
DNA replication stress response (Figure 60A-D). This effect size is similar in magnitude
to that reported in previous studies of RHNO1 (21, 22). RHNO1 loss impairs ATR-CHK1
signaling in HGSC cells and potentially impairs their ability to respond to endogenous
levels of DNA replication stress, resulting in increased DNA damage. To directly determine
whether RHNO1 knockdown impacts DNA damage, we used flow cytometry to measure
γ-H2AX as a function of cell cycle phase. We observed a significant increase in γ-H2AXexpressing cells in S and G2 phases. This was to a lesser extent than ATRi, as expected
(Figure 60E). In agreement, COMET analyses of DNA breakage revealed significant
increases with RHNO1 knockdown (Figure 60F).
RHNO1 interacts with 9-1-1 checkpoint proteins but these interactions have not
been investigated in ovarian cancer cells, nor in the context of treatments that specifically
cause DNA replication stress. To test if RHNO1 interacts with 9-1-1, we first
overexpressed HA-tagged wild-type and SWV mutant RHNO1 in 293T cells then coimmunoprecipitated RHNO1 protein complexes. The RHNO1-SWV, which has mutations
within the APSES DNA binding domain, was previously shown to has disrupt the
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interaction with 9-1-1 proteins but not TOPBP1 (Figure 61A) (100). As expected, Western
blotting of the immunoprecipitated protein complexes and cell lysates showed that wildtype RHNO1 interacts with RAD9 and RAD1 in 293T cells; however, RHNO1-SWV mutant
was deficient for these interactions (Figure 61B). We then tested if these interactions,
specifically RHNO1-RAD9, may be enhanced under conditions of DNA replication stress.
We overexpressed HA-tagged RHNO1 in 293T cells and treated the cells with
hydroxyurea (HU) prior to harvesting protein for co-immunoprecipitation, and observed
that RHNO1 and RAD9 interaction was enhanced with HU treatment (Figure 61C). Finally,
we investigated RHNO1 localization and 9-1-1 protein interactions in HGSC cells. We first
tested if endogenous RHNO1 localized to chromatin in OVCAR8 cells following HU
treatment. We observed that RHNO1 is present at chromatin without treatment, but HU
further enriched chromatin localization (Figure 61D). We then tested if RHNO1 interacts
with 9-1-1 proteins in OVCAR8 cells, and if this interaction was dependent on the APSES
DNA binding domain. We used an shRNA to knock down endogenous RHNO1 in
OVCAR8 cells then reconstituted the expression with HA-tagged wild-type and SWV
mutant, shRNA-resistant RHNO1 in a doxycycline inducible manner. Following
immunoprecipitation and Western blotting, we observed that wild-type RHNO1 interacts
with all 9-1-1 proteins and TOPBP1, but the RHNO1 SWV mutant only interacted with
TOPBP1 (Figure 61E). Together, these data provide strong support for RHNO1 as a
significant contributor to the DNA replication stress response and DNA damage protection
in HGSC cells.
Based on the data presented above, we hypothesized that RHNO1 wild-type, but
not SWV mutant, would rescue the decreased clonogenicity following loss of endogenous
RHNO1 in HGSC cells. To test this, we knocked down RHNO1 with an shRNA then reexpressed shRNA-resistant RHNO1 wild-type and SWV mutant and measured their ability

135

to rescue clonogenic survival in OVCAR8 cells (Figure 62A). We found that only wild-type
RHNO1 partially rescues the defect in clonogenic survival (Figure 62B). Next, to determine
if the reduced survival following RHNO1 loss is retained in non-cancer cells, we used
CRISPR to knock out RHNO1 in immortalized FTE cells and measured their viability
(Figure 63A-B). RHNO1 knockout and wild-type FTE cells showed no difference in
viability, but RHNO1 knockout and knockdown HGSC cells showed significant decrease
in survival as compared to control HGSC cells suggesting that HGSC cells have an
increased dependency on RHNO1 for growth survival as compared to non-transformed
FTE cells (Figure 63C).

FOXM1 and RHNO1 promote homologous recombination-mediated DNA repair
FOXM1 functions as a transcription factor to regulate the expression of genes
involved in a variety of essential processes, including cell cycle progression and DNA
repair. FOXM1 has also been shown to promote homologous recombination (HR) (195198). However, we observed that loss of FOXM1 in OVCAR8 cells did not alter the
expression of a gene involved in the DNA damage response, and more specifically,
BRCA2 which has been reported as a FOXM1 target gene (Figures 58 and 59). RHNO1
interacts with the 9-1-1 checkpoint clamp to promote ATR-CHK1 signaling upon exposure
of single stranded DNA resulting from end resection at a DNA double strand break or due
to helicase-fork uncoupling during DNA replication stress.
Together, based on their genomic arrangement, co-regulation, reported function,
and our novel data, we hypothesized that FOXM1 and RHNO1 may cooperatively promote
homologous recombination. To test this hypothesis, we used the well-established,
chromosomally integrated HR reporter assay, DR-GFP (direct repeat green fluorescent
protein system) in U2OS cells (127,128). These cells were chosen because they are the
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most widely used model to study factors that regulate HR. We engineered U2OS cells for
inducible FOXM1 and RHNO1 knockdown alone and in combination (Figure 64A). We
also engineered these cells for RAD51 knockdown as a positive control for HR impairment
(Figure 64B) (100). Upon transient transfection of the I-SceI expressing plasmid, we found
that U2OS DR-GFP cells had impaired HR efficiency following RAD51 knockdown, as
expected (Figure 64E). RHNO1 knockdown decreased HR efficiency, but surprisingly,
FOXM1 knockdown did not (Figure 64E). However, dual knockdown of FOXM1 and
RHNO1 showed a greater impairment in HR efficiency as compared to the knockdown of
RHNO1 alone, suggesting cooperativity (Figure 64E). We next used OVCAR8 DR-GFP
cells to validate these findings in a HGSC-relevant context. OVCAR8 cells have a
methylated BRCA1 promoter and show decreased BRCA1 expression but still maintain a
minimal level of HR proficiency (108). We engineered OVCAR8 cells for inducible FOXM1
and RHNO1 knockdown alone and in combination (Figure 64C). We also engineered
these cells for RAD51 knockdown as a positive control for HR impairment (Figure 64D)
(100). Similar to U2OS cells, in OVCAR8 cells, FOXM1 loss slightly reduced HR and
RHNO1 loss also reduced HR, but dual loss resulted in a more signification reduction in
HR proficiency (Figure 64F). These data indicate that both FOXM1 and RHNO1 promote
HR in HGSC cells and further suggest a functional interaction between these two genes.

FOXM1 and RHNO1 loss sensitizes HGSC cells to the PARPi olaparib
Homologous recombination (HR) is defective in about half of the HGSC tumors
primarily through BRCA1/2 mutations (30). Furthermore, HR can be impaired by defects
in other genes. HR-deficient tumors are highly sensitive to PARP inhibition due to the
excess of single strand breaks that ultimately are converted into double strand breaks
(DSBs) during DNA replication (45,48). Our data thus far suggests that FOXM1 and
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RHNO1 promote the DNA damage response, where we see decreased HR proficiency
following their loss. FOXM1 expression and its downstream targets have been linked to
the drug resistance for a wide variety of drugs in various cancer types including resistance
to platinum, paclitaxel and PARP inhibitors in epithelial ovarian cancer (130,199-201). In
addition, RHNO1 functions in the ATR-CHK1 signaling pathway in response to ssDNA
and dsDNA breaks, and intriguingly, it was recently reported that ATRi synergizes with
PARPi (202). These data suggest that RHNO1 loss may promote PARPi sensitivity
potentially in combination with FOXM1. A PARP inhibitor, olaparib, received FDA approval
in 2014 for the treatment of germline BRCA-mutated ovarian cancers after third-line
therapy (53,54). Furthermore, FOXM1 has been studied for its ability to sensitize ovarian
cancer cells to olaparib treatment (130,200). Therefore, we focused on the FOXM1 and
RHNO1 bidirectional gene partners to determine if their loss sensitizes HGSC cells to the
olaparib. To test this, we engineered OVCAR8 cells for single and dual inducible shRNA
mediated knockdown of FOXM1 and RHNO1. To determine the impact of FOXM1 and
RHNO1 loss on olaparib sensitivity, we knocked down FOXM1 and RHNO1 in OVCAR8
cells and determined the IC50 using AlamarBlue viability assays following 8 days of
treatment. We observed that FOXM1 and RHNO1 loss alone sensitized OVCAR8 cells to
olaparib treatment, while OVCAR8 cells with loss of both FOXM1 and RHNO1 had a
significant increase in sensitivity to olaparib (Figure 65A-B). To address a potential
mechanism whereby FOXM1 and RHNO1 loss promotes sensitivity to olaparib, we
characterized the cell cycle profile under the same conditions, and loss of both FOXM1
and RHNO1 resulted in an increased number of cells in G2/M as compared to either
knockdown alone (Figure 66). Together, our data suggest that FOXM1 and RHNO1 not
only play a role in maintaining a basal level of genomic stability, but they also promote
genomic stability when challenged with PARPi, suggesting they play cooperative roles in
the DNA damage response.

138

To validate these findings, we next used OVCAR8 cells with KRAB-mediated
inhibition of the FOXM1 and RHNO1 bidirectional promoter. We then determined the IC50
of olaparib with the AlamarBlue viability assay following 8 days of treatment. In agreement
with the shRNA knockdown data, we observed that the combined loss of FOXM1 and
RHNO1 sensitized OVCAR8 cells to olaparib treatment (Figure 67A-C). Next, we
measured the percentage of apoptotic cells following FOXM1 and RHNO1 loss after
PARPi treatment. We found OVCAR8 cells with FOXM1 and RHNO1 depletion had
increased apoptotic cells as compared to control (Figure 68A). Moreover, PARPi treatment
significantly increased cell death in the FOXM1- and RHNO1-depleted cells as compared
to control cells (Figure 68B). We performed cell cycle analysis on FOXM1- and RHNO1depleted cells following PARPi treatment. In agreement with the apoptosis data, we found
that OVCAR8 cells with FOXM1 and RHNO1 depletion had increased G2/M arrest as
compared to control when treated with PARPi (Figure 68B).

FOXM1 and RHNO1 loss re-sensitizes PARPi-resistant HGSC cells to olaparib
In vitro and in vivo experimental studies have confirmed that BRCA1/2 deficient
tumor cells are more sensitive to PARP inhibitors than are BRCA1/2 wild-type tumor cells
(45,46,203). However, only a fraction of BRCA1/2 mutation carriers respond to PARPi
therapy and even those who respond subsequently develop resistance (48,55-57). Thus,
a strategy to overcome PARPi resistance in BRCA-deficient cancers is needed to improve
this otherwise promising targeted therapy. In this context, we obtained two isogenic
derivatives of UWB1.289, a BRCA1 null HGSC cell line, that were treated in vitro with
olaparib, and subsequently developed acquired resistance in vitro (202). Furthermore,
these two PARPi-resistant BRCA1-deficient cell lines, SyR12 and SyR13, are dependent
on ATR for cell survival in the presence of PARPi, and GSEA analysis showed enriched
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G2/M checkpoints and activation of ATR signaling, respectively (202). We first validated
these cell lines by determining the IC50 of olaparib with the AlamarBlue viability assay after
8 days of treatment (Figure 69A). As expected, both PARPi resistant clones, SyR12 and
SyR13, had resistance to olaparib relative to parental cells. It was reported that the UWB1
clone SyR13 showed an enriched gene expression signature for ATR activation. We
measured ATR mRNA by RT-qPCR and observed that the SyR13 clone had increased
expression of ATR as compared to the parental line and resistant clone SyR12 (Figure
69B). These data suggest that FOXM1 and RHNO1 may show increased expression in
the PARPi-resistant clones. To test this, we performed RT-qPCR and observed that the
SyR13 clone had increased expression of FOXM1 and RHNO1 mRNA expression as
compared to the parental line and resistant clone SyR12 (Figure 69C).
Based on the reported data and our expression data together, we hypothesized
that targeting FOXM1/RHNO1 may re-sensitize these PARPi-resistant clones to olaparib.
To test this, we engineered UWB1.289 parental and PARPi-resistance cells for KRABmediated inhibition of the FOXM1/RHNO1 bidirectional promoter. We found that the KRAB
repressor targeting the FOXM1/RHNO1 bidirectional promoter efficiently silenced FOXM1
and RHNO1 mRNA expression in the PARPi-resistant cells (Figure 70A). We then tested
the olaparib sensitivity by assessing the IC50 after 8 days of treatment. We observed that
the loss of FOXM1 and RHNO1 re-sensitized both SyR12 and SyR13 PARPi-resistant
cells to olaparib by 3-fold and 4-fold, respectively, but did not completely restore the
sensitivity to the level observed in the UWB1 parental cells (Figure 70B-C). In support of
the magnitude of IC50 shift that we observed for olaparib with FOXM1 and RHNO1 loss in
both PARPi-resistant cells, an ATR inhibitor was reported to shift the IC50 by ~3-fold and
did not completely restore the sensitivity observed in parental cells (202). These data
suggest FOXM1 and RHNO1 targeting as a potential means to combat PARPi resistance.
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Furthermore, a FOXM1 inhibitor has very recently been reported to sensitize ovarian
cancer cell lines to PARPi treatment (130). Potentially FOXM1 inhibitors could be
combined with ATR inhibitors to re-sensitize PARPi-resistant cells to these agents.

Summary
Our analysis of 12p13.33 identified that FOXM1 shares a bidirectional promoter
with RHNO1, a gene shown to promote efficient ATR-CHK1 signaling. We hypothesized
that FOXM1 and RHNO1 would have frequent co-expression and play cooperative roles
in cell survival, HR and chemoresistance. Our analysis of in silico genomic data sets
showed a strong correlation between FOXM1 and RHNO1 mRNA expression in normal,
HGSC and pan-cancer tissues. The relationship was validated in our independent HGSC
tumor banks and HGSC cell lines and using scRNA analyses. In agreement with the
genomic analyses, we found that the FOXM1 and RHNO1 intergenic space functions as
a bidirectional promoter in immortalized FTE and HGSC cells. We found that depletion of
FOXM1 and RHNO1 reduced HR efficiency and survival in HGSC cells. Furthermore, we
found that FOXM1 promotes cell cycle progression and RHNO1 promotes ATR-CHK1
signaling, and this is dependent on interactions with the 9-1-1 checkpoint clamp. The
depletion of FOXM1 and RHNO1 promoted PARPi sensitivity in HGSC cells. Furthermore,
loss of FOXM1 and RHNO1 re-sensitized HGSC PARPi-resistant cells to olaparib. These
data support additional studies of FOXM1 and RHNO1 gene partners, specifically, to
further the understanding of HGSC biology through in vivo modeling of FOXM1 and
RHNO1, and to determine if RHNO1 and FOXM1 cooperate in normal and other cancer
cells. Broadly, these data support the study of other bidirectional gene partners to
determine their cooperativity in normal and cancer biology.
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Figures

Figure 40. Genomic features of the FOXM1/RHNO1 bidirectional gene partners.
UCSC Genome Browser (http://genome.ucsc.edu, human genome build hg19 with
genomic coordinates chr12:2,966,265-2,999,264) displaying FOXM1 and RHNO1 genes.
The following tracks are displayed in the browser: FOXM1 and RHNO1 mRNA, CpG
island, Encode E2F1, H3K4Me3 and H3K27Ac ChIP-seq track, and conserved genome
tracks 100 vertebrates and mammalian. The putative FOXM1/RHNO1 bidirectional is
highlighted with the light blue vertical line.
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Figure 41. FOXM1 and RHNO1 expression correlation in normal and cancer tissues.
A-D. FOXM1 and RHNO1 mRNA expression in A. Riken normal mouse tissues (RNAseq), B. GTEx normal human tissues (RNA-seq), C. TCGA pan-cancer tissues (RNA-seq)
and D. CCLE pan-cancer cell lines (microarray).
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Figure 42. FOXM1 and RHNO1 mRNA expression (RNA-seq) in normal and pancancer tissues. A. FOXM1 and RHNO1 expression (RNA-seq) in GTEx and TCGA
normal tissues and TCGA tumor tissues. B. FOXM1 and RHNO1 expression ratio in
normal and cancer, and Ki67 normalized ratio on the far right for TCGA normal and tumor
tissues.
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Figure 43. FOXM1 and RHNO1 mRNA expression correlation in single cell RNA-seq
from normal and cancer tissues. A. Single cells isolated from normal mouse epithelium
tissue (single cell RNA-sequencing) (GSE92332). B. Single cells isolated from human
melanoma tissue (single cell RNA-sequencing) (GSE72056). C. Single cells isolated from
HGSC primary tumors (single cell RNA sequencing) (Winterhoff et al, 2017).
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Figure 44. DNA methylation at the FOXM1/RHNO1 bidirectional promoter in TCGA
normal and tumor pan-cancer tissues, and CCLE pan-cancer cell lines. Beta values
represent the level of DNA methylation, averaged across 7 CpG sites within the
FOXM1/RHNO1 CpG island. A value of 1 is the highest level of methylation and 0 is the
lowest level of methylation.
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Figure 45. FOXM1/RHNO1 bidirectional promoter methylation analysis by bisulfite
sequencing. Sodium bisulfite clonal sequencing of the FOXM1/RHNO1 bidirectional
promoter region was performed on the indicated samples. The NCBI predicted TSS is
indicated by the red broken arrows. The intergenic space spans between the two arrows.
Filled and open circles indicate methylated and unmethylated CpG sites, respectively, and
each row represents one sequenced allele.
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Figure 46.
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Figure 46. FOXM1 and RHNO1 copy number and expression in HGSC tissues. A.
FOXM1 and RHNO1 expression (RNA-seq) in TCGA HGSC tissue as compared to GTEX
normal fallopian tube tissues. B. FOXM1 mRNA expression vs RHNO1 mRNA expression
(RNA-seq) from TCGA HGSC tissues. C. FOXM1 mRNA expression vs RHNO1 mRNA
expression from Karpf lab HGSC tissues. D. FOXM1 vs RHNO1 copy number from TCGA
HGSC tissues E. FOXM1 and RHNO1 mRNA expression (RNA-seq) correlated with copy
number in TCGA HGSC tissues. The p value for ANOVA with post-test for linear trend is
shown. Lines represent group medians. t-test P value is shown. P value designation: ****
< 0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 47.
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Figure 47. FOXM1 and RHNO1 expression in HGSC cell lines. A. FOXM1 and RHNO1
mRNA expression from FTE and OSE cell lines compared to HGSC cell lines as measured
by RT-qPCR. B. FOXM1 mRNA expression vs RHNO1 mRNA expression (microarray)
from CCLE HGSC cell lines. C. FOXM1 mRNA expression vs RHNO1 mRNA expression
from Karpf lab HGSC cell lines as measured by RT-qPCR. D. FOXM1 vs RHNO1 copy
number among CCLE HGSC cell lines. E. FOXM1 and RHNO1 mRNA expression
(microarray) correlated with copy number in CCLE HGSC cell lines. The p value for
ANOVA with post-test for linear trend is shown. Lines represent group medians. t test P
value is shown. P value designation: **** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 48. FOXM1 expression comparison in FTE and HGSC cell lines. A. FOXM1
and RHNO1 mRNA expression were measured RT-qPCR. B. FOXM1 and RHNO1 protein
expression were measured by Western blot. Lamin B and Histone H3 are shown as
loading controls. The arrow below panels A and B indicates the increasing FOXM1 and
RHNO1 copy number status from left to right.
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Figure 49. FOXM1 and RHNO1 mRNA expression in FTE and HGSC single cells. A.
FOXM1 and RHNO1 mRNA expression correlation among FTE single cells (single cell
RNA sequencing). B. FOXM1 and RHNO1 mRNA expression correlation among HGSC
single cells (single cell RNA sequencing). C. FOXM1 and RHNO1 mRNA expression
comparison in FTE and HGSC single cells. t-test P value is shown. P value designation:
**** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 50. FOXM1 and RHNO1 mapping of transcription start sites (TSS). RLM-RACE
mapping the 5' end of FOXM1 and RHNO1 mRNA. The red left and right arrows indicate
the orientation of each gene. The left y-axis indicates the sequenced clones from the
respective HGSC and FTE cell line. NCBI predicted TSS is show on the bottom. The green
line at the top indicates the bidirectional promoter cloned for reporter assays in subsequent
experiments. The bottom lines represent a scale in bp length.
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Figure 51. FOXM1/RHNO1 bidirectional reporter assay. A. FOXM1/RHNO1
bidirectional reporter construct with the promoter colored in green. FOXM1 drives Renilla
luciferase and RHNO1 drives Firefly. luciferase. Secreted embryonic alkaline
phosphatase (SEAP) was co-transfected and used as the internal normalization control.
B. Correlation of FOXM1 and RHNO1 promoter activity in a panel of FTE and HGSC cells.
C. Correlation of FOXM1 promoter activity and mRNA measured by RT-qPCR. D.
Correlation of RHNO1 promoter activity and mRNA measured by RT-qPCR.
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Figure 52.
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Figure 52. CRISPR mediated activation and repression of the endogenous
FOXM1/RHNO1 bidirectional promoter. A. FOXM1/RHNO1 bidirectional reporter and
guide RNAs indicated below. B. CRISPR mediated activation of the FOXM1/RHNO1
bidirectional promoter in FTE cells expressing synergistic activation mediator (VP64) and
a guide RNA targeting the bidirectional promoter and the corresponding changes in mRNA
expression as measured by RT-qPCR. C. CRISPR mediated inhibition of the
FOXM1/RHNO1 bidirectional promoter in HGSC cells expressing Krüppel associated box
(KRAB) transcriptional repressor and a guide RNA targeting the bidirectional promoter
and the corresponding changes in mRNA expression as measured by RT-qPCR. NT1 and
NT2 – non-targeting control guide RNAs.
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Figure 53.
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Figure 53. Clonogenic survival for HGSC cells following FOXM1 or RHNO1
knockdown. OVCAR8 and CAOV3 cells engineered for inducible FOXM1 or RHNO1
knockdown were seeded for protein extraction and Western blot or clonogenic survival. A.
Cells were grown in the presence of doxycycline for 72 hours to harvest protein followed
by Western blot analysis to confirm knockdown efficiency. B. Cells were seeded into a 6well dish, in triplicate, at a density of 500 or 1,000 cells, respectively. Doxycycline was
added at the time of seeding and media containing doxycycline was replenished every 48
hours. Clonogenic survival was measured at 12 and 14 days, respectively, after the cells
were fixed with methanol and stained with crystal violet. C. Colonies containing more than
50 cells were counted and clonogenic survival was quantified as an average of the
replicates. NS = non-targeting shRNA. t test P value is shown. P value designation: **** <
0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 54.
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Figure 54. Clonogenic survival for HGSC cells following FOXM1 or RHNO1
knockout. OVCAR8 and CAOV3 cells engineered for FOXM1 or RHNO1 knockout were
seeded for protein or clonogenic survival. A. Cells were for 72 hours to harvest protein
followed by Western blot analysis to confirm knockout efficiency. B. Cells were seeded
into a 6-well dish, in triplicate, at a density of 500 or 1,000 cells, respectively. Media was
replenished every 48 hours. Clonogenic survival was measured at 12 and 14 days,
respectively, after the cells were fixed with methanol and stained with crystal violet. C.
Colonies containing more than 50 cells were counted and clonogenic survival was
quantified as an average of the replicates. D. Total apoptotic cells for OVCAR8 FOXM1
or RHNO1 knockout cells was determined by Annexin V staining and FACS. Etoposide
was used a positive control CTL = non-targeting guide RNA. test P value is shown. P value
designation: **** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 55.
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Figure 55. Clonogenic survival for HGSC cells following FOXM1 and/or RHNO1
knockdown. OVCAR8 cells engineered for FOXM1 and/or RHNO1 knockout were
seeded for protein or clonogenic survival. A. Cells were seeded in the presence of
doxycycline and grown for 72 hours to harvest protein followed by Western blot analysis
to confirm knockdown efficiency. B. Cells were seeded into a 6-well dish, in triplicate, in
the presence of doxycycline at a density of 500 cells. Media containing doxycycline was
replenished every 48 hours. Clonogenic survival was measured at 12 days after the cells
were fixed with methanol and stained with crystal violet. C. Colonies containing more than
50 cells were counted and clonogenic survival was quantified as an average of the
replicates. NS = non-targeting shRNA. test P value is shown. P value designation: **** <
0.0001, *** < 0.001, ** < 0.01, * < 0.05.
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Figure 56. Cell cycle analysis of HGSC cells following knockdown of FOXM1 and/or
RHNO1. OVCAR8 cells engineered for FOXM1 and/or RHNO1 knockout were seeded in
the presence of doxycycline and grown for 72 hours to harvest cells for cell cycle analysis.
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Figure 57. RNA sequencing for HGSC cells with FOXM1 knockdown. CAOV3 and
OVCAR8 cells with inducible non-targeting or FOXM1 shRNA were grown in the presence
doxycycline for 48 hours and cells were harvested for RNA or protein. Sample were
prepared in triplicate for each group. A. Western blot analysis of FOXM1 protein
expression to confirm knockdown efficiency. B. RNA sequencing performance
characteristics.
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Figure 58. OVCAR8 and CAOV3 enriched pathway signatures. A-B. GSEA analysis
of the top two hallmark pathways for OVCAR8 FOXM1 knockdown cells A. Cell Cycle and
B. G, G2/M checkpoint. C-D. GSEA analysis of the top two hallmark pathways for CAOV3
FOXM1 knockdown cells C. Cell Cycle, mitotic and D. cell cycle. Enrichment analysis as
a function of OVCAR8 and CAOV3 with knockdown of FOXM1 using RNA-seq expression
data. Normalized enrichment score (NES), and false discovery rate q values (FDR) are
shown.
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Figure 59. Validation of top differentially expressed genes from the RNA-seq
analysis for HGSC cells with knockdown of FOXM1. A-D. A. CCNA2 B. CCNB1 C.
CDC25B and D. BRCA2 mRNA expression measured by RT-qPCR from CAOV3 and
OVCAR8 cells expressing control or FOXM1 targeting shRNA. BRCA2 did not show
differential expression in the RNA-seq analysis, but instead was included used as a
negative control.
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Figure 60.
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Figure 60. RHNO1 promotes ATR-CHK1 signaling in FTE and HGSC cells. FT282 and
OVCAR8 cells were engineered for doxycycline inducible RHNO1 knockdown. A-B.
Inducible FT282 RHNO1 knockdown cells were seeded and grown in the presence of
doxycycline for 72 hours to harvest RNA followed by A. RT-qPCR to confirm RHNO1
knockdown and protein followed B. Western blot analysis to measure the efficiency of
ATR-CHK1 signaling. Cells for protein harvest received 2-hour treatment with 2 mM HU
to induce DNA replication stress and ATR-CHK1 signaling. C-D. Inducible OVCAR8
RHNO1 knockdown cells were seeded and grown in the presence of doxycycline for 72
hours to harvest protein followed by Western blot analysis to C. confirm RHNO1
knockdown or D. measure the efficiency of ATR-CHK1 signaling at basal levels without
HU treatment. E-F. Under the same conditions in C-D, Cells were harvested for the E. yH2AX FACS analysis. ATRi was added at the indicated dose for 24 hours as a positive
control. or F. Comet Assay. t test P value is shown. P value designation: **** < 0.0001,
*** < 0.001, ** < 0.01, * < 0.05.
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Figure 61.
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Figure 61. RHNO1 interactions with 9-1-1 checkpoints proteins in 293T and OVCAR8
cells. A. Comparison of RHNO1 wild-type and SWV mutant proteins. The proteins are
the same molecular weight, but they are different for residues 55-61. The residues at 5561 were all converted to alanine for the SWV mutant, thus disrupting its ability to interact
with 9-1-1 checkpoint proteins. B. 293T were transfected with empty vector, vector
expressing HA tagged RHNO1 wild-type or SWV mutant. Protein was harvested 24 hours
post transfection for co-immunoprecipitation and Western blot analysis. C. 293T cells were
transfected with vector expressing HA tagged RHNO1 wild-type. Cells with treated with
vehicle or 5 mM HU for 1 hour at 24 hours post transfection then protein was harvested
for co-immunoprecipitation and Western blot analysis. D. OVCAR8 cells were seeded for
growth for 24 hours then treated with vehicle or 5 mM HU for 1 hour then cells were harvest
for subcellular fraction into soluble nuclear and chromatin bound protein followed by
Western blot analysis to determine RHNO1 localization. Histone H3 was used as the
chromatin control and Sp1 as the soluble nuclear control. E. OVCAR8 inducible RHNO1
knockdown cells were engineered for inducible expression of HA tagged RHNO1 wildtype or SWV mutant and grown in the presence of doxycycline for 72 hours then protein
was harvested for co-immunoprecipitation and Western blot analysis.
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Figure 62.
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Figure 62. RHNO1 interaction with 9-1-1 checkpoint clamp is important for survival
in HGSC cells. OVCAR8 inducible RHNO1 knockdown cells engineered for inducible
expression of HA tagged RHNO1 wild-type or SWV mutant were seeded for protein or
clonogenic survival. A. Cells were seeded in the presence of doxycycline and grown for
72 hours to harvest protein followed by Western blot to confirm knockdown efficiency. B.
Cells were seeded into a 6-well dish, in triplicate, in the presence of doxycycline at a
density of 500 cells. Media containing doxycycline was replenished every 48 hours.
Clonogenic survival was measured at 12 days after the cells were fixed with methanol and
stained with crystal violet. C. Colonies containing more than 50 cells were counted and
clonogenic survival was quantified as an average of the replicates. NS = non-targeting
shRNA. test P value is shown. P value designation: **** < 0.0001, *** < 0.001, ** < 0.01, *
< 0.05.
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Figure 63. RHNO1 knockout in FTE cells does not impact cell viability. Homozygous
deletion of RHNO1 in FT282 cells was achieved with CRISPR-Cas9 and guide RNAs that
targeted near the start and stop codon. A. RHNO1 homozygous knockout was confirmed
by A. PCR with genomic DNA and B. RHNO1 mRNA expression measure by RT-PCR. C.
FT282 parental and RHNO1 clonal knockout cells were seeded in quadruplicate and
grown for a period of one-week. Cell viability was measured with the AlamarBlue assay
every 24 hours.
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Figure 64.

175

Figure 64. FOXM1 and RHNO1 bidirectional gene partners promote HR in U2OS and
OVCAR8 cells. A-D. Cells were treated with doxycycline to induce shRNA expression
and knockdown was confirmed by measuring A and C. FOXM1 and RHNO1 mRNA
expression and B and D. RAD51 mRNA expression by RT-qPCR. E-F. Following
knockdown, the HR repair rate of I-SceI-induced DSBs was measured in E. U2OS and F.
OVCAR8 DR-GFP cells. Each value is relative to the percentage of GFP-positive cells in
I-SceI-transfected (U2OS) and transduced (OVCAR8) control cells. Results are shown as
mean ± SE from three independent experiments; Student’s t-test was used for
comparisons. RAD51 knockdown was used as a positive control. All results are shown as
mean ± SE from three independent replicates (*P < 0.05, **P < 0.01, ***P < 0.005).
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Figure 65.
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Figure 65. FOXM1 and RHNO1 knockdown sensitizes OVCAR8 cells to olaparib.
OVCAR8 cells engineered for FOXM1 and/or RHNO1 knockout were grown in the
presence of doxycycline for 72 hours prior to seeding cells for olaparib IC50 or clonogenic
survival. A. Cells were harvested then seeded in 96-well plates in quadruplicate in the
presence of doxycycline at a density of 500 cells per well. Twenty-four hours later cells
received media containing doxycycline and vehicle or olaparib, and this was repeated
every 48 hours. Cell viability was measured at 8 days using AlamarBlue and the IC50 for
olaparib was determined. B. Cells were harvested and seeded into a 6-well dish, in
triplicate, in the presence of doxycycline at a density of 5,000 cells per well. Twenty-four
hours later cells received media containing doxycycline and vehicle or olaparib, and this
was repeated every 48 hours. Media containing doxycycline was replenished every 48
hours. After 8 days of growth, cells were fixed with methanol and stained with crystal violet.
NS = non-targeting shRNA.
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Figure 66. OVCAR8 FOXM1 and/or RHNO1 knockdown cells show increased cell
cycle arrest following olaparib treatment. OVCAR8 FOXM1 and RHNO1 knockdown
cells were treated with olaparib for 24 hours and the corresponding changes in Cell cycle
analysis was were measured with PI staining.
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Figure 67.
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Figure 67. FOXM1/RHNO1 CRISPR inhibition sensitives OVCAR8 cells to olaparib
treatment. A. OVCAR8 cells expressing KRAB transcriptional repressor and a guide RNA
targeting the bidirectional promoter, and the corresponding changes in mRNA expression
as measured by RT-qPCR. NT1 – non-targeting guide RNA. B. Cells were seeded in 96well plates in quadruplicate at a density of 500 cells per well. Twenty-four hours later cells
received media containing vehicle or olaparib, and this was repeated every 48 hours. Cell
viability was measured at 8 days using AlamarBlue and the IC50 for olaparib was
determined. C. Cells were seeded into a 6-well dish, in triplicate, at a density of 5000 cells
per well. Twenty-four hours later cells received media containing vehicle or olaparib, and
this was repeated every 48 hours. After 8 days of growth, cells were fixed with methanol
and stained with crystal violet.
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Figure 68. OVCAR8 FOXM1 and RHNO1 depleted cells show increased cell death
and G2/M arrest after olaparib treatment. A-B. OVCAR8 cells expressing KRAB
transcriptional repressor and a guide RNA targeting the bidirectional promoter were
treated with olaparib for 24 hours and the corresponding changes in A. apoptosis were
measured by Annexin V staining and FACS, and B. cell cycle were measure measured
with PI staining. t test P value is shown. P value designation: **** < 0.0001, *** < 0.001, **
< 0.01, * < 0.05.
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Figure 69.
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Figure 69. Differential FOXM1 and RHNO1 expression and olaparib sensitivity for
UWB1.289 parental cells and isogenic PARPi resistant clones. A. Cells were seeded
in 96-well plates in quadruplicate at a density of 750 cells per well. Twenty-four hours later
cells received media containing vehicle or olaparib, and this was repeated every 48 hours.
Cell viability was measured at 8 days using AlamarBlue and the IC50 for olaparib was
determined. B-C. Cells were seeded and grown for a period of 72 hours before RNA was
harvested for RT-qPCR measurement of B. ATR mRNA expression and C. FOXM1 and
RHNO1 mRNA expression. t test P value is shown. P value designation: **** < 0.0001, ***
< 0.001, ** < 0.01, * < 0.05.
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Figure 70.
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Figure 70. Inhibition of FOXM1/RHNO1 in UWB1 resistant clones restores olaparib
sensitivity. UWB1 parental and PARPi resistant cells were engineered to express KRAB
transcriptional repressor and a control guide RNA or guide RNA targeting the bidirectional
promoter. A. Cells were seeded and grown for 72 hours to harvest RNA followed by RTqPCR to confirm knockdown efficiency. B-C. UWB1 parental KRAB and B. SyR12 KRAB
or C. SyR13 KRAB cells were seeded in 96-well plates in quadruplicate at a density of
750 cells per well. Twenty-four hours later cells received media containing vehicle or
olaparib, and this was repeated every 48 hours. Cell viability was measured at 8 days
using AlamarBlue and the IC50 for olaparib was determined. NT1 – non-targeting guide
RNA.
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CHAPTER 6: DISCUSSION AND FUTURE DIRECTIONS

Genetic Determinants of FOXM1 Expression in HGSC
Several mechanisms have been reported to contribute to FOXM1 overexpression
in cancer, including gene amplification, loss of negative regulation by p53, Rb, and
FOXO3, and transcriptional activation by E2F and Myc (2,73-76,81,82). To date, the
mechanisms underlying FOXM1 upregulation in HGSC have not been described, although
FOXM1 pathway activation is extremely frequent in this malignancy. Here we demonstrate
that, in HGSC, FOXM1 is upregulated at the transcriptional level by combined loss of Rb
and p53, and show that FOXM1 copy number gains correlate with increased FOXM1
expression in primary tumors and cell lines. Combinatorial loss of p53 and Rb in murine
and human OSE cells synergistically induced FOXM1 expression, and murine ovarian
cancer arising in a p53/Rb compound deletion model led to FOXM1 overexpression. In
addition, we demonstrate that E2F1 contributes to FOXM1 overexpression in cell models,
and closely correlates with FOXM1 expression in primary tumors. Genetic manipulation of
the RB-E2F pathway in FTE cell models further supports a role for their regulation of
FOXM1 expression in HGSC. Moreover, basal/TNBC breast cancer show similar patterns
of FOXM1 copy number gains as HGSC. Thus, our data establish p53 loss, RB-E2F
deregulation and copy number gain as positive regulators, of FOXM1 expression in EOC.
Consistent with our p53 data, it was recently shown that Nutlin 3 (an MDM2 inhibitor)mediated p53 activation repressed FOXM1 in EOC cells (204).
Consistent with our findings, loss of Rb function leads to activation of E2F
transcription factors (205), and two putative E2F sites have been identified in the FOXM1
promoter (81). Second, the Rb-E2F pathway is regulated by p21, a potent negative
regulator of cyclin-dependent kinases (CDKs) and a direct transcriptional target of p53.
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Therefore, functional loss of p53 may relieve p21-mediated repression of E2F1, which in
turn may promote FOXM1 expression. In agreement, prior work shows that p53-mediated
repression of FOXM1 is partially p21-dependent (74,81). p53-mediated negative
regulation of FOXM1 may also be independent of any effects on the Rb-E2F pathway,
although this remains to be determined. In addition to p53, Rb, and E2F1, other relevant
mechanisms of FOXM1 regulation involve Myc and FOXO3 (2,76). These may act
independently or in concert with p53 and Rb loss, and require further study using EOC
models.

Implications of FOXM1 Expression in HGSC
Importantly, a recent study showed increased FOXM1 IHC staining in STIC
lesions, early HGSC precursor lesions, and that FOXM1 expression is maintained in
invasive tumors (2). As TP53 mutations appear to be a ubiquitous early event in human
HGSC, and Cyclin E1 overexpression occurs in STIC lesions (2,155), we speculate that
during HGSC tumor progression, deregulation of the RB-E2F pathway and/or FOXM1
amplification, coupled with the p53 impairment already present, leads to high level FOXM1
expression. Consistent with this model, our data indicate that FOXM1 expression is
markedly elevated in late stage, high-grade disease. FOXM1 is not only expressed in STIC
lesions and HGSC tumors, but also in FTE stem cells (2,206). These observations suggest
that FOXM1 may have oncogenic potential that contributes both to early and late stages
of HGSC progression. To test this hypothesis and determine if FOXM1 is important for
HGSC development and/or progression, an HGSC mouse model should be engineered
for inducible and temporal regulation of FOXM1 expression in the fallopian tube
epithelium.
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FOXM1 has three known splice variants: FOXM1a, b, and c, which encode
proteins with varying activities (10). An earlier study showed that FOXM1c is the
predominant isoform expressed in pancreatic cancer, while another study showed that
FOXM1b is the major isoform expressed in other cancer types (79,207). FOXM1c has
alternative exon A1; residues in this region can be phosphorylated by the RAF/MEK/MAPK
signaling cascade, providing a distinction with FOXM1b (65). Considering the differential
expression and functional potential of different FOXM1 isoforms, it is important to
determine which variants are responsible for oncogenic activity in EOC. We performed a
comprehensive analysis of FOXM1 isoform expression in normal, HGSC and pan-cancer
tissue and cell lines to determine isoform expression profile and if normal and cancer show
differential isoform expression. We found that the predominant FOXM1 isoform expressed
in all contexts was FOXM1c. Furthermore, our cell cycle data suggests that FOXM1c, but
not FOXM1b, drives cell cycle progression in hOSE cells. In agreement, FOXM1c
promoted cell cycle progression in FTE cells. In contrast to the cell cycle phenotype, we
found that all FOXM1 isoforms interacted with DNA replication proteins suggesting these
isoforms may have important functions that are independent of their transcriptional activity.
This is especially true for FOXM1a which is transcriptionally inactive. Alternatively, FOXM1
isoforms may complement each other to perform certain functions and possibly regulate
each other through direct interaction, considering FOXM1 is capable of dimerizing
(208,209). However, the knowledge of FOXM1 dimerization has been in the context of
studies overexpressing a single isoform, FOXM1c and FOXM1b. In this setting, the
homodimerization has been shown to repress transcriptional function until posttranslational modifications relieve the protein-protein interaction, thus activating the
protein (209,210). Furthermore, the functional role and regulation of dimerization may be
cell context dependent based on the genetic background of the cell type, suggesting there
might be differences between normal and cancer cells. Therefore, it remains unknown if
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FOXM1 isoforms dimerize and if these interactions promote or inhibit function or give rise
to a new function. Notably, a recent study discovered the expression of additional isoforms
of FOXM1 in ovarian cancer and speculated that these isoforms may be constitutively
active (211).

FOXM1 and CCNE1 and Genomic Instability in HGSC
Prior to this study, the role of FOXM1 in DNA replication stress and genomic
instability had not been explored in HGSC, a disease characterized by FOXM1
overexpression and genomic instability. It was also unknown if FOXM1 promoted DNA
replication stress in any context. Many phenotypes associate with genomic instability
including increased proliferation, cell cycle progression and DNA replication stress, and
we show that FOXM1 is associated with these phenotypes in HGSC. STIC lesions have
both increased DNA damage and FOXM1 expression, suggesting they may be related. In
the current study, we demonstrated a role for FOXM1 in cell cycle progression using
primary and immortalized human HGSC precursor models and HGSC cell lines.
Additionally, it is plausible that FOXM1 overexpression, combined with p53 gain of function
mutations, may synergistically promote genomic instability in ovarian cancer. For example,
FOXM1 upregulation induced genomic instability in normal human keratinocytes, and
FOXM1 is a member of a conserved gene expression profile for genomic instability in
human cancer (37,85,89). Furthermore, p53 gain of function mutations can positively
regulate FOXM1 and correlate with higher levels of genomic instability as compared to
p53 null mutations (204,212).
Interestingly, we observed a novel phenotype for FOXM1 where FOXM1
overexpression in FTE cells increased DNA fork rate suggesting a novel form of DNA
replication stress unlike CCNE1 which decreased DNA fork rate. This phenotype appears
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to be independent of FOXM1 transcriptional activity, but instead related to FOXM1 protein
interacting with DNA replication proteins. However, this is speculative at this point and it
requires additional studies to confirm this mechanism. Based on the data in our study and
reports in the literature, it is possible that FOXM1 contributes to HGSC genesis and
progression, through its promotion of genomic instability in STIC lesions, and promoting
progression to HGSC. Notably, in our study, FOXM1 activation occurred downstream of
Cyclin E1. We found that CCNE1 increased the transcriptional activity of FOXM1,
promoted cell cycle progression and contributed to genomic instability. Cyclin E1 and
FOXM1 are both expressed in STIC lesions, thus supporting a potential role for
cooperativity in promoting genomic instability early in HGSC development (2,155).

FOXM1 and RHNO1 in HGSC Development and Progression
Our data thus far showed that FOXM1 and RHNO1 are frequently expressed in
normal and cancer cells and tissues. Importantly, HGSC shows overexpression of both
FOXM1 and RHNO1. The FOXM1/RHNO1 bidirectional promoter and copy number gains
contribute to their frequent co-expression, but DNA methylation does not appear to
regulate their expression. It remains unknown which transcription factors regulate the
bidirectional promoter. Bidirectional promoters are overrepresented with following
transcription factor motifs: GABPA, MYC, E2F1, E2F4, NRF-1, CCAAT, and YY1 (119).
E2F1 appears to be a potential candidate for future studies related to the regulation of the
bidirectional promoter based on our data showing a relationship between FOXM1 and
E2F1 expression. In agreement, the bidirectional promoter has two E2F motifs.
Additionally, FOXM1 is reported to regulate its own promoter through a positive feedback
loop suggesting it may also regulate the bidirectional promoter, thus promote RHNO1
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expression (213). However, we did not see a difference for RHNO1 expression in the
RNA-seq analysis from FTE cells expressing FOXM1 or HGSC with FOXM1 knockdown.
We focused on FOXM1 and RHNO1 in the context of HGSC cell lines, specifically
survival, genome stability and chemoresistance. Taken together, our data suggest a dual
role for FOXM1: 1) promoting genomic instability in FTE cells, which suggest that FOXM1
promotes genomic instability early in HGSC development, contributing to the evolution of
the disease, and 2) promoting genomic stability in HGSC cells, thus promoting survival
and chemoresistance in tumors. Therefore, it is important to further differentiate and
understand these phenotypes, but most importantly, to determine how RHNO1
contributes, in vitro and in vivo. FOXM1 has been studied for its ability to promote tumor
formation in mouse models, and it was necessary but not sufficient for tumor formation,
while RHNO1 has never been studied in vivo. Our data suggests cooperatives roles for
FOXM1 and RHNO1 using in vitro models, therefore, in vivo studies should be further
revealing. More broadly, bidirectional gene partners have never been studied in vivo,
therefore, these experiments would provide much needed knowledge to expand the
concept of cooperativity between bidirectional gene partners in oncogenesis

FOXM1 and RHNO1 in Chemoresistance and HR DNA Repair, and Potential for
Therapeutic Targeting
We showed that FOXM1 and RHNO1 loss decreased homologous recombination
DNA repair and sensitized HGSC cells to the PARP inhibitor olaparib. We observed that
FOXM1 loss alone sensitized HGSC cells to PARP inhibitor, but surprisingly, our RNAseq analysis did not reveal DNA repair genes as transcriptional targets of FOXM1.
However, we observed that FOXM1 regulated genes involved in the G2/M checkpoint and
in agreement, cell cycle analysis showed that FOXM1 loss increased the number of G2/M
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cells. Furthermore, we observed that FOXM1 promoted DNA fork progression in FTE cells,
a function that appears to be independent of its transcriptional activity. Therefore, we
hypothesize that FOXM1 may be promoting chemoresistance in HGSC cells through
protein interactions with DNA repair and chromatin modifying proteins, and not through its
transcriptional activity. Further studies are needed to test this hypothesis.
Importantly, we observed that PARP inhibitor sensitization was greatest when both
FOXM1 and RHNO1 were inhibited. These data support additional studies to determine if
FOXM1 and RHNO1 loss will sensitive HGSC cells to other chemotherapeutic agents.
Potential candidates for these studies include carboplatin and paclitaxel based on
previous studies showing that FOXM1 promotes resistance to these drugs (199201,214,215). CHK1 inhibitor has been shown to be synthetically lethal with ATR inhibitor,
suggesting that RHNO1 loss may synergize with a CHK1 inhibitor (216). RHNO1 functions
proximal to ATR, therefore, we would expect there to be synergy with a CHK1 inhibitor
and potentially not an ATR inhibitor. We also observed a novel function for FOXM1 in
promoting increased DNA fork rate so potentially inhibition of FOXM1 and RHNO1 in
combination with CHK1 inhibition will show the greatest synergy.
Based on growing recognition of the oncogenic role of FOXM1 in cancer, there is
great interest in developing drugs to target this protein. This is particularly true in HGSC,
for which the current therapeutic regimens are inadequate. Until recently, FOXM1
targeting drugs, such as the thiazole antibiotics Siomycin A and Thiostrepton, were nonspecific and had global effects on proteasome-dependent pathways (217,218). However,
Gormally et al. recently reported the identification and characterization of a specific
inhibitor of FOXM1, which they named FDI-6 (219). Importantly, FDI-6 specifically inhibited
the DNA binding activity of FOXM1, but not other FOX family members, and inhibited
cancer cell growth in vitro. However, FDI-6 will need further validation because there are
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concerns about its specificity for FOXM1 only and not other forkhead family members
specificity (220), and the potency will need improvement for in vivo treatment of FOXM1dependent cancers. Regardless, the existence of a specific inhibitor of FOXM1 provides
a new opportunity for translational studies of FOXM1-dependent cancers, including
HGSC. Furthermore, there are currently no inhibitors of RHNO1. Therefore, ATR inhibitors
could be used in lieu of RHNO1 inhibition to combine with FOXM1 inhibitors as a
potentially feasible and novel treatment strategy for HGSC.

CONCLUSION
Our data identified genetic mechanisms that contribute to FOXM1 overexpression
in HGSC. More importantly, we determined the functional consequences of FOXM1
overexpression in HGSC, showing that FOXM1 promotes cell cycle progression and alters
DNA replication dynamics, thus providing a mechanistic link to its association with
genomic instability. We identified FOXM1 activation downstream of Cyclin E1-induced
DNA replication stress, which cooperatively promoted cell cycle progression, increased
transcriptional activity and enriched the CIN70 gene expression signature. In agreement,
HGSC tumors with copy number gain for both FOXM1 and CCNE1 showed increased
genomic instability. Furthermore, for the first time, we investigated the contribution of
FOXM1 and its bidirectional gene partner, RHNO1, in HGSC cell survival and
chemoresistance, showing that FOXM1 and RHNO1 augment the phenotypes to a greater
extent than either gene alone. Finally, taken together, our data support additional in vitro
and in vivo studies focusing on the cooperativity of FOXM1 and RHNO1 bidirectional gene
partners, to further understand their contribution to HGSC development, progression and
survival.
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